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Gremlin, a 184 amino acid glycosylated protein, is one of several high-affinity 
endogenous antagonists of the bone morphogenetic protein (BMP) cytokines including 
BMPs -2, -4 and -7. Both gremlin and its BMP ligands have been shown to bind tightly 
to heparan sulfate (HS) polysaccharides present on cell surfaces. However, the role 
played by HS in the interaction between gremlin and its BMP ligands remains 
unknown. In this study, the heparin binding site on gremlin was characterised. Since the 
three-dimensional structure of gremlin remains experimentally unresolved, prediction of 
its heparin binding site was based on docking calculations using its homology models. 
Within the primary sequence, the predicted heparin binding site comprises interspersed 
basic residue clusters of arginines and lysines. Using site-directed mutagenesis, strategic 
combinatorial substitutions of these basic clusters were made. Six C-Myc-tagged 
gremlin mutants, MGRs 1 - 6, were cloned and expressed in parallel with a C-Myc-
tagged wildtype gremlin protein. All six gremlin-Myc mutants showed markedly 
reduced heparin binding compared to the wildtype, using heparin affinity 
chromatography and a heparin-binding ELISA. This verified the predicted mapping of 
the heparin/HS binding site on gremlin. Ion-exchange chromatography of these gremlin-
Myc proteins on sulfopropyl (SP)-Sepharose columns showed comparatively weak 
binding, thus indicating that the interaction between gremlin and heparin/HS is specific. 
Using a novel Myc-capture GREM1/BMP-4 double sandwich ELISA, the BMP-4 
binding capability of both wildtype gremlin-Myc and mutant MGR5 were 
demonstrated. Moreover, the addition of either soluble unfractionated heparin or the low 
molecular weight heparin, tinzaparin, in this ELISA neither markedly promoted nor 
inhibited the interaction between wildtype gremlin-Myc and BMP-4. Overall, these 
showed that heparin binding is not essential for BMP-gremlin binding.  
In order to study the functional activities of three selected gremlin-Myc mutants 
alongside wildtype, their capabilities to inhibit BMP-SMAD1/5/8 signalling were 
investigated in two functional assays established in C2C12 myoblastic cell lines. Firstly, 
SMAD1/5/8 phosphorylation was responsive to both BMPs -4 and -7, but this assay 
failed to generate a graded phospho-SMAD1/5/8 dose response on a sufficiently 
consistent basis to allow comparison of these gremlin-Myc proteins. This was resolved 
in the second assay, which employed a SMAD1/5/8-specific luciferase reporter 
construct. In this reporter assay, the functional activities of concentrated wildtype 
gremlin-Myc, MGR5 and MGR6 were confirmed.  
4 
 
Table of contents 
 
Title page ..................................................................................................................................... 1 
Declaration of authorship ............................................................................................................. 2 
Abstract ........................................................................................................................................ 3 
Table of contents .......................................................................................................................... 4 
List of figures ............................................................................................................................... 9 
List of tables ............................................................................................................................... 12 
List of abbreviations .................................................................................................................. 13 
Chapter 1: Introduction .............................................................................................................. 18  
1.1           The BMPs: discovery and the subfamily ................................................................... 18 
1.2          Synthesis and processing of BMPs. ............................................................................ 19 
1.3    General structure of BMPs .......................................................................................... 20 
1.4    Mechanism of receptor activation by BMPs ............................................................... 23 
1.5    BMP-induced downstream signalling via SMAD proteins ......................................... 26 
1.6    Regulation of BMP signalling ..................................................................................... 27 
1.7    Structural features of the CAN family of BMP antagonists........................................ 31 
1.8          Binding sites on sclerostin and PRDC ........................................................................ 35 
1.8.1       Amino acid numbering system ................................................................................... 35 
1.8.2       Binding sites on sclerostin .......................................................................................... 35 
1.8.3       Binding sites on PRDC ............................................................................................... 36 
1.9    Heparan sulfate and heparin: glycosaminoglycan subclass ........................................ 39 
1.10    Biosynthesis of unmodified nascent HS and heparin chains....................................... 40 
1.11    Post-modification incorporations of nascent HS/ heparin chains ............................... 42 
1.12    Heparin and HS: Conformations and dynamics .......................................................... 43 
1.13    Specificity of binding interactions of HS/heparin to diverse cytokine proteins ......... 46 
1.14    Biological roles of HS/heparin interactions with cytokine proteins ........................... 47 
1.15    Gremlin and its biological functions ........................................................................... 51 
1.16    Prediction of the heparin binding site on gremlin ....................................................... 54 
1.17    Use of homology modeling and docking calculations in structural predictions ......... 60 
1.18        Hypotheses .................................................................................................................. 60 
1.19        Aims ............................................................................................................................ 61 
1.19.1     Aim 1: To clone and express C-Myc-tagged wildtype and mutant gremlin proteins..61 
1.19.2     Aim 2: To detect gremlin-Myc expression and assess the heparin binding  
                properties of wildtype gremlin-Myc .......................................................................... 61 
1.19.3     Aim 3: To assess the heparin binding capabilities of gremlin-Myc mutants  
5 
 
               compared to the wildtype ............................................................................................ 62 
1.19.4     Aim 4: To indicate that binding of gremlin to heparin occurs via specific  
                ionic interactions and to purify expressed gremlin-Myc proteins .............................. 62 
1.19.5     Aim 5: To investigate BMP binding capabilities in wildtype gremlin-Myc 
                and its mutants and assess the effect of heparin on these capabilities ....................... 63 
1.19.6     Aim 6: To assess whether expressed gremlin-Myc proteins are functionally 
               active and investigate the role of HS in gremlin interaction with BMPs .................... 64 
 
Chapter 2: Materials and methods ............................................................................................. 66 
2.1          DNA digestion reactions with restriction endonuclease enzymes .............................. 66 
2.2    Agarose gel electrophoresis ........................................................................................ 66 
2.3    DNA extraction and purification from agarose gels ................................................... 67 
2.4    DNA quantitation ........................................................................................................ 67 
2.5    GREM1 cDNA clone .................................................................................................. 67 
2.6    Polymerase Chain Reaction (PCR) using Taq and Pfu DNA polymerases ................ 68 
2.7    Processing of PCR products ........................................................................................ 69 
2.8    DNA ligation reactions ............................................................................................... 69 
2.9    Mammalian expression vectors ................................................................................... 70 
2.9.1       pCMV-Tag5A expression vector (Figure 3.8) ............................................................ 70 
2.9.2       pEGFP-C1 expression vector ...................................................................................... 71 
2.9.3       pGL3-basic expression vector ..................................................................................... 72 
2.10    Bacterial growth media ............................................................................................... 73 
2.11    Preparation of bacterial glycerol stocks ...................................................................... 74 
2.12    Transformation of competent E. coli bacterial cells ................................................... 74 
2.13    DNA purification ........................................................................................................ 74 
2.13.1     Small scale purification of DNA (Mini prep) ............................................................. 74 
2.13.2     Large scale purification of plasmid DNA (Maxi prep) ............................................... 75 
2.14    Plasmid DNA sequencing ........................................................................................... 75 
2.15    Confirmation of positive integrative transformants .................................................... 76 
2.16    Gremlin-Myc expression in mammalian cell cultures ................................................ 77 
2.16.1     Chinese Hamster Ovary S-strain (CHO-S) cell cultures ............................................. 77 
2.16.2     CHO-S cells: sub-culture ............................................................................................ 77 
2.16.3     CHO-S cells: transient transfections, harvests and microscopy .................................. 78 
2.17    Commercially purified recombinant proteins ............................................................. 78 
2.18    Concentration of crude gremlin-Myc CHO-S culture supernatants ............................ 79 
2.19    Sandwich enzyme-linked immunosorbent assay (ELISA) ......................................... 79 
2.19.1     Sandwich ELISA general procedure ........................................................................... 79 
6 
 
2.19.2     Heparin-binding ELISA .............................................................................................. 80 
2.19.3     Myc-capture gremlin ELISA ...................................................................................... 80 
2.19.4     Myc-capture GREM1/BMP-4 double sandwich ELISA ............................................. 80 
2.20    Synthesis of heparin-BSA conjugate .......................................................................... 80 
2.21    Heparin affinity chromatography ................................................................................ 82 
2.22    Ion-exchange chromatography .................................................................................... 83 
2.23    SDS-polyacrylamide gel electrophoresis (SDS-PAGE) ............................................. 84 
2.24        Silver staining of polyacrylamide gels ........................................................................ 84 
2.25    Western blotting and development of blots ................................................................ 85 
2.26    Gremlin-Myc immunoprecipitation (IP) ..................................................................... 85 
2.27    IP of BMP-4 on gremlin-Myc-bead complexes .......................................................... 86 
2.28    Murine C2C12 myoblastic cells: supply and maintenance ......................................... 86 
2.29    BMP-SMAD1/5/8 phosphorylation assay in C2C12 cell cultures .............................. 87  
2.30    Luciferase reporter assay in C2C12 cell cultures ........................................................ 88 
2.30.1     Preparation of the 12XSBE-Oc-Luc+-pGL3 construct ................................................ 88 
2.30.2     Transient transfections of C2C12 cells ....................................................................... 89 
2.30.2.1  Lipofectamine 2000 transfection method.................................................................... 89 
2.30.2.2  Fugene 6 transfection protocol .................................................................................... 90 
2.30.3     BMP-4 and gremlin treatments of C2C12 cell cultures .............................................. 90 
2.30.4   Measurement of luciferase activity…………………………………………………..91 
 
Chapter 3: Cloning of wildtype and mutant GREM1-Myc constructs…………………………93 
3.1          Introduction ................................................................................................................. 93 
3.2    Cloning of the wildtype GREM1 insert ...................................................................... 94 
3.3    Design of site-directed mutagenesis within the GREM1 insert .................................. 98 
3.4    PCR-based methods used for site-directed mutagenesis ........................................... 102 
3.5    Application of PCR-based methods in cloning of mutant GREM1 inserts ............... 105 
3.6    Subcloning the GREM1 inserts into the pCMV-Tag5A expression vector .............. 112 
3.6.1       The pCMV-Tag5A expression vector ....................................................................... 112 
3.6.2       Preparing the pCMV-Tag5A expression vector ........................................................ 113 
3.7    Screening of bacterial transformants ......................................................................... 114 
3.7.1       Preliminary screening by restriction endonuclease digestion ................................... 114 
3.7.2       Sequencing of GREM1-Myc constructs ................................................................... 116 
3.8   Discussion…………………………………………………………………………..120 
 
Chapter 4: Mapping of the heparin binding site on wildtype gremlin-Myc…………………..123 
4.1          Introduction ............................................................................................................... 123 
7 
 
4.2    Gremlin detection in crude gremlin-Myc culture supernatants ................................. 123 
4.3    Investigating the Myc and heparin binding properties of the 50 kDa protein ........... 128 
4.4          Partial purification of wildtype gremlin-Myc ........................................................... 130 
4.5    Synthesis of the heparin-BSA conjugate .................................................................. 133 
4.6    Assessing the heparin binding capability of expressed His- and Myc-tagged 
               wildtype gremlin-Myc proteins using the heparin-binding ELISA .......................... 135 
4.7    Assessing the heparin binding activity of expressed wildtype and mutant 
               gremlin-Myc proteins using the heparin-binding ELISA ......................................... 137 
4.8   Heparin affinity chromatography…………………………………………………...142 
4.8.1       Assessment of the Myc-capture gremlin ELISA for heparin affinity       
               chromatographic analyses…………………………………………………………..142 
4.8.2       Heparin affinity chromatography of wildtype gremlin-Myc protein……………….143 
4.8.3       The heparin affinity chromatography of mutant gremlin-Myc proteins……………149 
4.9    SP-Sepharose ion-exchange chromatography of gremlin-Myc proteins ................... 151 
4.10   Discussion…………………………………………………………………………..154 
 
Chapter 5: Investigating the BMP antagonist activity of wildtype gremlin-Myc 
                  against its mutants………………………………………………………………...159 
5.1           Introduction………………………………………………………………………...159 
5.2          Assessing the BMP-4 binding capability of wildtype gremlin-Myc and 
               its mutants by immunoprecipitation (IP)……………………………………………160 
5.2.1       IP of gremlin-Myc proteins on anti-C-Myc agarose beads…………………………160 
5.2.2   IP of purified BMP-4 on gremlin-Myc-bead complexes……………………………161 
5.3   Assessing the BMP-4 binding capability of wildtype gremlin-Myc and its  
               mutants by ELISA…………………………………………………………………..165 
5.3.1   Establishment of a novel Myc-capture GREM1/BMP-4 double sandwich  
               ELISA……………………………………………………………………………….165 
5.3.2   Assessing the BMP-4 binding capabilities of expressed gremlin-Myc  
               proteins using the Myc-capture GREM1/BMP-4 double sandwich ELISA………..167 
5.3.3       Effects of soluble heparin on wildtype gremlin-Myc binding  
               interaction with BMP-4 in ELISA………………………………………………….168 
5.4         SMAD1/5/8 phosphorylation assay in C2C12 cell cultures………………………....171 
5.4.1      BMPs -4 and -7-induced SMAD1/5/8 phosphorylation…………………………......171 
5.4.2      Effect of gremlin-His treatment on SMAD1/5/8 phosphorylation……...…………...174 
5.4.3      The effect of gremlin-His in the BMP-7-induced SMAD1/5/8 phosphorylation……175 
5.4.4      Effect of gremlin-His in the BMP-4-induced SMAD1/5/8 phosphorylation……..…178 
5.5          Investigating the functional activity of wildtype gremlin-Myc and its 
8 
 
               low heparin-binding mutants using a luciferase-secreted reporter assay…………...180 
5.5.1       Establishment of a luciferase-secreted reporter assay………………………………180 
5.5.2   Investigating the functional activity of wildtype gremlin-Myc and its mutants……183 
5.6          Discussion…………………………………………………………………………..186 
 
Chapter 6: General discussion and conclusion……………………………………………….190 
6.1   Mapping of the heparin binding site on gremlin…..………………………………..190 
6.2   Mapping of the heparin binding site on the predicted gremlin  
               model based on the crystal structure of PRDC……………………………………..193 
6.3          Comparison of experimentally mapped heparin binding sites within 
               the BMP antagonist family…………………………………………………………196 
6.4   Nature of the binding interaction between gremlin and heparin……………………196 
6.5   Effects of Myc and His tags on gremlin binding to heparin/HS……………………199 
6.6   Effects of soluble heparin on gremlin interaction and its BMP ligands……………199 
6.7   Refining the location of the BMP binding site on gremlin…………………………201 
6.8   Significance of the BMP antagonist activity of wildtype gremlin-Myc 
               versus mutants………………………………………………………………………202 
6.9   Gremlin binds to heparan sulfate on cell surfaces…………………………………..203 
6.10   Does gremlin forms a dimer? ....................................................................................203 
6.11   Limitations of this study…………………………………………………………….205 
6.12   Future work…………………………………………………………………………206 






List of figures 
 
Figure 1.1     BMP-4 synthesis and processing .......................................................................... 20 
Figure 1.2     Structural features of a BMP-7 monomer ............................................................. 22 
Figure 1.3     High resolution structures of BMP-7 dimers ........................................................ 23 
Figure 1.4     A BMP-7 dimer complexed with activin receptor type II ectodomains ............... 25 
Figure 1.5     Activation and regulation of the canonical BMP-SMAD signalling pathway ..... 28 
Figure 1.6     The Noggin-BMP-7 complex ............................................................................... 30 
Figure 1.7     High resolution structure of sclerostin .................................................................. 32 
Figure 1.8     High resolution structures of the BMP antagonist, PRDC ................................... 34 
Figure 1.9     Comparison of the BMP and heparin binding sites on sclerostin and PRDC……38 
Figure 1.10   Heparin and heparan sulfate (HS) biosynthesis .................................................... 41 
Figure 1.11   Structural conformations of heparin ..................................................................... 45 
Figure 1.12   Molecular models of CAN family of BMP antagonists based on sclerostin. ....... 57 
Figure 1.13   Docking of a predicted gremlin model with a heparin oligosaccharide. .............. 58 
Figure 1.14   Homology model of gremlin based on PRDC. ..................................................... 59 
 
Figure 2.1     Plasmid map of the pEGFP-C1 expression vector construct ................................ 72 
Figure 2.2     pGL3-basic expression vector map                                                                        73 
Figure 2.3     BSA standard curve .............................................................................................. 82 
Figure 2.4     Conductivity standard curve ................................................................................. 83 
Figure 2.5     Standardizing the Luciferase Assay System ......................................................... 92 
 
Figure 3.1     Base substitutions incorporated into the 5’- and 3’-ends of all cloned  
                      murine GREM1 inserts cloned ............................................................................. 95 
Figure 3.2     Cloning of the wildtype GREM1 insert  ............................................................... 97 
Figure 3.3     Standard PCR amplification of the wildtype GREM1 insert  ............................... 98 
Figure 3.4     Predicted basic clusters in the precursor wildtype GREM1 primary 
                      sequence  .............................................................................................................. 99 
Figure 3.5     Schematic diagram of the overlap extension PCR (OE PCR) method of 
                      site-directed mutagenesis ................................................................................... 104 
Figure 3.6     Schematic diagram of the one-step overlap extension PCR (OOE PCR) ........... 105 
Figure 3.7     Intermediate DNA fragments of GREM1 mutant inserts generated  
                      using OE PCR .................................................................................................... 110 
Figure 3.8     Plasmid map of the pCMV-Tag5A expression vector  ....................................... 113 
Figure 3.9     Thermolabile SAP treatment of the pCMV-Tag5A expression vector ............... 114 
Figure 3.10   Preliminary screening by restriction endonuclease (RE) digestion .................... 115 
10 
 
Figure 3.11   Sequence alignment of all GREM1-Myc constructs  ......................................... 118 
 
Figure 4.1     Myc-capture gremlin ELISA of crude gremlin-Myc CHO-S culture  
                      supernatants ........................................................................................................ 125 
Figure 4.2     Dose response curves of expressed gremlin-Myc proteins ................................. 126  
Figure 4.3     Equalising gremlin-Myc immunoreactivity using the Myc-capture  
                     gremlin ELISA .................................................................................................... 126  
Figure 4.4     Western blot detection of gremlin in crude CHO-S culture supernatants .......... 128 
Figure 4.5     Investigating the source, Myc and heparin binding of the unknown 50 kDa  
                      protein detected in CHO-S culture supernatants ................................................ 130   
Figure 4.6     Partial purification of wildtype gremlin-Myc using SP-Sepharose and its 
                     stability ................................................................................................................ 132 
Figure 4.7     Gel filtration profile of heparin and BSA conjugates ......................................... 134 
Figure 4.8     Detection of conjugated heparin-BSA complexes .............................................. 135 
Figure 4.9     The heparin binding properties of expressed gremlin-Myc and 
                      purified gremlin-His wildtype proteins .............................................................. 137 
Figure 4.10   Effect of high NaCl concentrations on the heparin-BSA capture layer .............. 139  
Figure 4.11   NaCl inhibition curves of wildtype versus mutant gremlin-Myc proteins  
                      generated using the heparin-binding ELISA ...................................................... 141  
Figure 4.12   Effects of varying the ionic strength on the Myc-capture gremlin ELISA  ........ 143 
Figure 4.13   Wildtype gremlin-Myc elution profiles generated using HiTrap  
                      heparin-Sepharose columns ............................................................................... 145  
Figure 4.14   Wildtype gremlin-Myc elution profiles generated using AF heparin  
                      HC650M bead columns ..................................................................................... 146 
Figure 4.15   Determining the true elution profile of expressed wildtype gremlin-Myc  
                      protein  ............................................................................................................... 148 
Figure 4.16   Heparin affinity chromatography of mutant gremlin-Myc proteins  
                     versus wildtype ................................................................................................... 150  
Figure 4.17   SP-Sepharose ion-exchange chromatography of mutant gremlin-Myc  
                     proteins  versus wildtype ..................................................................................... 153 
 
Figure 5.1     Immunoprecipitation (IP) of expressed gremlin-Myc proteins .......................... 160  
Figure 5.2     IP experiment of BMP-4 on wildtype gremlin-Myc-bead complex ................... 162 
Figure 5.3     IP of BMP-4 on mutant gremlin-Myc-bead complexes...................................... 164 
Figure 5.4     Effect of the Myc capture antibody loading in the Myc-capture 
                     GREM1/BMP-4 double sandwich ELISA .......................................................... 166 
Figure 5.5     Effects of BMP-4 loading in the Myc capture-GREM1/BMP-4  
11 
 
                     double sandwich ELISA ..................................................................................... 167  
Figure 5.6     Effects of soluble unfractionated heparin and tinzaparin on the binding 
                     interaction between wildtype gremlin-Myc and BMP-4 ..................................... 170  
Figure 5.7     BMP-4 dose response curve in the SMAD1/5/8 phosphorylation assay ............ 173 
Figure 5.8     BMP-7 induced dose response curve in the SMAD1/5/8 phosphorylation 
                      assay ................................................................................................................... 174  
Figure 5.9     Effect of wildtype gremlin-His treatment alone on SMAD1/5/8 
                      phosphorylation .................................................................................................. 175  
Figure 5.10   Effect of purified gremlin-His on BMP-7-induced SMAD1/5/8  
                      phosphorylation .................................................................................................. 176  
Figure 5.11   Effect of higher doses of purified gremlin-His on BMP-7-induced  
                     SMAD1/5/8 phosphorylation .............................................................................. 178 
Figure 5.12   Effect of purified gremlin-His on BMP-4-induced SMAD1/5/8  
                      phosphorylation .................................................................................................. 179 
Figure 5.13   BMP-4 dose response curves in the secreted-luciferase reporter assay .............. 182  
Figure 5.14   Investigating the functional activities of expressed gremlin-Myc proteins ........ 184 
 
Figure 6.1     Polypeptide sequence alignment of the experimentally mapped heparin  
                     binding site on Noggin, gremlin and sclerostin .................................................. 194  













List of tables 
Table 2.1    GREM1-Myc plasmid construct sequencing primer oligonucleotides ................... 76 
 
Table 3.1    Summary of design of site-directed mutagenesis of gremlin ................................ 101 
Table 3.2    List of all GREM1 mutant inserts cloned ............................................................. 106 
Table 3.3    List of primers and GREM1 mutant inserts cloned by standard PCR method ..... 108      
Table 3.4    List of primers and GREM1 mutant inserts cloned by OE PCR-based method ... 109 
Table 3.5    List of primers and GREM1 mutant inserts cloned by OOE PCR method ........... 111  
Table 3.6    Effects of using different PCR-based strategies on the DNA yields of all 
                   GREM1-Myc constructs ....................................................................................... 119 
 





List of abbreviations 
3-D   Three-dimensional 
ActR   Activin receptor 
ALK   Activin receptor-like kinase 
Ampr   Ampicillin resistance 
ANOVA  Analysis of variance 
APC   Antigen-presenting cell 
APS   Ammonium persulphate 
ATCC   American Type Culture Collection 
BAMBI  BMP and activin membrane-bound inhibitor 
BCA   Bicinchoninic assay 
bFGF   basic fibroblast growth factor 
bHLH   Basic helix-loop-helix 
Bla   Blasticidin 
BMP   Bone morphogenetic protein 
BMPR   Bone morphogenetic protein receptor 
bp   Base pair 
BSA   Bovine serum albumin 
CAN family  DAN and Cerberus family 
CDMP   Cartilage-derived morphogenetic protein 
cDNA   Complementary deoxyribonucleic acid 
CDS   Coding sequence 
CHO   Chinese hamster ovary 
CMV   Cytomegalovirus 
CO2   Carbon dioxide 
CV2   Crossveinless 2 
Cys   Cysteine 
DAN   Differential screening-selected gene aberrative in neuroblastoma 
dATP   Deoxyadenosine triphosphate 
DCTA   1,2-diaminocyclohexane-N.N,N’,N’-tetraacetic acid 
14 
 
dCTP   Deoxycytidine triphosphate 
dGTP   Deoxyguanosine triphosphate 
DMSO   Dimethyl sulfoxide 
DN   Diabetic nephropathy 
DNA   Deoxyribonucleic acid 
DTT   Dithiothreitol 
dTTP   Deoxythymidine triphosphate 
ECD   Extracellular domain 
ECM   Extracellular matrix 
EDTA   Ethylenediaminetetraacetic acid 
EGFP   Enhanced green fluorescent protein 
ELISA   Enzyme-linked immunosorbent assay 
EMT   Epithelial-to-mesenchymal transition 
EndMT   Endothelial-to-mesenchymal transition 
EXT   Exostosin 
EXTL   Exostosin-like 
FBS   Fetal bovine serum 
FGF   Fibroblast growth factor 
FGFR   Fibroblast growth factor receptor 
GAG   Glycosaminoglycan 
GDF   Growth differentiation factor 
GDNF   Glial cell derived neurotrophic factor 
GlcA   β-D-glucuronic acid 
GlcNAc  α-N-acetylglucosamine 
GlcNS6S  N-sulpho-N-glucosamine 6-O-sulfate 
GREM1  gremlin (gremlin-1) 
GS domain  Glycine and serine rich domain 
HBGF   Heparin-binding growth factor 
HME   Hereditary multiple exostoses 
HPLC   High performance liquid chromatography 
HRP   Horseradish peroxidase 
HS   Heparan sulfate 
15 
 
HSQC   Heteronuclear spin quantum convergence 
HSV   Herpes simplex virus 
I.M.A.G.E.  Integrated Molecular Analysis of Genomes and their Expression 
I-SMAD  Inhibitory SMAD 
ID genes  Inhibitor of differentiation genes 
IdoA   L-iduronic acid 
IdoA2S   2-O-sulfated L-iduronic acid 
IFNγ   Interferon gamma 
Ig   Immunoglobulin 
IL   Interleukin 
IP   Immunoprecipitation 
Kan   Kanamycin 
kb   Kilobase 
Kd   Disociation constant 
kDa   KiloDalton 
LB   Luria-Bertani 
luc+ gene  Luciferase gene 
MAD   Mothers against decapentaplegic 
MAE   Murine aortic endothelial  
MALDI  Matrix-assisted laser desorption/ionization 
MAPK   Mitogen-activated protein kinase 
Maxi prep  Large scale DNA purification 
MCS   Multiple Cloning Site 
MES   2-N-morpholinoethanesulfonic acid  
MH1 and 2  Mothers against decapentaplegic homology 1 and 2 
Mini prep  Small scale DNA purification 
mRNA   Messenger ribonucleic acid 
MW   Molecular weight 
NA domain  N-acetylated domain 
NDST   N-deacetylase/N-sulfotransferase 
Neo   Neomycin 
NIBSC   National Institute of Biological Standards and Control 
16 
 
NMR   Nuclear magnetic resonance 
NOESY  Nuclear Overhauser effect spectroscopy 
NS domain  N-sulfated domain 
Oc    Osteocalcin  
OE PCR  Overlap extension polymerase chain reaction 
Oligo   Oligonucleotide 
OOE PCR  One-step overlap extension polymerase chain reaction 
OP   Osteogenic protein 
ORF   Open reading frame 
Ori   Origin of replication 
p-SMAD  Phospho-SMAD 
pA   Polyadenylation 
PAGE   Polyacrylamide gel electrophoresis 
PAPS   3’-phosphoadenosine 5’-phosphosulfate 
PBS   Phosphate buffer saline 
PCR   Polymerase chain reaction 
PDB   Protein data bank 
PP1   Protein phosphatase-1  
PPM1A  Metal-ion protein phosphatase-1A   
PRDC   Protein related to DAN and Cerberus 
QS   Quick-Stick 
R-SMAD  Regulatory SMAD 
RANTES  Regulated on activation normal T cell expressed and secreted 
RE   Restriction endonuclease 
RGM   Repulsive guidance molecule 
RLU   Relative light unit 
RNA   Ribonucleic acid 
ROS   Rat osteosarcoma 
SAP   Shrimp alkaline phosphatase 
SAXS   Small angle X-ray scattering 
SBE   SMAD binding element 
SDS   Sodium dodecyl sulfate 
17 
 
SEM   Standard error of mean 
SeMet   Selenomethionine 
SMAD   Signalling mothers against decapentaplegic 
SP-Sepharose  Sulfopropyl-Sepharose 
SPR   Surface plasmon resonance 
ssDNA   Single-stranded deoxyribonucleic acid 
SV40   Simian virus 40 
T-SMAD  Total-SMAD 
TAE   Tris-acetate-ethylenediaminetetraacetic acid 
TBS   Tris buffer saline 
TEMED  Tetramethylethylene-diamine 
TGFβ   Transforming growth factor beta 
TGN   Trans-Golgi network 
TK   Thymidine kinase 
USAG-1  Uterine sensitization-associated gene-1 
UTR   Untranslated region 




Chapter 1: Introduction 
1.1 The BMPs: discovery and the subfamily 
The BMP subfamily of cytokines consists some of twenty secreted molecules 
that regulate a wide spectrum of developmental processes during embryonic 
development and several cellular processes in postnatal and adult animals. 
Embryogenic processes include dorso-ventral patterning, dorsal neural tube 
development, skeletogenesis and organogenesis of some major organs such as the eye, 
lung, liver and kidney (Macias et al., 1997; Ducy and Karsenty, 2000; Liu and 
Niswander, 2005; Little and Mullins, 2006). Therefore, the tight regulation of BMP 
activity is essential for healthy development.  
BMP activity was first discovered by Urist (1965) who demonstrated that in 
demineralised matrix of bone and dentin, an inductive factor caused de novo bone 
formation at ectopic sites in rats when transplanted intramuscularly. However, cloning 
and purification of the first BMPs, BMPs -1, -2 and -3, was only achieved over two 
decades later (Sampath et al., 1987; Wang et al., 1988; Luyten et al., 1989). BMP-1 
was identified as a novel regulatory protease whereas BMP-2 and BMP-3 were found 
to be novel members of the transforming growth factor beta (TGFβ) superfamily 
(Wozney et al., 1988).  
To date, at least 35 members of the TGFβ superfamily have been identified and 
are subdivided into four main subfamilies namely, activins/inhibins, TGF-βs, 
BMPs/growth and differentiation factors (GDFs) and the neurotrophic factors such as 
glial cell derived neurotrophic factors (GDNFs), (Weiskirchen and Meurer, 2013). 
Their common grouping stems from the high sequence homology they share, indicating 
evolution from a common ancestral gene (Kingsley, 1994; Rider and Mulloy, 2010). 
The increasingly divergent biological roles of individual BMP members also led to 
progressive changes in their naming, from osteogenic proteins (OPs) and cartilage-
derived morphogenetic proteins (CDMPs) to BMPs and GDFs, predominantly (Ducy 
and Karsenty, 2000; Rider and Mulloy, 2010). 
Phylogenetic analyses based on the sequence homology of their conserved 
cystine-knot domain present in their mature forms results in further subgrouping of the 
BMPs (Kingsley, 1994; Hogan, 1996; Yamashita et al., 1996; Rider and Mulloy, 2010). 
Most notably, BMP-4 and BMP-7, both of which are used in this study, are allocated to 
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different subgroups with the former subcategorised with BMP-2 only, and the latter 
with the BMPs -5, -6 and -8 (Newfeld et al., 1999; Hinck, 2012).  
1.2 Synthesis and Processing of BMPs. 
BMPs are synthesised as large monomeric pre-pro-polypeptides within the 
endoplasmic reticulum. Such polypeptide consist of a short N-terminal signal sequence 
pre-domain linked to a latency associated polypeptide pro-domain that regulates proper 
folding and in turn is linked to the mature polypeptide region itself (Xiao et al., 2007). 
This varies in size for each BMP ranging between 400 - 500 amino acids in length (Ali 
and Brazil, 2014).). The model for synthesis and processing of BMP-4 is shown in 
Figure 1.1. 
To achieve the active mature BMP-4 ligand, sequential post-translational 
modifications of the pre-pro-polypeptide takes place in the trans-Golgi network (TGN). 
First, the signal peptide is cleaved off proteolytically at a consensus R-X-K-R site (S1 
site, Figure 1.1) releasing the pro-polypeptide domain. In the case of BMP-4, the 
precursor protein is cleaved at both S1 and S2 sites by the proprotein convertase, furin 
(Ali and Brazil, 2014). For most BMPs including BMPs -4 and -7, glycosylation of the 
monomeric pro-polypeptide takes place at a conserved NXS/T site in the mature 
polypeptide region. Next, proteolytic cleavage of the pro-domain occurs at a consensus 
R-X-X-R site, which is rendered accessible due to the acidic environment within the 
post-TGN (S2 site, Figure 1.1). This liberates a stable glycosylated mature monomeric 
BMP ligand from its pro-domain. Homo-dimerization of this secreted BMP-4 
monomers then takes place via a covalent disulfide linkage (Rider and Mulloy, 2010). 
This then results in the secretion of a stable biologically active dimeric BMP-4 ligand 
into circulation for BMP receptor activation at distant target tissues (Nelsen and 
Christian, 2009, Ali and Brazil, 2014). It is worth noting that although this processing 
is axiomatic for all BMPs, non-covalent dimerization has also been reported, such as 
for BMP-15 (Nelsen and Christian, 2009).    
Dissociation of the pro-domain from the active mature ligand is not always the 
case. A crystal structure of active BMP-9 revealed that its pro-domain remains non-
covalently bound to the mature peptide region resulting in a biologically active BMP-





Figure 1.1: BMP-4 synthesis and processing. 
The model shown above serves as a general model for synthesis and processing of 
BMPs. BMPs are synthesised as large pre-pro-mature ligand complexes within the 
endoplasmic reticulum (ER) and transported to the trans-Golgi network (TGN) for 
post-translational modifications. Furin cleavage (blue coloured-bolted arrow) at S1 site 
is thought to occur in the TGN and results in release of a pro-domain-mature ligand 
complex within the post-TGN. This released complex is further cleaved at the S2 site 
by furin which then results in the release and secretion of a mature monomeric BMP 
ligand. Dimerization of this BMP monomer with another BMP monomer yields then a 
biologically active dimeric ligand. PM = Plasma membrane. Adapted from Ali and 
Brazil, 2014. 
 
1.3 General structure of BMPs 
The structural hallmark of all members of the TGFβ superfamily is the presence 
of a conserved cysteine-rich ring structure motif, the cystine-knot motif (McDonald and 
Hendrickson, 1993; Avsian-Kretchmer, 2003). As members of the TGFβ superfamily, 
all BMPs, with the exception of BMP-1, possess the characteristic TGFβ cystine-knot 
motif. The crystal structures of a number of BMPs have been resolved to date including 
that of BMP-7 (Figure 1.2; Greenwald et al., 2003). Although BMP-4 crystallography 
has not yet been achieved, that of its closest homologue, BMP-2, has (PDB file: 3BMP; 
Scheufler et al., 1999).  
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Analyses of the BMP-7 crystal structure revealed that the cystine ring of BMPs 
comprises eight residues, four of which are cysteines (Cys). These Cys residues form 
two intrachain disulfide bonds in a pairwise manner; Cys 2 and Cys 5 and between Cys 
3 and Cys 6. A third disulfide bond formed between Cys 1 and Cys 4, threads back 
through the ring giving it its characteristic 3-D knot structure (refer to Figure 1.2A), 
(Avsian-Kretchmer, 2003). Also present around the cystine-knot motif (not shown in 
figure), is another cysteine residue (Cys 7) that is directly involved in Cys 7:Cys’ 7 
covalent dimerization of two BMP-7 monomers. In terms of the overall tertiary 
structure, analogy to the “palm” of the hand is often made in reference to the cystine-
knot motif (Figure 1.2B) (Griffith et al., 1996; Rider and Mulloy, 2010).  
Projecting from the cystine-knot motif are two pairs of anti-parallel β-stranded 
loops, which are analogous to “fingers” (Figure 1.2B). In Figure 1.2A, these are formed 
between Cys 1 and Cys 2 and between Cys 4 and Cys 5. Also present is a C-terminal 
loop located opposite the fingers that in most BMPs forms a four-turn α-helix 
analogous to the “wrist” of the hand (Figure 1.2B). In Figure 1.2A, this “wrist” region 
would replace the uncoiled loop between Cys 3 and Cys 4 (Avsian-Kretchmer, 2003). 
The analogy making use of hand features to describe BMP structures is best illustrated 
using ribbon structure of the BMP-7 monomer as shown in Figure 1.2B. 
Dimerization of most BMPs including BMPs -4 and -7, takes place in a head-to-
tail orientation via covalent formation of a disulfide bond via the unpaired cysteine 
residue just outside the cystine-knot motif of each monomer. In this head-to-tail 
orientation, the wrist region (head) of one monomer is tucked into the concave face of 
the β-fingers (tail) of the other monomer (Griffith et al., 1996; Rider and Mulloy, 














Figure 1.2: Structural features of a BMP-7 monomer.  
BMP-7 structure representative of general structural features of most BMP subfamily members 
A) Cartoon representation of eight-membered cystine ring (palm region) possessing a pair of 
disulfide bonds formed between C2:C5 and C3:C6. The disulfide bond between C1:C4 passing 
through the ring, gives it its three-dimensional structure. A pair of anti-parallel β-stranded loops 
emanate from the cystine ring forming the finger loops, f1(β1 and β2)  and f2 (β3 and β4). 
Opposite the finger region, at the C-terminal end of the cystine ring, is another loop that 
typically forms a four-turn α-helix forming the wrist (W). The unpaired cysteine residue 
located outside the cystine ring used for dimerization is not shown. Adapted from Avsian-
Kretchmer and Hsueh, 2003. B) Ribbon representation of the crystallographic structure of a 
BMP-7 monomer highlighting the wrist, palm and finger regions. Disulfide bridges within the 
cystine ring are coloured in yellow. Adapted from McClarence, 2011. Original source, Griffith 






Figure 1.3: High resolution structures of BMP-7 dimers.  
Ribbon representations of the three-dimensional crystal structure of a BMP-7 dimer as 
viewed A) from the front and, B) from above. A covalent disulfide bond is formed 
between the unpaired cysteine residue (in this case, C103) located outside the cystine 
ring of each BMP monomer that joins the palm regions of both monomers together. 
The dimer oriented head-to-tail, has the 4-turn α-helix (coloured in red) in the wrist 
region (W), (head) of one monomer tucked into the concave surface of the finger 
region (tail) of the other monomer. The β-finger loops are coloured in turquoise with 
patches of grey, green and red colours. All α-helices are coloured in red. All disulfide 
bridges in the palm regions are coloured in yellow. Adapted from McClarence, 2011. 
Original source: Griffith et al., 1996. PDB file, 1LXI.   
 
1.4 Mechanism of receptor activation by BMPs  
Members of the TGFβ superfamily elicit biological effects by binding to type I 
and type II serine (Ser)/threonine (Thr) receptors on the cell surfaces of target cells 
(Yamashita et al., 1996; Chen et al., 2004b; Ali and Brazil, 2014). This is illustrated in 
Figures 1.4 and 1.5. Both types of TGFβ receptors possess an N-terminal extracellular 
ligand binding domain, a transmembrane region and a C-terminal cytoplasmic Ser/Thr 
kinase domain (Shi and Massagué, 2003). Also present on cell surfaces are several co-
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receptors that structurally resemble the type I/II receptors themselves, but lack the 
kinase domain. These include the BMP and activin membrane-bound inhibitor 
(BAMBI) illustrated in Figure 1.5, the membrane-associated receptors of the repulsive 
guidance molecule (RGM) family of facilitators and enhancers of BMPs-2/-4 signalling 
and the type III class of receptors (endoglin and betaglycan) that enhance BMP -2/-4/-
7/-9 signalling (David et al., 2007; Onichtchouk et al., 1999; Babitt et al., 2006; Camus 
and Lambert, 2007; McLean and Guglielmo, 2010). In short, these kinase domain-
deficient co-receptors regulate BMP signalling by either inhibiting or enhancing 
assembly of the types I and II receptor complex. 
In the human genome, the 12 members that make up the TGFβ receptor family 
are dedicated entirely to TGFβ signalling, seven of which are type I and the remaining 
five, type II receptors (Manning et al., 2002). BMP ligands bind to three type I 
receptors namely: activin-like receptor kinase (ALK)2, ALK3 also called BMP receptor 
1A (BMPRIA) and ALK6 or BMPRIB, and to three type II receptors: BMP type II 
receptor (BMPRII), activin A receptor type II (ActRII) and activin B receptor type II 
(ActRIIB), (Nohe et al., 2004).  BMP ligand binding to a pair of type I receptor ligand 
binding domains results in the recruitment of a pair of type II receptors required for the 
full activation of the type I receptors via which a downstream signal transduction is 
propagated (ten Dijke and Hill, 2004). This order of recruitment of type I to type II 
receptors is the reverse of that seen with TGFβ-1 (Ali and Brazil, 2014).   
 A considerable degree in promiscuity of BMP ligands is observed in their 
interactions with the different types I/II receptor subsets. Nonetheless, preferential high 
affinity binding of BMP ligands to each receptor type also takes place.  For instance, 
BMPs -2/-4 show preferential high affinity binding to both ALK3 and ALK6, and 
although BMP-7 can also show bind to ALK3 at low affinity, it shows preferential high  
affinity binding to both ALK2 and ActRII, instead (Kirsch et al., 2000a; Greenwald et 
al., 2003; Ali and Brazil, 2014).   
The crystal structures of the BMPs -2 and -7 complexed with the ligand binding 
ectodomains of BMPRIA and ActRII have been resolved by Kirsch et al. (2000b) and 
Greenwald et al. (2003), respectively. These have helped elucidate the general 
mechanism of receptor activation of the BMPs. As shown in Figure 1.4, in the 
tetrameric assembly complex, a dimeric BMP-7 ligand is complexed to two molecules 
of ActRII ECDs.  A predominantly hydrophobic surface cavity on the convex binding 
surface of both pair of BMP-7 monomer β-fingers makes direct contact with a similarly 
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charged concave binding surface on each ActRII ECD (refer to Figure 1.4). Another 
important observation in this complex is that no direct physical interaction occurs 
between the individual receptor ECDs which is strongly indicative of downstream 
signalling activation via a ligand-mediated cooperative mechanism (Greenwald et al., 
2003).  
It follows that the binding of a BMP ligand to its receptor ECDs, results in 
conformational changes that occur in the cytoplasmic kinase domains of the pair type I 
receptors. This then facilitates their phosphorylation and sequential recruitment of pair 
type II receptors. It is worth noting that, although BMP-7 demonstrates high affinity to 
ActRII, signalling activation occurs primarily via low affinity binding to a pair of type I 
receptor ECDs that subsequently results in the recruitment of its high affinity pair of 
ActRII ECDs (Greenwald et al., 2003). Full activation of type I receptors is achieved 
by the type II receptor phosphorylation of the unique Gly and Ser rich GSGSGS 
sequences (GS domain) located immediately N-terminal of the cytoplasmic kinase 




Figure 1.4: A BMP-7 dimer complexed with activin receptor type II ectodomains.  
Shown is a ribbon representation of the three-dimensional crystal structure of the BMP-
7 dimer complexed to two molecules of activin A receptor type II (ActRII) 
ectodomains (ECDs). The convex binding surface of the pair of β-fingers on each 
BMP-7 monomer makes direct contact with a concave binding surface on each ActRII 
molecules. As observed, ActRII ECDs do not make direct contact with each other. The 
four-turn α-helices in the wrist region of one monomer are tucked as described in the 
previous figure legend. ActRII ECDs are coloured purple. Adapted from McClarence, 





1.5 BMP-induced downstream signalling via SMAD proteins 
Two modes of BMP signalling have been described that are each linked to a 
different signalling mechanism. In the first mode, the BMP ligand binding to pre-
assembled types I and II receptor complexes at cell surfaces results in BMP signalling 
via canonical SMADs-dependent pathways (Massagué et al., 2005). In the second 
mode, the BMP-ligand first induces assembly of receptor complexes at cell surfaces. 
This results in SMADs-independent signalling that induces p38 mitogen-activated 
protein kinase (MAPK), (Nohe et al., 2002). Herein, focus is placed on the canonical 
SMADs-dependent signalling pathway as illustrated in Figure 1.5. 
 SMAD proteins discovered by Derynck et al. (1996), are the vertebrate 
homologues of the Drosophila melanogaster mothers against decapentaplegic (MAD), 
(Sekelsky et al., 1995) and Caenorhabditis elegans Sma gene (Riggins et al., 1996). 
Three classes of SMAD proteins exist based on their activators and functions (Shi and 
Massagué, 2003; Ali and Brazil, 2014). The first subclass of regulatory SMADs (R-
SMADs), SMAD1, SMAD5 and SMAD8 (SMAD1/5/8), responds to BMPR1 
activation by BMP ligands. The second subclass of R-SMADs, SMAD2 and SMAD3 
(SMAD2/3), respond to TβRI receptor activation by other TGFβ superfamily ligands 
and inhibit SMAD1/5/8 downstream signalling (Massague et al., 2005; Murakami et 
al., 2003). Recent findings have, however, demonstrated that there are exceptions in 
this rigid paradigm of specific ligand type to R-SMADs activation. For instance, 
endothelial homeostasis has been linked to TGFβ-mediated phosphorylation of 
SMAD1/5 via BMPR1 in endothelial cells (Chen and Massagué, 1999; Lux et al., 
1999, 2013; Guillot et al., 2012). Phosphorylated R-SMADs bind to a common 
cytoplasmic co-mediator SMAD (Co-SMAD), SMAD4, which forms the second class 
of SMAD proteins. The inhibitory SMADs (I-SMADs), SMAD6 and SMAD7 down-
regulate R-SMAD signalling by binding competitively to SMAD4 and BMPR1 
receptors, respectively (Hata et al., 1998; Kavsak et al., 2000).  
Phosphorylation of R-SMADs occurs directly via activated type I receptors 
(Macias-Silva et al., 1996). The MAD homology 2 (MH2) domain conserved in all 
types of SMADs, serves as the receptor recognition domain. Phosphorylation of R-
SMADs via the MH2 domain induces conformational changes that increase their 
affinity for SMAD4 and also leads to the exposure of a nuclear import region present in 
this domain (Xu et al., 2000; Shi et al., 2007). The MH1 domain conserved only in R-
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SMADs and SMAD-4 antagonises the functions of the MH2 domain and is responsible 
for SMAD-mediated DNA binding and interaction with certain DNA binding cofactors 
(Miyazono et al., 2010). The stable R-SMADs:SMAD4 complexes formed accumulate 
within the nucleus following their nucleocytoplasmic shuttling against released R-
SMADs from dissociated complexes within the nucleus (Liu et al., 1997; Hoodless et 
al., 1999; Watanabe et al., 2000; Shi and Massagué, 2003). Although several models 
have been proposed, the mechanism of nucleoplasmic shuttling is not yet clearly 
understood. 
 Within the nucleus, R-SMADs:SMAD4 complexes induce the assembly of 
various transcription factors and together, regulate expression of various target genes 
such as SMAD6, inhibitor of differentiation (ID) genes, BAMBI and SMAD7 (Ali and 
Brazil, 2014). Regulation of target gene expressions is achieved by binding of the 
active complexes to the SMAD binding elements (SBEs) motif which constitute of GC 
rich sequences located upstream and within the promoters of these target genes 
(Miyazono et al., 2010). Increased binding affinity of an active R-SMAD/SMAD4 
complex to the SBE motif is observed with an increase in the size of the SBE motif. 
Hence, because only one or two SBEs are found within the putative promoters of target 
genes, it follows that their binding affinity to active R-SMAD:SMAD4 complexes is 
weak (Shi et al., 1998; Massague et al., 2005). In vitro, increased binding affinity of the 
active complexes to the SBE motif has been achieved by using concatemers with 
multiple SBE repeats hence driving stronger expression of the BMP target gene (Zawel 
et al., 1998; Zhao et al., 2003 and 2004). These findings have enabled the routine 
cloning of several SMADs-specific luciferase reporter constructs, which as 
demonstrated later in this study, are useful tools in functional studies of BMP-induced 
signalling. 
1.6 Regulation of BMP signalling  
Modulation of BMP signalling actions is achieved both intracellularly and 
extracellularly. Multiple levels of modulatory processes are established in these cellular 
compartments that collectively down-regulate SMAD1/5/8 signalling. Both intra- and 






Figure 1.5: Activation and regulation of the canonical BMP-SMAD signalling 
pathway.  
The active dimeric BMP ligands bind directly to and activate both TGFβ type I and II 
serine/threonine kinase receptors (BMPRs -I and –II, respectively as shown). 
Following phosphorylation of R-SMADs, SMAD1/5/8, the heteromeric R-
SMADs:SMAD4 complex translocates into the nucleus. There, it binds to specific 
SMAD binding elements (SBEs) within the promoters of its target genes in concert 
with various DNA binding co-factors (DBC). The signalling cascade is tightly 
regulated intra- and extra-cellularly. Presence of pseudo-receptors such as BAMBI on 
the plasma membrane (PM), down-regulate signalling by trapping active BMP ligands 
extracellularly. Secreted extracellular BMP antagonists such as Noggin and 
crossveinless 2 (CV2), bind directly to BMP ligands and prevent their subsequent 
binding to their receptors. Intracellularly, the pathway is inhibited by the I-SMADs, 
SMADs -6 and -7. SMAD6 prevents complexing of R-SMADs and SMAD4. SMAD7 
complexed with Smurf1/2 compete with R-SMADs for BMPR-1-mediated 
phosphorylation. PP1 (protein phosphatase-1) and PPM1A (metal-ion protein 
phosphatase-1A) are inhibitory phosphatases. Adapted from Ali and Brazil, 2014. 
 
 
Introduced in the previous section, the I-SMADs, SMAD6 and SMAD7, inhibit 
SMAD signalling by binding directly to the phosphorylated R-SMADs or to the 
activated type I receptors, respectively. Direct binding of SMAD6 to activated R-
SMADs prevents the formation of R-SMADs:SMAD4 complexes, thus inhibiting 
downstream signal transduction (Hata et al., 1998). On the other hand, competitive 
binding of SMAD7 to the activated pair of type I receptors antagonises R-SMADs 
activation (Suzuki et al., 2002). The independent cytoplasmic interactions of both I-
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SMADs with the E3-ubiquitin ligases, Smurf1 and Smurf2, result in the poly-
ubiquitination and subsequent proteasomal degradation of the corresponding signalling 
component they are complexed with (Murakami et al., 2003; Guglielmo et al., 2003).  
In addition, protein phosphatases such as protein phosphatase 1 (PP1) and the 
metal ion-dependent protein phosphatase (PPM1A) catalyse the dephosphorylation of 
both phosphorylated TGFβ/BMP receptors and R-SMADs hence dampening 
downstream signal transductions (Chen et al., 2006; Lin et al., 2006). Furthermore, 
transcriptional regulation can be achieved by a number of transcriptional processes 
such as BMP promoter methylation and hypermethylation, recruitment of various co-
repressors, histone deacetylation and silencing of the messenger RNA (mRNA) 
transcripts by small interference RNAs (siRNAs), (Wen et al., 2006; Kimura et al., 
2008; Walsh et al., 2010 ; Takeda  et al., 2004).  
As implied in Section 1.4, BMP signalling can be also down-regulated 
extracellularly by the coreceptor BAMBI. BAMBI is similar in structure to both types 
I/II receptors, however, it lacks their intracellular kinase domain and, therefore, cannot 
propagate signal transduction intracellularly. This pseudoreceptor acts by competing 
negatively for the same BMP ligands as do types I/II receptors thus trapping the ligands 
themselves and blocking their activities (Onichtchouk et al., 1999). More importantly, 
extracellular modulation of BMP-SMADs signalling can also be achieved by a 
subfamily of secreted cytokine molecules, the BMP antagonists (Figure 1.5).  These 
antagonist molecules bind directly to the mature BMP ligands and prevent subsequent 
activation of the type I receptors, which abolishes direct signal transductions 
downstream (Walsh et al., 2010; Ali and Brazil, 2014).  
To date, a diverse number of BMP antagonists have been discovered in 
vertebrates that, like the BMPs, play critical roles in early developmental and 
homeostatic processes in adult organs (Rider and Mulloy, 2010; Walsh  et al., 2010). 
Early clues into the mechanism of BMP ligand-antagonist interactions were drawn 
from high resolution crystallographic structures of the TGFβ superfamily dimer, 
Noggin complexed with the BMP-7 dimer (Figure 1.6; Groppe et al., 2002) and the D. 
melanogaster homologue, crossveinless 2 (CV2) complexed with the BMP-2 (Zhang et 
al., 2008). Both CV2 and Noggin exhibit incredibly similar mechanisms of BMP 
antagonism despite sharing a remarkably low sequence homology. Both antagonists 
form head-to-head dimers (wrist-to-wrist dimers) that bind the BMP ligand at the same 
convex interface of the β-finger epitope pair as was shown earlier in the BMP-7:ActRII 
30 
 
ECDs tetrameric complex (refer to Figure 1.4 and Figure 1.6).  This head-to-head 
orientation of both antagonists is such that the β-finger pairs projecting from opposite 
directions form a clamp around the ligand thus trapping it. This leads to its 
sequestration in an inactive complex that is unable to activate both type I and II 






Figure 1.6: The Noggin-BMP-7 complex.  
Shown is the ribbon representation of the three-dimensional crystal structure of the 
BMP antagonist, Noggin (in gold) complexed with BMP-7 as labelled. Unlike the 
head-to-tail BMP-7 homodimer, Noggin forms a head-to-head ‘clamp-shaped’ 
homodimer in which the disulfide bonded cystine-knot motif in the palm region and 
wrist (W) region on both monomers form a centralised core structure. The wrist region 
in Noggin is extended and possesses an extra α-helical coil. This arrangement enables 
its projecting finger loops to form a clamp around the active BMP-7 ligand thereby 
trapping it. Adapted from McClarence, 2011. Original source: Groppe et al., 2002. 






1.7 Structural features of the CAN family of BMP antagonists  
Many BMP antagonists have been identified in both vertebrates and 
invertebrates (Zimmerman et al., 1996; Hsu et al., 1998; Waterston et al., 2002). Like 
the BMPs themselves, many BMP antagonists also possess in them the characteristic 
cystine-knot motif. Therefore, they are regarded as distant members of the TGFβ 
superfamily that evolved divergently from a common ancestral gene (Avsian-
Kretchmer and Hsueh, 2004; Rider and Mulloy, 2010).  
Avsian-Kretchmer and Hsueh (2004) categorised all cystine knot-containing 
BMP antagonists within the human genome using different bioinformatics tools and 
phylogenetic analyses. This was based on their sequence homology, predicted 
structures and the sizes of their cystine rings. Three subfamilies were identified which 
included, the eight-membered ring which included Cerberus and DAN (CAN) 
subfamily members, nine-membered ring which included twisted gastrulation protein 
(TSG), and the ten-membered ring which included the chordin and Noggin. The CAN 
subfamily members were further subcategorised into four subgroups that included, 
gremlin and protein related to DAN and Cerberus (PRDC) also known as gremlin-2, 
Cerberus and COCO (dand5), uterine sensitization-associated gene-1 (USAG-1) and 
sclerostin, and DAN. Their conserved CAN (or DAN) domain is defined with 
consensus sequence CX6QX6CX6NX2CXGXCXSX3PX(8–13)CX2CXPX8XLXCX(15–
18)CXX which highlights all the six conserved cysteine residues that form the core 
cystine-knot motif and two extra cysteine residues also conserved (Pearce et al., 1999; 
Balemans and Van Hul, 2002).  
Avsian-Kretchmer and Hsueh (2004) predicted that on the basis of sequence 
homology, the CAN family members are likely to share close tertiary structural 
resemblance to the BMPs (Figure 1.7A). In most, they also possess an extra pair of 
cysteine residues at the tip of the β-fingers that forms an extra intrachain disulfide bond 
linking both finger tips together (Figure 1.7). This results in a more stable and compact 
cystine-knot motif in the CAN family members. The first experimental clues into the 
structural features of CAN family members were obtained from the high resolution 
NMR structure of sclerostin generated by Veverka et al. (2009) (refer to Figure 1.7B).  
In this structure, the two pairs of β-finger loops are consistent with BMPs except linked 
at their tip by the extra disulfide bond. The BMP cystine-knot motif is conserved as 
demonstrated by Veverka et al. (2009) using MALDI mass spectroscopic data. The 
pairing arrangement of six cysteine residues was also consistent with that within the 
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cystine-knot motif of BMPs (Figure 1.7A). On the other hand, a disorientated loop in 
sclerostin replaced the four-turn α-helix in the wrist region of BMPs (Figure 1.7B).  
 
Figure 1.7: High resolution structure of sclerostin.  
The structural features of sclerostin shown serve as a general representation of 
structural features of the CAN family of BMP antagonists. As can be observed, both A) 
Cartoon representation and, B) Inverted ribbon representations of the three-dimensional 
NMR structure of sclerostin share close resemblance with the BMPs themselves as 
described earlier in the legend of Figure 1.2. However, sclerostin, which exists as a 
monomer, possesses an additional pair of cysteine residues (C’: C’) that join the tips of 
the finger loop pair (f1 and f2) by forming a disulfide bridge. This disulfide linkage is 
highlighted with a pink circle. Moreover, a disordered loop in the wrist region (W) of 
sclerostin replaces the four-turn α-helix typically present in the wrist regions of BMPs. 
Both C- and N-terminal chains are also disordered and flexible. The disulfide bridges 
within the cystine-knot motif and at the fingertip are shown in yellow. Diagrams 
adapted from Avsian-Kretchmer and Hsueh, 2003 and Veverka et al., 2009, 
respectively. PDB file, 2K8P.  
 
Previous, homology modeling of CAN family members as conducted by 
Avsian-Kretchmer and Hsueh, 2004, were based on the X-ray crystallographic structure 
of the TGFβ superfamily member, human chorionic gonadotropin, which is distantly 
related to CAN family members. Therefore, by resolving the NMR structure of 
sclerostin, it was made possible to obtain more accurate predicted models of the CAN 
family members despite its monomeric structure, which is atypical of most BMP 
antagonists such as Noggin and CV2. It follows that all sclerostin-based models of 
CAN family members are monomeric and have also inherited all of its disordered loops 
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(Rider and Mulloy, 2010). Although, such predictions may not be truly representative 
of each individual unresolved CAN member, the elucidation of the NMR structure of 
sclerostin was pivotal. This represented major advance towards our understanding of 
the general features and properties of CAN family members, themselves.  
More recently, the X-ray crystallographic structure of PRDC, a second CAN 
family member, has been resolved by Nolan et al. (2013). As mentioned earlier in this 
section, PRDC is the closest homologue of gremlin, the focus of this study. Contrary to 
its sclerostin-based monomeric model, the crystal structure has revealed that PRDC 
does exist as a dimer. Like the BMPs, PRDC forms a head-to-tail oriented dimer 
however, whose monomers are non-covalently linked (Figure 1.8B). This dimeric 
orientation of PRDC is contrary to that of Noggin and CV2, which as mentioned 
previously in Section 1.6, formed head-to-head oriented covalently-linked dimers 
(Groppe et al., 2002; Zhang et al., 2008). In a PRDC dimer, the amino acids in the 
wrist region (head) of one monomer create intimate contact with the fingertips (tail) of 
the adjacent monomer via van der Waals interactions (Nolan et al., 2013). Extensive 
hydrogen bonding between the extending β-fingers of each monomer also helps to 
stabilise the dimer. Interestingly, the odd unpaired cysteine residue (Cys7) located just 
outside the cystine-knot motif BMPs is also present in PRDC, but here is not utilised 
for covalent dimerization.  
The CAN family members share high sequence homology within the cystine-
knot motif, however, significant sequence variations are observed around their terminal 
ends, which results in variable loop ends conformations (Nolan et al., 2013). While 
both N- and C-terminal loop ends are highly disordered in sclerostin (refer to Figure 
1.7B), an α-helix is formed in the highly flexible N-terminal loop in PRDC that may 
interact with neighbouring PRDC dimers (Figure 1.8A), (Veverka et al., 2009; Nolan et 























Figure 1.8: High resolution structures of the BMP antagonist, PRDC.  
The dimeric PRDC crystal structure is both represented as a centralised ribbon diagram and as 
pale blue and green rotated solution structures (B). The PRDC monomer is represented as 
either a blue or green ribbon diagram, isolated (A) and overlaid on a dimeric solution structure 
(B). As observed, the PRDC monomer closely resembles the sclerostin monomer shown in the 
previous figure possessing disordered and flexible chains at the C-terminal and in the wrist 
region (W). The N-terminal chain remains fairly disordered and flexible, but possesses a 
conserved α-helical coil, α1 helix, at its end (A). PRDC forms a head-to-tail dimer (B, central) 
in a similar oriented manner to BMPs themselves as described previously in the legend of 
Figure 1.3. In addition to the ‘wrists-tucked in fingers’ Van der Waals stabilisation, this dimer 
is also stabilised by extensive hydrogen bonding along the long axis of the interacting anti-
parallel finger pair (F1 and F2) of both monomers (Van der Waals and hydrogen bonds are not 
shown). This then creates extended convex and concave binding surfaces which remain 











Given high sequence homology both within and outside the conserved cysteine 
residues between gremlin and PRDC, it is plausible that gremlin may also adopt a 
similar dimeric structure. Thus, the PRDC structure may serve as the better template 
than sclerostin for homology modeling of the gremlin structure. Unfortunately, the 
PRDC structure only became available after this current study was underway. 
Nonetheless, such PRDC-based gremlin model was generated by our collaborator, 
Professor Barbara Mulloy, Royal Holloway, University of London and has been 
incorporated into this study. Fortunately, apart from aspects of dimerization and a 
conformational change in the N-terminal loop, both sclerostin-based and PRDC-based 
gremlin models are fundamentally consistent.   
1.8 Binding sites on sclerostin and PRDC 
1.8.1 Amino acid numbering system 
A consensus has yet to be agreed on for the numbering of amino acid residues 
in primary sequences of proteins. Typically, crystallographers assign the number one to 
the first amino acid residue in the resolved crystal structures which may not necessarily 
correspond with the first amino acid residue in their full length primary sequences.  
This gets further confusing when homology modeling is conducted on such high 
resolution structures. In this thesis, sequence alignments are provided for assistance 
whenever there is a conflict in numbering assignments. The numbering system adopted 
matched that of the primary polypeptide sequence of the Mus musculus gremlin-1 
precursor (NCBI reference sequence: NP_035954.1). 
1.8.2 Binding sites on sclerostin 
The work by Veverka et al. (2009) involved the generation of a high resolution 
NMR structure of sclerostin, using purified Escherichia coli cell-expressed 15N, 13C and 
1H-isotopic backbone-labelled sclerostin. For complete sequence-specific resonance 
assignments, the cross-relaxations were measured between isotopic-labelled nuclei in 
spatial proximity at varying 1H-1H distance constraints in order to generate multiple 
nuclear Overhauser effect spectroscopy (NOESY) spectra. These were achieved by 
generating two-dimensional 15N, 1H- and 13C, 1H-heteronuclear spin quantum 
convergence (HSQC)-NOESY spectra and the 15N, 13C, 1H- triple resonance spectra. 
The NOE cross peak assignments generated were automatically combined to produce 
preliminary structures that were further processed (by multi-cycling annealing under 
36 
 
redundant dihedral angle constraints) in order to generate a small family of converged 
sclerostin highly precise NMR solution structures. To determine the binding sites on 
sclerostin, heparin oligosaccharides prepared from its NMR structure (PDB file: 1HPN; 
Mulloy et al., 1993) were docked onto those converged NMR structures with lowest 
intermolecular energy. The heparin oligosaccharides included two pentasaccharide 
chains in the 1C4 chair and 
2S0 skew-boat conformations, endecasaccharide and 
dodecasaccharide chains. Surface contact residues were either extracted automatically 
or monitored by the backbone changes induced in the positions of the 15N, 1H-HSQC 
amide signals in sclerostin. The heparin binding site predicted using docking 
calculations was mapped as a linear positively charged patch of largely arginine and 
lysine residue side chains.  This spanned across an entire surface of the long axis of 
sclerostin encompassing both f2 loop and the disordered loop in the wrist region (refer 
to Figure 1.7).  
Mapping of the heparin binding site achieved by NMR spectral analyses of 
amide signals in the sclerostin backbone following its binding to a dodecameric heparin 
fragment, were highly consistent with initial predictions. Subsequently, fresh docking 
calculations also observed an overlap with the heparin binding site predicted following 
initial docking of converged sclerostin NMR structures with the two other heparin 
oligosaccharides. The arginine and lysine contact residue side chains are highlighted in 
the sequence alignment shown in Figure 1.9. Altogether, this demonstrated that binding 
of sclerostin to heparin was stabilised mainly via specific electrostatic interactions 
which are supported by a network of hydrogen bonding between polar groups on 
heparin and backbone amide groups on sclerostin.  
A potential hydrophobic protein binding site was also predicted from these 
docking calculations. It was located on the concave face of the disordered and flexible 
loop in the wrist region and f2 loop (refer to Figure 1.7B), on the opposite side to the 
heparin binding site. It is plausible this protein binding site may overlap with the BMP 
binding site, which is expected to share a similar charge. The predicted contact amino 
acid residues in this significantly hydrophobic patch are highlighted in the sequence 
alignment shown in Figure 1.9.  
1.8.3 Binding sites on PRDC 
In the studies by Nolan et al. (2013), recombinant wildtype PRDC was over-
expressed in E. coli inclusion bodies that were then extracted, solubilized and 
components separated using size exclusion chromatography.  The wildtype PRDC was 
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purified by ion-exchange chromatography under denaturing conditions and then 
subjected to oxidative refolding of its disulfide bonds. The refolded PRDC was further 
purified using reverse phase high performance liquid chromatography (HPLC), 
(Kattamuri et al., 2012). Selenomethionine (SeMet)-substituted PRDC was expressed 
initially in transformed E. coli batch cultures grown to saturation in SeMet-labelling 
auto-inducing media (Studier, 2005). Both wildtype and SeMet-substituted PRDC 
crystals were grown by hanging-drop vaporising diffusion under mild dehydrating 
conditions for better defined X-ray diffraction patterns. X-ray crystallography 
generated a high resolution three-dimensional structure of PRDC which forms a dimer 
(refer to Figure 1.8).  
Lower resolution PRDC structures were generated from the wildtype PRDC 
crystal using small angle X-ray scattering (SAXS) in order to validate further the high 
resolution PRDC structure and also to visualise the molecular envelope of the full 
length PRDC protein. Based on these experimental structures, predictions were made 
on the BMP binding site of PRDC following docking to NMR structures of various 
BMP ligands. These predictions were validated experimentally by site-directed 
mutagenesis of these contact residues followed by surface plasmon resonance (SPR) of 
the generated PRDC mutants on immobilised BMPs -2 and -4 biosensor chips. In this 
study, the putative heparin binding site on wildtype PRDC was also predicted by 
analysis of the distribution of electrostatic charges across its surface envelope.  
Binding of the dimeric PRDC protein to BMP ligands was shown using site-
directed mutagensis and SPR to be stabilised mainly via hydrophobic interactions with 
contact residues located mainly on the convex binding surface of its centralised cystine-
knot domain. The most critical hydrophobic contact residues formed a partially buried 
hydrophobic patch and included Trp-72, Tyr-98, Phe-104 and Phe-114. These residues 
appeared to be strongly conserved across all other CAN family members including 
gremlin, DAN and COCO. These hydrophobic contact residues have been highlighted 
in the sequence alignment shown in Figure 1.9.    
Strong binding of PRDC to heparin was demonstrated experimentally (Kd 54 
nM) by SPR on immobilised heparin biosensor chips. By scanning the electrostatic 
surface of the PRDC structure, a large electropositive potential was identified in the 
same convex binding surface of the cystine-knot or DAN domain which partially 
overlaps with the BMP binding site. A similar charged patch was also identified in the 
helical region of the disordered N-terminal loop. Based on these observations, Nolan et 
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al. (2013) suggested that binding sites on mainly the f2 loop within the cystine-knot 
domain and α1 N-terminal helical region contribute to heparin binding which when 
occupied may allosterically inhibit BMP ligand binding to its BMP binding site (refer 
to Figure 1.8). In other words, both heparin and BMP binding sites may be physically 
distinct from one another however, may allosterically regulated each other in the 
presence of a ligand. The arginine and lysine contact residues within the predicted 
heparin binding site on PRDC are highlighted in Figure 1.9. Interestingly, a 
considerable overlap is observed in the contact residues that form the heparin binding 
site on both sclerostin and PRDC (Figure 1.9). Moreover, it can be seen that gremlin 
shares similar positively charged residues at these key positions in both PRDC and 
sclerostin. Moreover, the amino acid residues at the dimer interface of PRDC (F96 – 




Figure 1.9: Comparison of the BMP and heparin binding sites on sclerostin and 
PRDC. 
The primary sequence alignment shows differently numbered contact residues within 
mapped binding sites on sclerostin and PRDC compared to gremlin thus providing a 
conversion platform between them. The putative heparin binding site residues are 
highlighted in light blue colour. The hydrophobic residues forming the BMP binding 
site and a potential protein binding site in PRDC and sclerostin are highlighted in 
purple and light green colours, respectively. The amino acid residues at the dimer 
interface on PRDC are underlined. The conserved cysteine residues are highlighted in 
yellow with solid lines connecting cystine ring residues and the broken line, indicating 
the disulfide bond joining the finger pair at their tip.  The unpaired cysteine residue 
located outside the cystine ring is highlighted in orange colour and is absent in 







1.9 Heparan sulfate and heparin: glycosaminoglycan subclass 
Heparin and heparan sulfate (HS) glycosaminoglycans (GAGs) are chemically 
related highly acidic unbranched polysaccharides that are covalently linked to HS 
proteoglycans, such as syndecans and glypicans (Gallagher and Walker, 1985; Esko 
and Lindahl, 2002). Both GAGs are characterised by alternating disaccharides of uronic 
acid [D-glucuronic acid (GlcA) or L-iduronic acid (IdoA)]-β1, 4-N-acetylglucosamine 
(GlcNAc) repeat units (Esko and Selleck, 2002). The numerous post-polymerisation 
modifications such as N-deacetylation and N-sulfation reactions that occur in the 
hexoses during nascent GAG chain polymerisation result in diversely patterned sulfated 
GAG sequences (Lindahl, 1989). Ultimately, these generate heparin and HS chains that 
share only subtle differences between them. Heparin undergoes more extensive 
modifications that render it typically more sulfated than heparan sulfate which 
possesses multiple unmodified regions along its chain length (Gallagher and Walker, 
1985; Murphy et al., 2004). Nevertheless, there are yet no agreed structural criteria for 
distinguishing both apart.   
Heparin has long been used therapeutically as an anticoagulant capable of 
inactivating main agents along the coagulation cascade via direct binding to 
antithrombin III (Rodén, 1989; Lindahl, 1989). Contrary to confined localisation of 
heparin in the secretory granules of mast cells, virtually all cells in humans possess the 
capability to produce HS (Esko and Lindahl, 2001). In spite of these natural differences 
in their relative abundance, extensive industrial and therapeutic use of heparin over the 
past years results in heparin being practically more abundant and readily available 
commercially than HS. This combined with their close structural resemblance has 
enabled heparin to be used routinely as a model agent in biochemical studies of binding 
interactions that in physiological context would involve HS.    
Both heparin and HS sequences are not encoded directly by gene templates, but 
rather are created by a cascade of specific enzymes along a shared biosynthetic 
pathway (Sugahara and Kitagawa, 2002). As such, the fine structure of the GAG chains 
depends ultimately on the regulated expression and concerted actions of these arrayed 
biosynthetic enzymes. This takes place principally within the lumen of the Golgi 
apparatus and involves multiple glycosyltransferases, sulfotransferases, and an 
epimerase; many of which have been purified and structurally characterised (Brandan 
and Hirschberg, 1988; Campbell et al., 1994; Kobayashi et al., 1996; McCormick et 
al., 2000). Concomitantly, concerted action by a series of cytoplasmic enzymes 
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maintains adequate supply of the nucleotide sugars, UDP-Xyl, UDP-Gal, UDP-GlcA, 
UDP-GlcNAc and nucleotide sulfate, PAPS into the lumen of the Golgi apparatus via 
multiple membrane transporters (Hirschberg et al., 1998; Berninsone and Hirschberg, 
2000).  
1.10 Biosynthesis of unmodified nascent HS and heparin chains  
Biosynthesis of all GAG chain types is initiated by the stepwise assembly of a 
tetrasaccharide linkage sequence, GlcAβ1,3Galβ1,3Galβ1,4Xylβ1-O-linked to serine 
residues within consensus sequences, Ser-Gly/Ala-X-Gly, on core HS proteoglycan 
polypeptides (Esko and Zhang, 1996; Sugahara and Kitagawa, 2000). Biosynthesis of 
heparin/HS is illustrated in Figure 1.10. This sequential addition of sugar residues to 
the Ser residue on the core glycoprotein is catalysed by four glycosyltransferases, 
xylosyltransferase (XylT), galactosyltransferase I (GalT-I), GalT-II and 
glucuronyltransferase I (GlcAT-I), in the reverse order respectively (Esko and Lindahl, 
2001). 
After assembly of the tetrasaccharide linkage, the biosynthetic pathway to 
heparin/HS chains is triggered by the addition of a fifth α1,4-linked αGlcNAc sugar 
residue by a key enzyme, α-N-acetylglucosaminyltransferase I (GlcNAcT-I), (Sugahara 
and Kitagawa, 2000). Thereafter, polymerisation of the heparin or HS chain takes place 
by alternating additions of GlcAβ1,4- and GlcNAcα1,4-linked residues to form the 
characteristic backbone repeat sequence of this class of GAGs. This is catalysed by 
glycosyltransferases of the exostosin (EXT) family of tumor suppressors, EXT1, EXT2 
and EXT-like (EXTL), EXTL1 and EXTL3 (refer to Figure 1.10), (McCormick et al., 
1998; Lind et al., 1998; Sugahara and Kitagawa, 2000). A third member to the latter 
family, EXTL2 possesses GlcNAcT-I activity and as such, is involved in chain 
initiation in the linker region (Kitagawa et al., 1999).  
EXT1 and EXT2 proteins are both heparin/HS co-polymerases. Both proteins 
demonstrate GlcA/GlcNAc transferase activity and form EXT1/EXT2 hetero-
oligomeric complexes that then accumulate in the lumen of the Golgi apparatus 
(McCormick et al., 1999). On the other hand, EXTL1 possesses only GlcNAcT-II 
activity and as such, adds only GlcNAc residues during heparin/HS chain 
polymerisation (Kim et al., 2001). EXTL3 however is bi-functional possessing both 
GlcNAcT-I and GlcNAcT-II activities and therefore can possibly contribute to both 















Figure 1.10: Heparin and heparan sulfate (HS) biosynthesis.  
Geometric symbols depicting each sugar residue are defined in the legend. The post-
modification reactions catalysed by the various enzymes are abbreviated above and below the 
sugar residues modified. The NA, NA/NS and NS domains are defined according to the 
sequential distribution pattern of unmodified N-acetylated and modified sulfated sugar 
residues. Abbreviations: EXT: exostosin family of tumour suppressors, EXTL: EXT-like 
family member, GlcNAc: N-acetylglucosamine, GlcA: glucuronic acid, NS: N-sulfation, 2S, 
3S, 6S: 2-O-, 3-O-,6-O-sulfations. PAPS: 3’phosphoadenosine 5’-phophosulfate. Adapted from 









1.11 Post-modification incorporations of nascent HS/ heparin chains 
As the nascent chain is polymerized, its hexose residues are subjected to a series 
of post-incorporation modifications that include, GlcNAc N-deacetylation and N-
sulfation, C5 epimerization of D-GlcA to L-IdoA residues and variable O-sulfations at 
C2 of IdoA and GlcA, at C6 of GlcNAc and N-sulfoglucosamine (GlcNS) residues, and 
at C3 of N-glucosamine (GlcN) residues. These modifications are catalysed by the bi-
functional N-deacetylase/N-sulfotransferases (NDSTs), uronyl C5-epimerase and 2-O-, 
6-O- and 3-O-sulfotransferases, respectively (Aikawa et al., 2000; Esko and Lindahl, 
2001). GlcNAc N-deacetylation and N-sulfation by NDSTs is a prerequisite to both 
epimerization and variable O-sulfations (refer to Figure 1.10), (Sugahara and Kitagawa, 
2002).  
Concerted actions of these enzymes on nascent unmodified heparin/HS chains 
result in variably sulfated chains that demonstrate strong aspects of sequence 
organisation and domain patterning. Close examination of the polymeric heparin/HS 
chain revealed three main domains which include; regions of contiguous N-acetylated 
disaccharides that form the NA domains, those with contiguous N-trisulfated 
disaccharides of variable length that form the NS domains and mixed regions with 
alternating NA/NS domains or variable region (refer to Figure 1.10), (Dietrich et al., 
1973; Gallagher, 2001; Murphy et al., 2004; Khan et al., 2013). In heparin and highly 
sulfated HS, the NS domains are unusually extended and encroach on the NA domains; 
conversely, in low sulfated HS, larger unmodified NA domains are predominant 
(Gallagher, 2001).  
Considerable variability is exhibited in these accompanying post-incorporation 
modifications. As a result, heparin/HS chains are highly heterogeneous in their 
sequences and length. As many as 48 different disaccharides combinations could occur 
in heparin of which 23 have been identified to date (Esko and Selleck, 2002).  
Given that other modifications depend first on actions of NDSTs, it follows that 
most modified disaccharides tend to cluster in the NS and NA/NS domains. These may 
then serve as potential docking sites for specific ligands (Lindahl et al, 1998). On the 
other hand, the NA domains have not yet been shown to directly influence protein 
binding and as such may serve as spacers between NS domains (Mulloy and Forster, 
2000). As discussed later in Section 1.13, the specificity in heparin/HS interactions 
with various proteins rather points to a deeper level of sequence organisation along the 
chain; the classic example being the binding of heparin to antithrombin III that is 
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strongly dependent on a specific pentasaccharide sequence on heparin containing a 
central 3-O-sulfated GlcN residue (Bourin and Lindahl, 1993).  
1.12 Heparin and HS: Conformations and dynamics 
Partial activity of NDSTs and variable N-sulfations in backbone disaccharide 
repeat units result in highly acidic three-dimensional heparin/HS structures flanked by 
spatially defined patterns of carboxylate and sulfate substituents (Figure 1.11).  
Heparin and its derivatives possess similar rigid glycosidic bond conformations 
differing mainly in their degree of flexibility due to different internal mobility (Mulloy 
et al., 1993). Given that all D-glucopyranose monosaccharide residues in GAGs are 
stable in 4C1 conformation, it is expected that most epimerised L-hexapyranoses, L-
IdoA monosaccharide residues would be stable in the inverted 1C4 solution 
conformation (Mulloy and Forster, 2000). As demonstrated in NMR studies and more 
recently with SAXS, L-IdoA residues are rather unusual in that they can exhibit both 
1C4 chair and 
2S0 skew-boat solution conformations within the heparin oligosaccharide 
(refer to Figure 1.11) (Khorramian and Stivala, 1986; Sanderson et al., 1987; Ferro et 
al., 1990; Mulloy et al., 1993; Pavlov et al., 2003). As such, the epimerisation of D-
GlcA to L-IdoA residues results in changes to the internal mobility of heparin which 
alters the equilibrium shifts between its different conformations. The dynamic 
interchange between these two conformations causes twists in the pyranose ring of 
IdoA residues that occur without disrupting the glycosidic bonds. It is these twists that 
provide a small degree of flexibility to the whole polysaccharide chain without 
necessarily causing it to bend (Hricovini et al., 1997; Mulloy and Forster, 2000). This 
is an important feature for its specific binding to different protein ligands.  
By contrast to heparin and its derivatives, it has been demonstrated that HS 
forms longer and more bent three-dimensional structures (Khan et al. 2013). This was 
demonstrated using SAXS crystallography on different length HS oligomers possessing 
only the NA domains. By extensive depolymerisation of HS using heparitinase I, an 
enzyme that cleaves only within the NS domain, Khan et al. (2013) were able to 
generate a suitable model for unsulfated heparan.  NMR spectroscopy on heparan, 
demonstrated that the NA domains in HS lacked both the rigidity and internal mobility 
shown by heparin and its derivatives. As such, it can be said that the flexibility and 
bending along a HS chain which possesses relatively more and larger NA domains is 
greater than that along a heparin chain with more NS domains instead. Another reason 
for this observed difference in rigidity between HS and heparin could be that HS is not 
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as much influenced by the greater repulsion between the regular repeats of acidic 
groups that occur in the more abundant NS domain of heparin (Khan et al., 2013).  
Overall, the greater flexibility of HS chains may account for their binding to a 
diverse range of protein ligands in all orientations. For example, this may explain HS 
binding to the platelet factor 4 ligand that possesses multiple heparin binding sites that 
are not linearly arranged to accessibility by a single extended NS domain on the 
heparin chain (Stringer and Gallagher, 1997; Stringer et al., 2002). With greater 
flexibility and bending in an NA domain that separates two NS domains, it is plausible 
that the same HS chain can still access the differently oriented heparin binding sites on 






Figure 1.11: Structural conformations of heparin.  
Ball and stick (A and C) and space fill (B and D) representations of a high resolution 
NMR heparin dodecasaccharide structure. Shown are the two conformations adopted 
by heparin: 1C4 chair (A and B) and 2S0 skew-boat (C and D) conformations caused by 
presence of 2-O-sulfated iduronic residues (IdoA2S) in its backbone disaccharide 
repeat. In the ball and stick representations, this backbone is visible and represented by 
repeat patterns of a carbon atom (grey ball) bonded to a single hydrogen, oxygen, 
nitrogen (white, red and purple balls, respectively) and/or another carbon atom via a 
single bond (grey stick). The different conformations result in arrangements of side-
chain trisulfate groups as indicated by the broken orange double headed arrows. For 
acidic side-chain groups: a sulfate group (SO3-) = one yellow ball (sulfur atom) bonded 
to three red balls, a carboxylate group (COO-) = one grey ball bonded to two red balls. 





1.13 Specificity of binding interactions of HS/heparin to diverse cytokine 
proteins 
  The projecting side chain carboxylate and sulfate groups and rigidity of the NS 
domains of both heparin and HS implies that binding interaction with proteins is mainly 
coulombic and occurs superficially at their surface interfaces (Esko and Selleck, 2002). 
For this reason, ionic strength elution using heparin affinity chromatography constitutes 
a standard method for isolating and characterising heparin binding proteins (Kjellén 
and Lindahl, 1991). As highly acidic macromolecules, heparin/HS can bind to basic 
patches on protein surfaces and in this high affinity ionic binding via its NS domain, 
nonionic interactions such as Van der Waals forces and hydrogen bonding may also 
contribute significantly. This was demonstrated by Thompson et al. (1994) in studies 
that analysed the heparin binding domain on basic fibroblast growth factor (bFGF) 
from heparin-bFGF co-crystals. Although the basic lysine and arginine contact residues 
constituted the majority, they only contributed to 30% of the binding free energy in 
context of pure electrostatic interactions with sulfated moieties on heparin. This may 
represent changes to the protein structure, leading to a more rigid protein as it binds to 
heparin, following the initial electrostatic attraction that brings them together. As such, 
this reinstated the importance of these interactions beyond charge-specific binding 
alone.     
Interestingly, analyses of both BMPs -2 and -7 crystal structures revealed larger 
binding cavities located on their convex surfaces opposite the receptor ECD binding 
sites forming arginine- and lysine-rich positive patches. These were predicted to form 
their putative heparin/HS binding sites (Griffith et al., 1996; Scheufler, 1999). This 
suggests that the presence of a defined heparin binding site on proteins may be 
mandatory for interactions with heparin and HS.   
As with the NMR structure of sclerostin and the PRDC crystal structure (refer 
to Sections 1.8.2 and 1.8.3), predicting the heparin binding site can be achieved using 
the high resolution structure of heparin in computational docking techniques. These 
techniques employ a primary sequence-based approach together with some extra 
geometrical information to predict heparin binding sites of proteins with no 
experimental three-dimensional structures (Hileman et al., 1998; Bitomsky and Wade, 
1999). These have led to the general characterisation of the heparin binding site. 
Typically, a heparin binding site on a protein, spans a distance about 20 Å (Margalit et 
al., 1993). This approximates to the distance between trisulfated clusters along one side 
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of heparin, about 17 Å, that itself matches the periodicity of the right-handed α-helix of 
heparin in solution formed typically by both 1C4 chair and 
2S0 skew-boat conformations 
(Mulloy et al., 1997; Mulloy and Forster, 2000).   
Interestingly, to current knowledge, heparin oligosaccharides bound to all 
growth factors are all derived from multiples of the main trisulfated disaccharide repeat 
unit in the NS domains (Mulloy and Forster, 2000). This differs from the antithrombin 
III central pentasaccharide recognition sequence that is unusual in many features. This 
include presence of a 3-O-sulfated glucosamine adjacent to GlcA residue that must be 
located at the non-reducing end of a fully modified trisulfated disaccharide repeat 
(Rosenberg and Lam, 1979; Lindahl et al., 1980; Choay et al., 1983).  
1.14 Biological roles of HS/heparin interactions with cytokine proteins 
HS being found on virtually all cell surfaces and in the extracellular matrix 
interacts with a litany of extracellular molecules including growth factors, adhesion 
molecules and cytokines playing important roles in a wide range of physiological and 
pathophysiological processes in humans (Takada et al., 2003; Esko and Selleck, 2002). 
As demonstrated by Solomon (1963), biosynthesis of HS is critical during early 
embryogenic development. Missense or frameshift mutations in either EXT1 or EXT2 
resulted in hereditary multiple exostoses (HME), a skeletal disorder characterised by 
cartilage-capped tumour outgrowths from the growth plate of endochondral bone.  The 
process of normal bone formation requires action of various morphogens and growth 
factors whose diffusion must be tightly regulated at their sites of action (Karsenty, 
2003; Nishimura et al., 2012). As such, unrestricted diffusion in HME, as a result of 
incorrect biosynthesis of HS, serves today as a natural demonstration of the important 
role HS may play in localising activities of these key extracellular molecules at their 
specific target sites.  
A similar circumstance in which HS provides a local tissue depot for active 
circulating cytokines such as the interleukins -2, -4 and -12 and morphogens including 
several BMPs, has also been reported (Hogan, 1996; Hasan et al., 1999; Mummery and 
Rider, 2000; McLellan et al., 2006; Zhong et al., 2007). This results in the initiation of 
immune responses and in the establishing and maintenance of morphogenic 
concentration gradients across fields of cells that result in body patterning, respectively.  
Commonly, the protective and stabilising functions of heparin/HS as shown in 
vitro go hand in hand with its binding interaction with several cytokines and growth 
factors. A fine example is its binding to the IL-12-induced macrophage and antigen 
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presenting cell (APC)-secreted cytokine, interferon gamma (IFNγ), which is critical for 
adaptive cellular immunity. High affinity binding of HS to IFNγ occurs at a C-terminal 
peptide of IFNγ that otherwise is highly susceptible to proteolytic degradation that 
decrease in its blood clearance and accumulation at target tissues (Lortat-Jacob, 1994 
and 1996). Similar protective role against proteases such as trypsin and plasmin was 
also previously reported in the binding of heparin to heparin-binding growth factor-I 
(also known as FGF-1), (Rosengart et al., 1988). Furthermore, heparin/HS-induced 
localised accumulation of both IFNγ and FGF-1, acidic FGF (aFGF) and the more 
prominent activated serine protease, thrombin, increases their stability within the 
extracellular microenvironment; hence increases protection from pH and thermal 
denaturation (Machovich and Arányi, 1977; Rosengart et al., 1988; Volkin et al., 1993; 
Lortat-Jacob, 1994).  
  Heparin has also been demonstrated to act as a catalyst in protein-protein 
interactions; it may either accelerate the rate of the protein-protein binding reaction or 
accelerate the rate of recognition of a protein for its binding partner. In the inactivation 
of thrombin by the serine protease inhibitor antithrombin III, the catalyic function of 
heparin is observed via the latter role (Gettins et al., 1993; Chuang et al., 2001). 
Antithrombin III is unique in that the recognition and binding to the sequence-specific 
pentasaccharide in heparin is required for its full activation (refer to the previous 
section). Interestingly, high affinity binding to heparin results in a conformational 
change in antithrombin III that accelerates its inhibition of thrombin via a bridging 
mechanism. In this mechanism, thrombin binding to a bridging site next to bound 
antithrombin III, along the same heparin chain, enhances the rate of recognition of 
antithrombin III for thrombin (Chuang et al., 2001); thus formation of a trimolecular 
complex of antithrombin III: heparin: thrombin in intimate contact.  
The function of heparin/HS as a co-receptor or as a stabiliser of FGF-1-FGF 
receptor-2 (FGFR-2) signalling complex has been demonstrated, although in recent 
years has remained much a subject of debate (Harmer, 2006). Two crystallographic 
models have been proposed to support both cases, the first by Pellegrini et al. (2000) 
and the second by Schlessinger et al. (2000), respectively. In the former, a single 
heparin decasaccharide chain serves as the fundamental organising unit of the 2:2 FGF-
1:FGFR-2 tetrameric complex by dimerising two bound FGFs molecules without 
causing any intermolecular protein-protein contact. This then results in a change in the 
FGFs that increases their affinity for two FGFR-2 molecules. In the latter, the 
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Schlessinger-Mohammadi model, two heparin decasaccharide chains are required to 
form a 2:2:2 FGF:FGFR-2:heparin hexameric complex, instead of the single heparin 
chain, pentameric complex in the previous Pellegrini model. Here, heparin-mediated 
binding of FGF-1 to FGFR-2 results in a stable 1:1:1 ternary complex in which highly 
sulfated sequences at the non-reducing end of heparin make extensive contacts with 
positively charged binding domains of both proteins. This then results in the 
recruitment of a second 1:1:1 FGF:FGFR-2:heparin ternary complex via both direct 
FGFR-2:FGFR-2 and FGF-1:FGFR-2 inter-ternary complex secondary interactions 
(Schlessinger et al., 2000). At this stage, heparin contributes only indirectly by 
promoting FGFR-2:FGFR-2 contacts hence, its suggested less fundamental role as a  
stabiliser (Schlessinger et al., 2000). Worth highlighting, the 6-O-sulfate in the heparin 
decasaccharide seemed to play a pivotal role in both 1:1 FGF-1:FGFR-2 interaction and 
2:2 FGFR-2:FGFR-2 interactions. Its desulfation was observed to markedly diminish 
both interactions thus demonstrating anew an aspect of binding specificity of 
heparin/HS binding ligands as argued previously (Schlessinger et al., 2000).  
The role of heparin/HS in BMP-mediated processes in vivo remains unclear 
although its BMP-mediated in vitro effects have been well established in functional 
studies. Traditionally, cell lines such as the murine C2C12 myoblastic cell line have 
served routinely as convenient cellular model for functional studies of BMP activity 
(Damon et al., 1992; Larrain et al., 1998; Jiao et al., 2007; Kuo et al., 2010). Restating, 
a hallmark of BMPs is their ability to induce de novo bone formation in vivo by 
promoting the transdifferentiation of myoblast cells to cartilage-forming chrondroblasts 
and bone-forming osteoblasts cells (Urist, 1965; Urist and Strates, 1971). In model cell 
lines such as C2C12 cells, this process is observed as a down-regulation of muscle-type 
markers and up-regulation of osteoblastic markers such as alkaline phosphatase that are 
easily quantitated in bioassays. In recent years, more sensitive reporter bioassays have 
enabled even earlier tracing and quantitation of BMP gene markers when co-expressed 
alongside a tractable reporter gene such as the firefly Photinus pyralis luciferase (luc+) 
gene. As mentioned previously in Section 1.5, this can be achieved by targeting 
enriched SBE concatemers incorporated within the promoter region of BMP target 
genes. Commonly targeted gene promoters include the osteocalcin and Id1 gene 
promoters. The former is employed in this study. The latter expresses the inhibitor of 
DNA binding-1 (Id1) protein, a basic helix-loop-helix (bHLH) transcription factor that 
lacks a DNA binding domain. Id1 binds with high affinity to bHLH E protein family 
50 
 
members inhibiting their binding to promoter E boxes thus regulating DNA 
transcription (Zhao et al., 2003; Perk et al., 2005; Korchynskyi and ten Dijke, 2002). 
Clear demonstrations of the effect of HS in BMP-mediated activities were seen 
in work conducted by Irie et al. (2003) when assessing its role in BMP-7-induced 
signalling in rat osteoblastic osteosarcoma 17/2.8 (ROS 17/2.8) cell cultures. They 
observed that BMP-7-induced SMAD1/5/8 phosphorylation is inhibited following pre-
treatment of cells with heparitinase and chlorate, which removes endogenous cell 
surface HS and inhibit GAG chain sulfation, respectively (Baeuerle and Huttner, 1986; 
Humphries and Silbert, 1988). This indicates that HS is involved in BMP-7-induced 
signalling activity. The addition of exogenous soluble unfractionated heparin to both 
heparitinase- and chlorate-treated cells did not restore BMP-7-induced SMAD1/5/8 
phosphorylation. This suggested that endogenous HS anchored to membrane surfaces 
of cells was essential for BMP-7 signalling.  
In contrast, pre-incubation of BMP-7 with other GAGs such as chrondroitin 
sulfate and keratan sulfate, and de-6-O-sulfated and de-N-desulfated/re-acetylated 
heparins, did not interfere with BMP-7-induced SMAD1/5/8 phosphorylation. This 
with reversed interpretation, demonstrated the importance of these modified residues in 
the intact HS chains themselves and served as further supporting evidence for structural 
organisation and sequence specificity in interactions of HS with cytokine proteins. As 
such, Irie et al. (2003) suggested two possible roles of heparin in BMP-7-induced 
signalling activity; either 1) as forming a local depot promoting augmentation of BMP-
7 concentrations at target sites, or 2) as a co-receptor facilitating binding of BMP-7 to 
its receptors.  
Unlike BMP-7, the effects of heparin/HS in BMPs -2 and -4-induced signalling 
activities are not so clearly understood owing to the contradictory observations reported 
to date. For example, in studies conducted in C2C12 cell cultures, Jiao et al. (2007) 
observed that pre-incubation of BMP-2 with intact soluble heparin inhibited signalling 
activity and that both heparitinase and chlorate treatments of cells potentiated BMP-2 
activity. On the other hand, similar studies by Takada et al. (2003) and Zhao et al. 
(2006) both observed a potentiation of BMP-2-induced activity following pre-
incubation with intact soluble heparin. Also, they observed that heparitinase treatment 
had no effects. Moreover, Zhao et al. (2006) showed that in the presence of intact 
soluble heparin, BMP-2 degradation was blocked and its half-life increased in vitro. 
When administered with BMP-2 simultaneously into mice in vivo, larger amounts of 
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mineralized bone were induced comparatively. Taken altogether, these various studies 
are conflicting making it difficult to suggest the role of heparin/HS in activities of 
BMPs -2 and -4, unlike BMP-7. It seems differences in precise experimental procedure 
and conditions under which each experiment was conducted may have accounted for 
these conflicting views. Therefore, more detailed studies on the interactions of HS with 
these BMPs will be required on individual basis in order to fully understand the role of 
HS in BMP signalling activities.  
1.15 Gremlin and its biological functions  
Gremlin also known as gremlin-1, is both a membrane-associated and secreted 
protein constituting of 184 amino acids. It also possesses the characteristic cystine-knot 
motif (DAN domain; residues 94 - 184) that is shared by all members of the CAN 
subfamily of BMP antagonists (Wordinger et al., 2008). The human gremlin gene, 
GREM1, also known as down-regulated by the oncogene mos (drm) encoding the 
gremlin protein, has been mapped to chromosome 15q13-q15 (Topol et al., 2000b). 
Upon expression, it is subjected to post-translational modifications including N-
glycosylation and phosphorylation that may account for the experimental variations in 
its reported molecular weight that ranges between 20 – 30 kDa (Topol et al., 1997; 
Topol et al., 2000a; Wordinger et al., 2008).  
The GREM1 gene was originally identified as drm by screening an ovary 
complementary DNA (cDNA) library for activities that induced formation of a 
secondary axis in Xenopus laevis embryos. Gremlin expression was observed mainly in 
neural crest regions (Hsu et al., 1998). In mouse embryos, gremlin is expressed in the 
intermediate mesenchyme, Wolffian duct and in mesonephric tubules from E9.5 
paralleling BMPs -2 and -4 expression patterns (Vainio and Lin, 2002; Ducy and 
Karsenty, 2000). As development proceeds, a shift in gremlin expression to the 
condensing metanephric mesenchyme is observed, now synchronising BMP-7 
expression pattern (Nishinakamura and Sakaguchi, 2014). Gremlin homozygous 
knockout (GREM1-/-) mice, exhibit conspicuous skeletal phenotype with deficient 
outgrowth and incorrect digitation events, and elsewhere, show complete failure of 
kidney development that lead to neonatal lethality (Khokha et al., 2003; Michos et al., 
2004).   
Gremlin is a BMP antagonist known to regulate extracellularly the activities of 
BMPs including those of the BMPs -2, -4 and -7. This has been demonstrated both in 
vivo and in vitro (Hsu et al., 1998; Sudo et al., 2004; Sun et al., 2006; Zanotti et al., 
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2008). In vivo, GREM1-/-:Bmp4+/- mice exhibit rescued normal kidney phenotype 
which in this case strongly demonstrates gremlin as a bona fide BMP-4 antagonist 
(Michos et al., 2007). It is believed that gremlin by binding directly to the active BMP 
ligands, prevents them from engaging their receptors thus abrogating BMP-induced 
SMAD1/5/8 signalling.  
This accepted paradigm as a common mechanism of BMP antagonism stemmed 
primarily from crystallographic studies of ligand-antagonist complexes such as the 
Noggin-BMP-7 and CV2-BMP-2 complexes (refer to Section 1.6). Interestingly, fresh 
emerging studies on the mode of gremlin action are now revealing this widely accepted 
paradigm may be overly simplistic. Indeed, Sun et al. (2006) reported a novel 
intracellular regulatory mechanism of BMP-4 activity by gremlin in addition to its 
axiomatic extracellular regulatory mechanism. In this novel mechanism, gremlin 
interacts directly with the BMP-4 precursor protein within cells to effectuate more 
efficient inhibition of BMP-4 activity. It appears however that such an interaction 
between gremlin and BMP-4 is tissue-specific, as it was detected only in embryonic 
lung and not embryonic kidney (Sun et al., 2006). Nonetheless, it remains the case that 
significant deviation from the existing paradigm on BMP antagonist actions may exist 
that will necessitate further investigations on an individual basis. Furthermore, 
Alborzinia et al. (2013) revealed extracellular binding of gremlin and Noggin to 
fluorescently-labelled BMP-2 did not prevent the ligand itself from binding to its 
receptors. Instead, interactions with both gremlin and Noggin altered the fate of BMP 
signalling by increasing the rate of BMP-2 endocytosis through endosomes for 
lysosomal degradation. Also, heparitinase treatment of the HeLa cells was also 
observed to reduce gremlin- and Noggin-induced BMP-2 endocytosis thus suggesting a 
co-receptor role of HS in modulating endocytosis of activated receptor complexes.   
Gremlin also has BMP-independent activity. Stabile et al. (2007) demonstrated 
a novel pro-angiogenic activity for gremlin occurring by its high affinity binding (Kd 
value 47 ± 15 nM) to vascular endothelial growth factor receptors (VEGFRs) on the 
surface of endothelial cells (ECs). This stimulates EC intracellular signalling and 
migration in vitro which ultimately lead to potent pro-angiogenic response in vivo 
(Stabile et al., 2007; Mitola et al., 2010; Chiodelli et al., 2011). Chiodelli et al. (2011) 
demonstrated high affinity binding (Kd value 20 nM) between gremlin and heparin to 
reminisce physiological interactions with endogenous HS on cell surfaces of ECs that 
localises gremlin within endothelial extracellular matrix. This highlights anew, the 
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importance of HS in pathophysiological processes. Another BMP-independent activity 
of gremlin has been reported elsewhere (Chen et al., 2004a). During early embryogenic 
development, Slit proteins mainly act as midline repellents of axon guidance cues and 
also act as inhibitors of leucocyte chemotaxis. Gremlin has been shown to bind directly 
to the Slit proteins 1 and 2 in a BMP-independent manner hence strongly potentiating 
their inhibitory effects on leucocyte chemotaxis (Chen et al., 2004a). However, this 
study has not been followed up on. 
In terms of disease involvement, gremlin is implicated in various chronic 
diseases. Increased levels of gremlin expression has been associated with ocular 
diseases such as diabetic retinopathy (Kane et al., 2005) and glaucoma (Wordinger et 
al., 2007), human tumours such as cervical and colon cancers (Namkoong et al., 2006; 
Karagiannis et al., 2014, respectively) and fibrotic disorders in the lung, liver, eye, 
heart, kidney, and osteoarthritis (Ali and Brazil, 2014). Gremlin expression in these 
pathological states is triggered by various stimuli such as mechanical stress, activation 
by TGF-β1, and elevated glucose.  
In recent years, particular attention and great interest have been invested in 
understanding the molecular events underlying chronic fibrotic disorders of the kidney. 
This interest is sparked in part by observations that in healthy adult kidney, gremlin 
expression is low, but re-emerges in fibrotic pathological states such diabetic 
nephropathy (Roxburgh et al., 2009), tubulointerstitial fibrosis reminiscent of early 
development (Wang et al., 2001; Nakamura and Yanagita, 2012).  
Fibrosis is a progressive healing process leading to excessive tissue scarring 
caused by insults such as hyperglycaemia, hypoxia and ischaemic stimuli. Fibrotic 
responses typically reflect an increase in the local pool of myofibroblasts that secrete 
extracellular matrix (ECM) proteins such as collagen-1 and fibronectin (Ali and Brazil, 
2014). The main origin of myofibroblasts during fibrosis remains divided in opinion 
however. Gaining wider interest are the processes of epithelial-to-mesenchymal 
transition (EMT) and endothelial-to-mesenchymal transitions (EndMT). In these 
processes insulted differentiated epithelial or endothelial cells adopt mesenchymal 
phenotypes endowed with motility (Iwano et al., 2002; LeBleu et al., 2013). 
  In terms of EMT and fibrosis, most interest has surrounded BMP-7, TGFβ-1 
and gremlin. In diabetic nephropathy (DN), genetic deficiency in BMP-7 is associated 
with pro-fibrotic activities involving over-expression of both TGFβ-1 and gremlin (Ali 
and Brazil, 2014). Conversely, GREM1-/+ mice are partially protected from DN and in 
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vivo delivery of gremlin siRNA restored BMP-7 levels in DN ameliorating the fibrotic 
process. These clinical findings revealed gremlin as a potential therapeutic target for 
the treatment of DN (Roxburgh et al., 2009; Zhang et al., 2010).  
An important study conducted by Rodrigues-Diez et al. (2014) revealed that 
gremlin can cause EMT of human renal proximal tubuloepithelial-2 (HK2) cells by 
early activation of SMAD2/3 signalling pathway. Gremlin is known to act as 
downstream mediator of TGFβ-1 which itself, activates SMAD2/3 signalling pathways, 
in turn inhibiting BMP-7-induced SMAD1/5/8 signalling pathways. Intriguingly in this 
study, gremlin early activation of SMAD2/3 pathways occurred in both a BMP- and 
TGFβ-1-independent manner. It is suggested that its prolonged incubation with the 
HK2 cells induced over-expression of TGFβ-1 itself that then sustained the gremlin-
mediated signalling activity. 
1.16 Prediction of the heparin binding site on gremlin 
Gremlin has been shown to bind directly to both the BMPs -2, -4 and -7 (Hsu et 
al., 1998; Sudo et al., 2004) and with high affinity to heparin/HS GAG chains on cell 
surfaces (Chiodelli et al., 2011). Likewise, it was also established that BMP ligands, in 
addition to possessing binding sites for their cell surface receptors, also possess in them 
distinct binding sites for heparin/HS docking (Griffith et al., 1996; Scheufler, 1999; 
Greenwald et al., 2003). This suggests that heparin/HS may play important role in the 
binding interactions of gremlin and its BMP ligands. In kidney fibrosis a significant 
decrease in levels of BMP-7 expression correlate with gremlin re-expression at high 
levels; a mechanism that remains to be elucidated (Ali and Brazil, 2014). In this current 
study, a question is addressed towards potential formation of a trimolecular complex of 
the BMP ligand and gremlin along the same heparin/HS chain as was seen earlier in the 
heparin-mediated interaction of antithrombin III and thrombin (refer to Section 1.14). 
This current study is aimed at mapping the heparin binding site on gremlin and 
investigating its role in gremlin-mediated antagonism of BMP signalling activities. 
With no experimental three-dimensional structure, a gremlin model was predicted by 
homology based on templates of the high resolution NMR and crystal structures of its 
closest homologues, sclerostin and PRDC, respectively (Veverka et al., 2009; Nolan et 
al., 2013). The high resolution structures of both sclerostin and PRDC have been 
discussed previously in Sections 1.8.2 and 1.8.3, respectively. Our research 
collaborator, Professor Barbara Mulloy, Royal Holloway, University of London, has 
generated these predicted models of gremlin and has predicted its putative heparin 
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binding site using docking calculations with short chain heparin ligands prepared from 
the parent NMR structure, 1HPN (Mulloy et al., 1993; Forster and Mulloy, 2006).  
Rider and Mulloy (2010) have studied the homology modeling of just not 
gremlin, but of all other CAN family members of BMP antagonists by basing 
themselves on the NMR template structure of sclerostin, (PDB file: 2K8P). In this 
current study, site-directed mutagenesis studies were based on predictions made by 
Rider and Mulloy (2010). As shown earlier in Figure 1.7B, sclerostin possesses 
disordered terminal tails, which in its NMR structure are undefined. Moreover, 
sclerostin possesses a variable loop in its wrist region that replaces the four-turn α-helix 
in BMPs. As a result of these structural variations in sclerostin, only the core sequences 
within the conserved cysteine residues for all the other CAN members were used in 
pair-wise alignments with the 2K8P sequences in order to generate the relevant 
homology models. The alignments were conducted using the Modeler module of 
InsightII (Accelrys) and models visualised in Discovery Studio 2.5 (Accelrys). In this 
work, gremlin like sclerostin is modelled as a monomer possessing the characteristic 
CAN family features as described previously in Section 1.16 (refer to Figure 1.13).  
To predict the heparin binding site on the predicted gremlin model and models 
for other CAN family members, Rider and Mulloy (2010) then conducted a series of 
docking calculations according to published protocol by Forster and Mulloy (2006). 
Gremlin was docked with two heparin pentasaccharide ligands in 1C4 chair and 
2S0 
skew-boat conformations with flexibility allowed in only their exocyclic bonds. These 
oligosaccharides were prepared from the parent NMR structure 1HPN to consist of 
three GlcNS6S (N-sulpho-N-glucosamine 6-O-sulfate) residues separated by IdoA2S 
(L-iduronic acid 2-O-sulfate) residues. In addition, docking was also made with a 
heparin endecamer ligand in which both glycosidic and exocyclic bonds were fixed. 
Using all three oligosaccharides is a useful approach as the pentasaccharide ligands will 
identify the ‘core’ binding site whereas the endecamer ligand may identify extensions 
to the heparin binding site on the protein and also provide clues into the preferred 
orientation of bound heparin. Docking calculations were conducted using Autodock, 
version 2.4 from which the intermolecular energies of binding and contact co-ordinate 
sets were extracted for the lowest energy docked complexes. 
  Based on these docking calculations, USAG-1, COCO, PRDC and gremlin, 
were all predicted to bind to heparin. They each possessed a marked positively charged 
patch along their long axes, which is characteristic of heparin binding sites seen so far. 
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Interestingly, DAN and Cerberus, which are both predicted not to bind to heparin, do 
not possess these basic patches. Comparison of all surface basic and acidic residues 
across the surfaces of these predicted models indicated that both DAN and Cerberus 
possessed fewer basic surfaces overall. This is illustrated in Figure 1.12. As discussed 
in more detail in Chapter 3, these last two antagonistic proteins were highly relevant in 
this study for design of site directed mutagenesis studies on the predicted heparin 
binding site on gremlin. This was done in order to generate several functional gremlin 
mutant proteins with the correct spacing and orientation of the conserved cysteine 
residues yet possessing reduced binding to heparin/HS. The sclerostin-based three-
dimensional structure of gremlin docked onto a heparin endecamer chain is shown in 
Figure 1.13, on which the pinpointed arginine and lysine contact residues in the 




Figure 1.12: Molecular models of CAN family of BMP antagonists based on 
sclerostin.  
Shown are the predicted solution structures of CAN family of BMP antagonists based 
on the NMR structure of sclerostin (PDB file, 2K8P). Models are displayed in the same 
orientation as the ribbon diagram shown in Figure 1.7B with fingers pointing upwards. 
DAN and Cerberus are the only two members within the CAN family that are predicted 
not to bind to heparin/HS. Comparison of their binding surfaces shows that DAN and 
Cerberus possess fewer basic surfaces (blue colour) and more hydrophobic patches (red 







Figure 1.13: Docking of a predicted gremlin model with a heparin oligosaccharide. 
Shown is a homology model of the wildtype gremlin monomer based on the NMR 
structure of sclerostin (PDB file: 2K8P) A) docked onto an 11-mer heparin 
oligosaccharide and B)  The docked gremlin monomer without the heparin 
oligosaccharide rotated through about 90° displaying all potential contact basic 
arginine (R) and lysine (K) residues that form its heparin binding site. This gremlin 
model shares similar structural features with sclerostin as described in the legend of 
Figure 1.7. The amino acid side chains are shown as green sticks. Homology modeling 
and docking calculations were conducted by our collaborator Professor Barbara 
Mulloy, Royal Holloway, University of London.  
 
PRDC also called gremlin-2 is a closer homologue of gremlin than is sclerostin. 
Therefore, recent resolution of its crystal structure by Nolan et al. (2013) which 
revealed its existence as a dimer rather stimulated the need for fresh homology 
modeling based on the PRDC template, 4JPH. This would allow direct analysis to be 
made into the degree of overlap between the coordinate set of contact residues within 
both predicted heparin binding sites. 
This homology modeling was kindly conducted by our collaborator, Professor 
Barbara Mulloy, Royal Holloway, University of London. Apart from the homology 
modeling itself that was conducted on the SWISS-MODEL server, docking calculations 
were conducted similarly, as described previously in this section when using sclerostin. 
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This new homology modeling server has the advantage of predicting whether a 
structure oligomerizes.  
Previously in Section 1.7, PRDC was described to form a head-to-tail oriented 
dimer consisting of two monomers that share the same structural features as sclerostin 
except for the flexible helical N-terminal tail (refer Figure 1.8). The gremlin model 
based on PRDC shared identical structural features with PRDC itself (Figure 1.14). 
Moreover, docking calculations extracted contact residues within its predicted heparin 
binding site were identical to those previously pinpointed on the sclerostin-based 
gremlin structure. Of note, both the experimentally determined BMP binding site and 
the amino acid residues at the dimer interface in PRDC are both conserved in this 
predicted gremlin dimer, and are also highlighted in Figure 1.14.   
 
Figure 1.14: Homology model of gremlin based on PRDC.  
Gremlin forms a dimer when modelled by homology based on the crystal structure of 
the PRDC dimer sharing the same features described previously in the legend of Figure 
1.8. The dimer interface is coloured in blue. Purple coloured patches represent amino 
acid residues that form the predicted BMP binding site on gremlin according to 
experimental mapping on PRDC (Nolan et al., 2013). The heparin binding sites are 
coloured in orange. All α-helices are coloured in red, β-strands are coloured in cyan 






1.17 Use of homology modeling and docking calculations in structural 
predictions 
Using docking calculations, the heparin binding sites on generated gremlin 
models have been predicted. It is important however to emphasise that these 
predictions, serve only as hypothesis generation tools. Therefore, validation of such 
predictions will require full experimental verification as aimed in this current study.  
The need of experimental verification relates directly to the underlying 
limitations of these predictive tools themselves. Homology modeling is based on the 
reasonable assumption that two homologous proteins will share very similar structures 
and, therefore, shows large bias towards the template structure. It cannot predict 
conformational changes in the new structure and also, cannot find new binding sites in 
the new structure that are not present in the template structure itself. Also, heparin and 
HS chains are highly heterogeneous in their sequence pattern which renders use of 
specific heparin oligomers in docking calculations limiting. Moreover, although the 
docking program, Autodock, version 2.4, allows for flexibility in the heparin ligand, it 
uses rigid protein approximation in order to speed up the calculation. Therefore, it 
cannot model proteins that require conformational changes in order to achieve a fit with 
the ligand. Not even rotation in amino acid side chains on the protein is allowed. 
1.18  Hypotheses  
The initial hypothesis in this study states that the heparin/HS binding site on 
gremlin is constituted mainly of positively charged clusters of arginine and lysine 
residues.  
The second hypothesis states that the heparin/HS binding site on gremlin is 
physically distinct and independently regulated from its BMP binding site, also present.  
The third hypothesis states that heparin potentiates gremlin binding interaction 
with its BMP ligands. 
The fourth hypothesis states that HS binding will have a significant effect on 









To test these hypotheses, the following experimental aims will be achieved:- 
1.19.1 Aim 1: To clone and express C-Myc-tagged wildtype and mutant 
gremlin proteins 
 
The initial aim of this study will be to test experimentally the predictions made 
by docking calculations on the heparin binding site in gremlin. Using site-directed 
mutagenesis, the predicted contact basic clusters will be targeted and substituted 
strategically by both neutral and acidic clusters as discussed in Chapter 3. The hope is 
to clone and express several functional gremlin mutants possessing reduced binding to 
heparin/HS.   
Commercially purified wildtype gremlin recombinant protein is supplied tagged 
only with a polyhistidine (His) tag comprising ten histidine residues that each carries on 
them a partial positive charge. Given that the binding interaction between the basic 
clusters on gremlin and the sulfate groups on heparin/HS chains is believed to be 
largely ionic, a potential caveat is introduced if basing this study on the His-tagged 
gremlin protein alone. It is possible that such polybasic structure of His-tag could serve 
or contribute artefactually to heparin/HS binding (Lacy and Sanderson, 2002; Alfano et 
al., 2007). Thus, wildtype gremlin protein will be cloned and expressed, with a 
substitute C-terminal Myc sequence possessing only one strongly positively charged 
lysine residue, EQKLISEEDL. The gremlin mutants generated will also incorporate the 
same C-Myc tag.    
The expression of both wildtype gremlin-Myc and mutant proteins will be 
achieved transiently in Chinese Hamster Ovary-S (CHO-S) mammalian cell cultures. 
Given that gremlin is mainly a secreted protein, this study will examine its expression 
in harvested CHO-S cell culture supernatants mainly. 
1.19.2 Aim 2: To detect gremlin-Myc expression and assess the heparin 
binding properties of wildtype gremlin-Myc  
 
In order to compare the level of wildtype gremlin-Myc expression to those of its 
mutants in crude CHO-S culture supernatants, a Myc-capture gremlin ELISA will be 
used. The expression of a gremlin protein of the correct molecular weight will be 
confirmed by Western blotting using a polyclonal gremlin primary antibody.  
In order to demonstrate that expressed wildtype gremlin-Myc in crude CHO-S 
culture supernatant does indeed maintain similar heparin binding properties to purified 
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gremlin-His protein, the heparin-binding ELISA will be used. In this ELISA, heparin 
coupled at its reducing end with bovine serum albumin (BSA), heparin-BSA, is used as 
capture layer for gremlin alongside mock-BSA (Najjam et al., 1997). The aim here will 
be to competitively inhibit binding of both Myc- and His-tagged gremlin proteins with 
soluble unfractionated heparin. The EC50 values extrapolated from both inhibition 
curves generated will be compared for similarities in their heparin binding properties.  
1.19.3 Aim 3: To assess the heparin binding capabilities of gremlin-Myc 
mutants compared to the wildtype 
 
The heparin binding capabilities of the gremlin-Myc mutants compared to 
wildtype will be assessed using both the heparin-binding ELISA and heparin affinity 
chromatography. Both methods will be based on the principle that at constant pH, 
altering the ionic strength alone of the applied buffer solution will disrupt the ionic 
bonds formed between interacting molecules. The change in ionic strength will reflect 
the strength of the ionic interactions themselves. In both methods, NaCl prepared at 
increasing concentrations will be used to vary the ionic strength of the buffer solution 
at pH, 7.5. Therefore, NaCl salt concentrations will serve as a surrogate measure of 
binding affinity between gremlin-Myc and heparin. In the heparin-binding ELISA, the 
heparin-BSA capture layer will be incubated with different crude gremlin-Myc CHO-S 
culture supernatants prepared at increasing NaCl concentrations. In heparin affinity 
chromatography, the bound gremlin-Myc proteins will be eluted from packed HiTrap 
heparin-Sepharose and AF-heparin HC650M bead columns using a step NaCl gradient.  
1.19.4 Aim 4: To indicate that binding of gremlin to heparin occurs via 
specific ionic interactions and to purify expressed gremlin-Myc 
proteins  
 
Having assessed the heparin binding capabilities of the gremlin-Myc mutants 
against wildtype, we will seek to shed some light into the nature of their ionic 
interactions; that is whether heparin binding is more specific than binding to a simple 
cationic exchanger sulfopropyl (SP)-Sepharose matrix. As a highly acidic 
polysaccharide, heparin has the capability to bind any positive point charge on other 
molecules. However, as elaborated previously in Sections 1.13, the contact amino acid 
residues on heparin-binding cytokines such as gremlin, constitute mainly of clusters of 
positively charged arginines and lysines whose spacing is likely to be defined. These 
experiments will test whether binding of gremlin to acidic sulfate and carboxylate side-
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chain groups on the heparin/HS chains is stronger than binding to sulfopropyl groups 
on the cationic exchange Sepharose matrix.  
Moreover, attempts will also be made at partially purifying the expressed 
gremlin-Myc proteins from their crude CHO-S culture supernatants. This will be 
achieved by scaling up the SP-Sepharose ion-exchange chromatography.            
1.19.5 Aim 5: To investigate BMP binding capabilities in wildtype 
gremlin-Myc and its mutants and assess the effect of heparin on 
these capabilities   
 
Most studies of TGFβ signalling have demonstrated that strong hydrophobic 
interactions promote affinity between ligand:antagonist and ligand:receptor functional 
pairs (Groppe et al., 2002; Thompson et al., 2005; Veverka et al., 2009; Nolan et al., 
2013). On the other hand, strong ionic interactions promote affinity between any 
cytokine and heparin/HS ligands (Ruppert et al., 1996; Scheufler, 1999; Veverka et al., 
2009; Nolan et al., 2013). This rather implies that both BMP and heparin binding sites 
on the same cytokine molecule can be distinguished as clusters of either hydrophobic or 
positively charged residues, respectively.      
Gremlin is one of several antagonists BMPs. Such affinity towards its BMP 
ligands strongly highlights presence of a specific BMP binding epitope on gremlin. By 
resolving the crystal structure of PRDC, Nolan et al. (2013) mapped its BMP binding 
site and showed this was distinct from its predicted heparin binding site. In this case 
however, both BMP and heparin binding sites are located in close proximity to each 
other such that ligand binding to one results in competitive inhibition of other. The 
existence of physically distinct BMP and heparin binding sites as observed on PRDC is 
in agreement with the second hypothesis of this current study on gremlin (Refer to 
Section 1.18). However, it proposes otherwise in competitive binding of their ligands.   
Therefore, an aim of this study will be to first demonstrate that the cloned 
wildtype gremlin-Myc and its mutants have maintained their natural BMP binding 
capabilities and also check if they are correctly folded.  First, this will be achieved by 
immunoprecipitation of purified BMP-4 protein on gremlin-Myc-bead complexes 
followed by Western blotting. Alternatively, the same aim will be achieved by a novel 
ELISA approach that will generate BMP-4 immunoreactivity only, the Myc-capture 
GREM1/BMP4 double sandwich ELISA. Moreover, this ELISA will also enable 
investigations into the effect of heparin on the binding interaction between gremlin-
Myc and BMP-4. This in a way, will mimic the approach of surface plasmon resonance 
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(SPR) used by Nolan et al. (2013) for similar studies on the effect of heparin in PRDC 
interaction with BMP-2 on immobilised BMP-2 sensor chips. In the ELISA, gremlin-
Myc will be immobilised on a 9E10 Myc antibody capture layer in wells of a 96-well 
ELISA plate, instead.  
1.19.6 Aim 6: To assess whether expressed gremlin-Myc proteins are 
functionally active and investigate the role of HS in gremlin 
interaction with BMPs   
 
In order to assess whether expressed wildtype gremlin-Myc alongside its 
selected low-heparin binding mutants are functionally active, two functional assays will 
be established in C2C12 myoblastic cell cultures. Both functional assays will assess the 
capability of gremlin to inhibit BMP-SMAD1/5/8 signalling in the cells following pre-
incubations with BMPs -4 and/or -7 purified proteins. Also, effort will be made at 
concentrating the expressed gremlin-Myc proteins from their crude CHO-S culture 
supernatants, beforehand.   
First, in the SMAD1/5/8 phosphorylation assay, both BMPs -4 and -7 dose 
response curves will be established, as a semi-quantitative measure of induced 
SMAD1/5/8 levels of phosphorylation. From the responsive ranges of these curves, a 
fixed dose will be chosen and inhibited using purified gremlin-His protein and/or the 
concentrated gremlin-Myc proteins. 
  Alternatively, functional activity of expressed gremlin-Myc proteins will be 
assessed using a luciferase-secreted reporter construct in a similar manner described by 
Sudo et al. (2004). In this quantitative assay, a BMP-2/4/7-specific reporter DNA 
construct is transiently transfected into P19 embryonal carcinoma cell cultures. 
Luciferase enzymatic activity is measured as a direct correlation of transcriptional 
activation of a BMP-SMAD1/5/8 downstream target promoter gene. Similarly to the 
SMAD1/5/8 phosphorylation assay, BMPs -4 and/or -7 dose response curves will be 
established prior to inhibition of a chosen responsive dose of BMPs -4/-7 with the 
concentrated gremlin-Myc proteins.  
In both functional assays, experiments assessing functional activities of 
gremlin-Myc proteins will also serve as an investigation into the role of HS in their 
interaction with BMPs. These next experiments are made interesting by comparing 
side-by-side wildtype gremlin-Myc against its low-heparin/HS binding mutants. Given 
that both wildtype gremlin-Myc and its BMP ligands can bind to HS, use of gremlin 
mutants possessing reduced binding for HS, provides a powerful tool in this 
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investigation. This will provide a way of investigating the direct role HS plays in 
gremlin activities. Additional investigations into the role of HS will be carried out on 
heparitinase and chlorate treated-C2C12 cells prior to addition of both BMP and 
gremlin-Myc proteins. Heparitinase treatment will deplete HS on cell surfaces entirely 
whereas chlorate treatment will inhibit sulfation in general. Therefore, these 
experiments seek to investigate whether HS is indispensable to the functional activities 
of both BMP and wildtype gremlin-Myc proteins and seek to comment on the specific 







CHAPTER 2: Materials and methods 
2.1 DNA digestion reactions with restriction endonuclease enzymes  
The restriction endonuclease enzymes, NotI and XhoI, and their accompanying 
preparation buffers were purchased either from Promega Corporation, USA or Fermentas 
International Inc, Canada.  A typical double digestion reaction consisted of the following 
components: 
DNA plasmid    1-2 µg 
10x restriction enzyme buffer  2.0 µl 
(10x Bovine Serum Albumin  0.2 µl if required) 
NotI enzyme    1.0 µl 
XhoI enzyme    1.0 µl 
Ultrapure distilled water  made up to 20 µl final volume 
(Sigma-Aldrich, USA) 
The reaction mixtures were mixed and incubated at 37 °C for 2 - 3 h.  
2.2 Agarose gel electrophoresis 
Agarose gel electrophoresis experiments were conducted in a similar manner described 
by Sambrook et al. (1989), replacing ethidium bromide as fluorescent dye with the less 
toxic WebGreen DNA dye (Web Scientific, UK). The samples were run on 1% (w/v) 
agarose gel prepared by dissolving molecular grade agarose (Bioline, UK) in Tris-
acetate-EDTA (TAE) buffer [40 mM Tris-acetate, 1 mM ethylenediaminetetraacetic 
acid (EDTA)]. The mixture was microwave heated to help dissolve the agarose. 
WebGreen DNA dye (1 µl) was added into the cooling agarose solution, which was 
then poured into a horizontal gel casting tray with inserted well combs. The agarose gel 
was left to set at room temperature. Once set, the gel was placed in an electrophoresis 
tank (Bio-Rad, USA) containing enough TAE buffer to cover the gel to a depth of 
about 1 - 1.5 mm. In analytical gel runs, a maximum of 300 ng DNA sample was 
prepared in 6x DNA loading dye (Bioline, UK) and ultrapure water to 10 µl final 
volumes. In preparative gel runs, the DNA amount was increased 5-fold and prepared 
only in 6x DNA loading dye to 20 - 30 µl final volumes.  
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Prepared DNA samples were loaded into the buffer-filled wells of the gel alongside 5µl 
Hyperladder I DNA molecular weight marker (Bioline, UK). The gel was then 
subjected to electrophoresis at 110 V until suitable migration of the leading visible 
bands was achieved. Separated DNA bands were visualised and photographed using a 
U:Genius 3 basic UV gel imaging system with camera and UV transilluminator 
(Syngene, UK). 
2.3 DNA extraction and purification from agarose gels 
Migrated DNA bands on agarose gels were visualised on a Dark Reader blue light 
transilluminator platform (Clare Chemical Research, USA). Each DNA gel slice was 
carefully excised to no more than 400 mg in weight using a sterile scalpel (Swann-
Morton, UK).  The embedded DNA was then extracted and purified using the QIAquick 
Gel Extraction Kit (Qiagen, UK), according to the supplier’s protocol. As recommended, 
silica membrane-bound purified DNA fragments were eluted into sterile 1.5 ml 
microcentrifuge tubes from the QIAquick spin columns by applying 30 µl elution buffer 
(10 mM Tris-HCl, pH 8.5), standing at room temperature for 1 min, and then centrifuging 
at 17900 x g for 1 min. 
2.4 DNA quantitation 
The concentrations of DNA fragments, extracted and purified, were estimated 
using the NanoDrop 1000 spectrophotometer and accompanying software, version 3.5.2 
(Thermo Scientific, UK). Blanking of the instrument was done using the QIAquick 
elution buffer. Per DNA sample, the average of three independent readings was taken. 
An independent reading is defined as a fresh measurement after a full close-restart cycle 
of the software program which requires blanking of the instrument.  
2.5 GREM1 cDNA clone 
A 1639 bp complementary DNA (cDNA) I.M.A.G.E clone containing the 
complete coding sequence of wildtype M.  musculus gremlin or gremlin-1 gene 
(GREM1), (Unigene ID: MM.166318, GenBank accession number: NM_011824), was 
purchased as a stab culture of E. coli colony from Source BioScience Lifesciences 
(Nottingham, UK). A streak plate was prepared on an ampicillin-selective Luria-Bertani 
(LB) agar plate (refer to Section 2.10). The purified GREM1 cDNA was obtained by 
Mini prep (refer to Section 2.13.1) of an isolated single colony. This served as a DNA 
template for PCR cloning of the wildtype GREM1 DNA insert described next.  
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2.6 Polymerase Chain Reaction (PCR) using Taq and Pfu DNA polymerases  
All PCR amplifications were carried out routinely using both Taq and Pfu 
polymerases together in the same reaction for high fidelity amplifications. Both DNA 
polymerases were supplied by Promega, USA. The Taq polymerase was present in the 
supplied ready-to-use GoTaq green master mix 2x solution (Promega, USA) used 
routinely. In this master mix solution, the Taq polymerase was supplied in 2x Green 
GoTaq reaction buffer (pH 8.5), 400 µM dATP, 400 µM dGTP, 400 µM dCTP, 400 µM 
dTTP and 3 mM MgCl2. Supplementation of the green master mix 2x solution with Pfu 
polymerase was done during assembly of the PCR reaction mix.    
Pfu DNA polymerase is from Pyrococcus furiosus DSM3638 (Fiala and Stetter, 
1986) and offers high fidelity amplification by possessing a proofreading 3’ to 5’ 
exonuclease activity that the Taq polymerase lacks (Cline et al., 1996). Taq DNA 
polymerase is from Thermus aquaticus (Chien et al., 1976). 
In a typical PCR reaction mixture, the following components were assembled in 
0.5 ml thin-walled sterile PCR tubes placed on ice:  
GoTaq green master mix 2x solution    25 µl 
Appropriately diluted DNA template    1 µl 
10 µM sense primer      1 µl 
(10 µM second sense primer if necessary   1 µl) 
10 µM anti-sense primer     1 µl 
(10 µM second anti-sense primer if necessary  1 µl) 
Sterile water        Make up to 49 µl final 
volume 
Pfu DNA polymerase      1 µl 
The number of pairs of non-complementary and complementary PCR primers 
used per PCR reaction mixture varied depending on the underlying PCR cloning strategy 
adopted. In the standard PCR and overlap extension (OE) PCR (Figure 3.5), only a pair 
of non-complementary PCR primers was used per reaction mix. In the one-step OE 
(OOE) PCR (Figure 3.6), at least one pair of non-complementary PCR primers together 
with a complementary pair of PCR primers were both used in the same reaction mix.  
The full sequences of PCR primers are listed in Tables 3.3 - 3.5. The annotations 
used in these tables are consistent with those in Figures 3.5 and 3.6.   
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The above listed components were mixed thoroughly and PCR was carried out in 
a G-Storm GS482248 well multi-block thermal cycler using the following parameters:  
Initial denaturation:  95 °C  2 min 
Denaturation:    95 °C  40 s 
Annealing:   60 °C  60 s              31 cycles 
Polymerase extension: 72 °C  2 min 
Final extension:  72 °C 10 min 
For gradient PCR, several PCR reaction mixtures were set up in the same thermal 
cycler, and an annealing temperature gradient was set up ranging between 60 – 72 °C. 
All other parameters were kept constant. PCR products were stored at -20 °C. PCR 
products were purified using the QIAquick PCR purification kit (Qiagen, USA) 
following the manufacturer’s protocol. The silica membrane-bound purified DNA inserts 
were eluted into sterile 1.5 ml microcentrifuge tubes as described previously in Section 
2.3.  
2.7 Processing of PCR products 
Following PCR purification of the full-length GREM1 DNA inserts, restriction 
digestion, agarose gel electrophoresis, agarose gel extractions and NanoDrop 
measurements were performed sequentially as described previously (refer to Sections 2.1 
– 2.6, respectively). DNA sequencing as described in Section 2.14, in the case of the full-
length GREM1 DNA insert, was conducted using the same pairs of outer non-
complementary PCR primers used for its cloning.   
2.8 DNA ligation reactions 
DNA ligation reactions were carried out using the Quick Stick (QS) ligase kit 
(Bioline, UK) according to the supplier’s protocol. For most ligation reactions, the molar 
ratio of vector DNA to insert DNA was maintained at 1:3 unless stated otherwise. Also, 
the recommended maximum limit of 100 ng total DNA per reaction was followed. 
Reactions were assembled in sterile 1.5 ml microcentrifuge tubes at room temperature 





GREM1 insert DNA      70 ng 
+/-TSAP- treated pCMV-Tag5A vector DNA   30 ng 
Sterile water        Adjust volume to 14 µl 
QS ligase        1 µl 
4x QS ligase buffer       5 µl 
Reactions were incubated at room temperature for 15 min and 1 - 10 ng ligation 
products were transformed into competent E. coli cells. In negative control reactions, 
only the empty +/-TSAP-treated vector was added. 
2.9 Mammalian expression vectors 
2.9.1 pCMV-Tag5A expression vector (Figure 3.8) 
The pCMV-Tag5 expression vector (Agilent Technologies, USA) was supplied 
with three shifted reading frames of its multiple cloning site (MCS) relative to the C-
terminal Myc sequence. These, designated as 5A, 5B and 5C, allowed flexible 
adaptations of the vector to different cloning strategies. In the MCS frame 5A (GenBank 
accession number: AF076312), the MCS is directly in frame with the C-terminal Myc 
sequence. Both frames 5B (GenBank accession number: AF076777) and 5C (GenBank 
accession number: AF076778) are out of frame with the C-terminal Myc sequence 
caused by the insertion of one and two alanine leading base nucleotides, respectively, 
between MCS frame 5A and the C-terminal Myc sequence. In this study, only the pCMV-
Tag5 vector with in frame 5A, hereafter called pCMV-Tag5A vector, was compatible 
with our chosen cloning strategy. This made use of only NotI and XhoI RE enzymes for 
subcloning of GREM1 inserts directly into the MCS of the vector such that it remained 
in frame with C-terminal Myc sequence. Vector digestion was carried out as described 
previously in Section 2.1. 
Typically, restriction digestion of the pCMV-Tag5A expression vector was 
followed by treatment with thermosensitive shrimp alkaline phosphatase (TSAP), 
purchased with its accompanying preparation buffers from Promega, USA. To 20µl 
pCMV-Tag5A double digest mixture, 1 µl TSAP and 1 µl multi-core 10X buffer were 
added and incubated at 37 °C for 10 - 15 min. After incubation, the TSAP was heat 
inactivated at 65 °C for 15 min. This was followed by agarose gel electrophoresis, 
agarose gel extraction and NanoDrop measurements as previously described in Sections 





2.9.2 pEGFP-C1 expression vector 
Because of the fluorescent property of EGFP protein, EGFP expression was used 
as an indirect means to monitor the levels of expression of gremlin-Myc proteins during 
the transfection process itself. Subsequently, because of a lack of reports into the specific 
binding of EGFP to BMPs, heparin/HS and gremlin, the EGFP culture supernatants 
became routinely employed as negative control supernatants in all immunoassays.  
The plasmid map, of the pEGFP-C1 expression vector shows several shared 
features with the pCMV-Tag5A expression vector map (refer to previous section) which 
are discussed in Chapter 3, Section 3.6.1. Notably, the former also possessed a CMV 
promoter driving strong expression of the downstream EGFP gene and other genes 
within its MCS at its C-terminal end (Figure 3.12). Other shared features included the 
SV40 ori and F1 ori also inversely oriented, the SV40 promoter and both SV40 and HSV 










Figure 2.1: Plasmid map of the pEGFP-C1 expression vector construct.  
The CMV enhancer-promoter drives expression of the EGFP gene and genes within the 
MCS (light blue colour). A stop codon (red colour) at the C-terminal end of the MCS 
terminates both expressions. Coloured in yellow: origin of replication (ori), f1 ori, SV40 
ori, neomycin resistance/kanamycin resistance (NeoR/KanR) gene, herpes simplex virus 
(HSV) TK and SV40 polyadenylation [poly(A)] signals. Arrows indicate direction of 
transcription by promoters. Restriction sites are indicated on the outside of the plasmid 
circle. Refer to legend of Figure 3.8 for abbreviation listing. Adapted from Clontech 
Laboratories, Inc, USA.    
 
2.9.3 pGL3-basic expression vector 
Subcloning of a SMAD1/5/8-specific DNA insert, 12XSBE-Oc insert DNA, into 
the MCS of the pGL3-basic expression vector (Promega Corporation, USA), was carried 
out by Zhao et al. (2003). More details on the 12XSBE-Oc-Luc+-pGL3 reporter construct 
are provided later in Section 2.30.1. This was a kind donation from Dr Zhao Ming, 
University of Texas Health Science Center, Texas.  
The pGL3-basic expression vector (4818 bp in size) on itself lacks eukaryotic 
promoter and enhancer sequences required to drive expression of its incorporated 
Photinus pyralis firefly luciferase gene (luc+). This provides maximum flexibility for 
cloning properly inserted and oriented putative regulatory sequences into its MCS as 
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Figure 2.2: pGL3-basic expression vector map.  
Functional promoter can be inserted upstream of the firefly luciferase gene (luc+) in the 
multiple cloning site (MCS). Potential enhancer elements can also be inserted upstream 
of the promoter in front of the luc+ gene or in the BamHI-SalI restriction sites 
downstream the luc+ gene. In addition, the vector possesses both an f1 and E. coli origin 
of replication (ori), a gene that confers ampicillin resistance (Ampr) and two 
polyadenylation (polyA) signals upstream and downstream the MCS and luc+ gene 
respectively. The polyA signals are grey shaded. The arrows indicate the direction of 
transcription and the numbering represent the respective regions of restriction sites along 
the vector circle map. 
2.10 Bacterial growth media 
 Luria-Bertani Broth (LB) medium (Sigma-Aldrich, USA): 10 g/L tryptone, 5 g/L 
yeast extract, 5 g/L NaCl, prepared in deionised water and autoclaved at 121 °C 
for 20 min.  
 
 Miller’s LB Agar medium (Merck KGaA, Germany): 15 g/L Agar, 10 g/L 
tryptone, 5 g/L yeast extract, 10 g/L NaCl, prepared in deionised water and 
autoclaved at 121 °C for 20 min. 
Both growth media were made selective by adding either kanamycin or ampicillin 
antibiotics to a final concentration of 10 µg/ml or 50 µg/ml, respectively, according to 
the specific antibiotic resistance gene incorporated in plasmids of the growing competent 




2.11 Preparation of bacterial glycerol stocks  
Glycerol stocks were prepared for long term storage of sequence-verified positive 
integrative transformants. A 1:1 dilution of the bacterial starter culture (refer to Section 
2.13) was made in 30% (v/v) sterile glycerol also prepared in selective LB medium. 
Glycerol stock aliquots were frozen immediately in liquid nitrogen and then transferred 
to -80 °C.  
2.12 Transformation of competent E. coli bacterial cells 
For transformations, the DH5α and Top10 E. coli strains were used. DH5α 
competent cells purchased from Invitrogen Life Technologies (California, USA) were 
used routinely. Top10 competent cells were a kind donation by the George Dickson’s 
laboratory, Royal Holloway, University of London and were used only when 
transformations into DH5α competent cells were unsuccessful. Top10 competent cells 
had originally been purchased from the same supplier above. 
Transformations of 1 - 10 ng ligation products into 100 µl aliquots of DH5α 
competent cells were carried out as outlined in the manufacturer’s protocol. Treated 
competent cells were plated on selective LB agar plates at low and high volumes of 20 
µl and 150 µl, respectively. Plates were incubated overnight at 37 °C. Next day, plates 
with bacterial colonies were parafilm-sealed and stored at 4 °C. Transformations into 
Top10 competent cells were also conducted in a similar manner as that described above 
except that only 50 µl aliquots of competent cells were used instead. 
For streak plate preparations, single bacterial colonies were picked and streaked 
onto new plates of selective LB agar or compartmentally onto the same plate. Streaked 
plates were then incubated overnight at 37 °C before sealing with parafilm and storing at 
4 °C. 
2.13 DNA purification  
2.13.1 Small scale purification of DNA (Mini prep)  
Mini prep of DNA was carried out using the QIAprep Spin Mini prep kit (Qiagen, 
USA) following the manufacturer’s protocol. Sterile selective LB medium (5 ml) was 
inoculated with a picked single bacterial colony and then incubated at 37 °C for 16 h with 
vigorous shaking at 225 rpm (orbital incubator, S150, Stuart, UK), under sufficiently 
aerated conditions.  
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This formed the bacterial starter culture and was carried out using a sterile 15 ml 
centrifuge tube (Orange Scientific, Belgium). Mini prep was then conducted as guided 
by the manufacturer’s protocol. The silica membrane-bound purified DNA was eluted 
into a sterile 1.5 ml Eppendorf tube by applying 30 µl elution buffer into QIAquick spin 
column and then centrifuging at 17900 x g for 1 min.  
2.13.2 Large scale purification of plasmid DNA (Maxi prep) 
Typically, the positive integrative transformants to be processed by Maxi prep, 
were picked either from an LB agar growth plate or from its frozen glycerol stock. In the 
latter case, frozen glycerol stocks at -80 °C were partially thawed in ice and a sterile 
inoculation loop was dipped into the thawing glycerol stock and then dropped into 5 ml 
selective LB medium for preparation of its starter culture (refer to previous section).  
Maxi prep of plasmid DNA was conducted routinely prior to sequencing, 
mammalian transfections and functional studies all of which required highly purified 
plasmid DNA material. Maxi prep of DNA was carried out using the Qiagen endofree 
plasmid maxi kit (Qiagen, USA) following the manufacturer’s protocol. Initially a 
selective starter culture was prepared as described in the previous section. Fresh selective 
LB medium (100 ml) in a sterile 500 ml conical flask was inoculated with 100 µl starter 
culture and then incubated under the same conditions stated in the previous section. The 
procedure hereafter was carried out as outlined in the manufacturer’s protocol. The eluted 
purified DNA was air-dried for 10 - 20 min, resuspended in 150 - 300 µl elution buffer 
(10 mM Tris-HCL, 1 mM EDTA; pH 8) and then transferred into a sterile 1.5 ml 
microcentrifuge tube. 
2.14 Plasmid DNA sequencing 
The same pair of sequencing primers was used for sequencing all Maxi prep 
purified DNA plasmids.  Their oligonucleotide sequences are listed in Table 2.1. The 
only exception occurred during sequencing of purified GREM1 inserts following PCR 
amplification. In this case, the sequencing primers constituted the same pair of non-
complementary outer primers used for the PCR amplification process itself. These are 







Table 2.1: GREM1-Myc plasmid construct sequencing primer oligonucleotides. 
Sequencing primer direction 
 
Sequencing primer oligonucleotides   









TAT AGG GCG AAT TGG GTA CAC 
 
 
The primers were designed to complement 60 - 100 base pairs upstream of the 
NotI restriction site and the Myc sequence/stop codon at the N- and C-terminal encoding 
regions of the GREM1 insert-in-vector, respectively, using the ApE plasmid editor 
software, version 1.17 supplied by Invitrogen, UK. Sequencing was conducted 
commercially by The Sequencing Service at the University of Dundee, Scotland (College 
of Life Sciences; http://www.dnaseq.co.uk). As required, 30 µl sequencing primers at 3.2 
pmol/µl and 30 µl DNA containing 600 ng were prepared for each sequencing reaction 
and then submitted. Results were decrypted using Chromas Lite software, version 2.0, in 
order to access and export relevant FASTA files for further analyses. The Transeq tool 
was used on these FASTA files for translations of base nucleotide sequences to 
polypeptide sequences. ClustalW2 was used for multiple polypeptide sequence 
alignments. Both tools are accessible from the European Bioinformatics Institute (EBI) 
website, http://www.ebi.ac.uk. 
2.15 Confirmation of positive integrative transformants  
Mini preps followed by NotI and XhoI double restriction digestions and agarose 
gel electrophoresis were carried out to preliminary screen for positive integrative 
transformants, post-transformations into E. coli cells. These were expected to possess 
both restriction sites. These were carried out as described previously in Sections 2.13.1, 
2.1 and 2.2, respectively. Maxi preps of selected colonies were then carried out using the 
same starter cultures generated initially during their mini preps.  Sequencing of Maxi 






2.16 Gremlin-Myc expression in mammalian cell cultures 
2.16.1 Chinese Hamster Ovary S-strain (CHO-S) cell cultures  
CHO-S cells are a stable aneuploid cell line established from the ovary of an adult 
Chinese hamster (Puck et al., 1958). Frozen vials of CHO-S cells were generously 
donated by Christine Ball, National Institute of Biological Standards and Control 
(NIBSC). Each frozen vial contained 1 ml aliquot of 1 x 107 CHO-S cells prepared in 
90% (v/v) Freestyle CHO expression medium (Invitrogen, USA) and 10% (v/v) dimethyl 
sulfoxide (DMSO), (Sigma-Aldrich, USA).  
Maintenance, sub-culturing and transfections of CHO-S cells were carried out in 
accordance with the protocols outlined in the Freestyle MAX CHO Expression System 
manual (version C, publication part number: 25-0920) provided by Invitrogen Life 
Technologies from whom the cells were purchased initially. All reagents used unless 
specified otherwise, were also purchased from this company.  
2.16.2 CHO-S cells: sub-culture 
For the establishment of CHO-S cells, liquid nitrogen frozen vials of CHO-S cells 
were thawed in a 37 °C water bath and transferred quickly into 125 ml sterile 
polycarbonate Erlenmeyer flasks (Corning Incorporated, USA) each containing 30 ml 
pre-warmed CHO expression medium supplemented with 8 mM L-Glutamine (Gibco 
Life Technologies, USA). The cells were then incubated in humidified atmosphere at 37 
°C in 8% CO2 with shaking at 135 rpm (microtitre plate shaker, Stuart, UK). After 48 h, 
cells were prepared for counting by preparing 2.5:1 a sample of cell suspension with 1% 
(w/v) nigrosine (VWR international, USA) in deionised water.  The prepared cell 
suspension was then counted using a Fuchs-Rosenthal hemocytometer (Hausser 
Scientific, UK) on a BH-2 model light microscope (Olympus, UK). The cells were then 
sub-cultured into new flasks by seeding at 0.2 - 0.3 x 106 cells/ml in pre-warmed L-
glutamine-supplemented CHO expression medium to 30 ml total volume and then 
incubating under the same conditions stated above. A minimum of 5 passages at interval 





2.16.3 CHO-S cells: transient transfections, harvests and microscopy  
Initially, transfections were carried out using cloned wildtype and mutants 
GREM1-pCMV-Tag5A constructs alongside a pEGFP-C1 construct, a kind donation 
from Dr. Philip Chen, Royal Holloway, University of London (Figure 2.1). The latter 
transfection served as a means to monitor the levels of protein expression by the CHO-S 
cells themselves. Prior to transfections, this previously sequence-verified construct was 
transformed into DH5α competent cells, grown on ampicillin-selective LB agar plates 
and a picked single bacterial colony was Maxi prep purified, as described in Sections 
2.12 and 2.13.2, respectively.  
Before transfection, 24 h before, sub-cultured CHO-S cells were seeded at 0.6 x 
106 cells/ml and incubated as specified previously. On the day of transfection, the cells 
were seeded at 1.0 x 106 cells/ml instead. The following preparations were then made in 
separate sterile 1.5 ml microcentrifuge tubes:  
Maxi prep DNA plasmid   37.5 µg 
OptiPro SFM medium   562.5 µl  
Freestyle MAX transfection reagent   37.5 µl 
OptiPro SFM medium    562.5 µl 
The separate preparations were then mixed together and stood at room 
temperature for 10 min and no longer than 20 min for the formation of DNA-lipid 
complexes. The mix was then added dropwise into the sub-cultured cell suspension 
whilst gently swirling the flasks. Transfected cells were incubated for 48 h in humidified 
atmosphere at 37 °C in 8% CO2 with shaking at 135 rpm (microtitre plate shaker, Stuart, 
UK). Harvesting of CHO-S cell culture supernatants was carried out 48 h post-
transfections by centrifuging the cell suspensions at 245 x g for 10 min. When 
appropriate, protease inhibitor cocktail (P8340, Sigma-Aldrich, USA) was added at a 
1:55 dilution ratio into the cell culture supernatants. Aliquots of treated cell culture 
supernatants were then stored at -20 °C.   
2.17 Commercially purified recombinant proteins 
The purified recombinant proteins of His-tagged recombinant murine gremlin 
(gremlin-His), human BMP-4 and human BMP-7 were purchased from R&D Systems, 
USA. These were reconstituted as recommended. 
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2.18 Concentration of crude gremlin-Myc CHO-S culture supernatants 
Where required, concentration of expressed gremlin-Myc proteins in their crude 
CHO-S culture supernatants was achieved using Amicon Ultra-15 centrifugal filter units 
with 10 kDa cut off (Merck Millipore Ltd, Germany). Crude CHO-S culture supernatants 
(15 ml) were loaded into the filter units and centrifuged at 4 °C for 60 min at 4000 x g. 
A 20-fold concentration of gremlin-Myc proteins was achieved. For optimal recovery, 
the concentrated samples were dispensed into sterile 1.5 ml microcentrifuge tubes 
immediately after centrifugation, as recommended by the manufacturer. For optimal 
gremlin-Myc activity, the concentrated samples were used on the same day of 
preparation avoiding any freeze-thaw cycles.     
2.19  Sandwich enzyme-linked immunosorbent assay (ELISA) 
2.19.1  Sandwich ELISA general procedure 
Microtiter plates (96-well, Nunc, Denmark) were coated with 100 µl/well of 
capture antibody prepared at 2 - 4 µg/ml. Plates were then incubated overnight at 4 °C 
on a gently rotating platform after which wells were washed thrice in PBS. Wells were 
blocked by adding 200 µl/well of PBS containing 0.5% (w/v) BSA blocker (PBS-0.5% 
(w/v) BSA) solution and incubated at room temperature for 1 h with gentle shaking. After 
incubation, the well washes were repeated with PBS-0.05% (w/v) BSA solution, instead. 
Both primary antibody and conjugated enzymes were prepared in this buffer. Next, 100 
µl/well experimental samples were loaded into the wells and incubated at room 
temperature for 90 min with gently shaking after which, washes were repeated in PBS-
0.05% (w/v) BSA solution. Biotinylated primary or detection antibody (100 µl/well) 
prepared at 0.8 µg/ml was added into washed wells and incubated, as described for 
experimental samples. After incubation, the wells were washed thrice in PBS-0.05% 
(v/v) Tween20 (Molecular Sigma Biology, UK) solution. Next, 100 µl/well alkaline 
phosphatase-streptavidin conjugated enzyme prepared 1:1000 was added into the wells 
and incubated at room temperature for 30 min with gentle shaking. Wells were then 
washed thrice in PBS-0.05% (v/v) Tween20 and then twice in PBS alone. After washing, 
100 µl/well substrate tablet solution of para (p)-nitrophenylphosphate tablets (Sigma, 
UK) dissolved in deionised water (5 ml per tablet pair) was added into the wells. It 
followed that the plate was then incubated in a non-illuminated 37 °C shaker incubator 
(Denley Wellwarm1, UK) until a yellow colour, not so intense, was apparent in 
experimental wells.  The absorbance readings at 405 nm wavelengths were then 
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measured using an Emax plate spectrophotometer (Molecular Devices, California, USA) 
on the Softmax Pro software, version 3.0. The blanks in all these experiments constituted 
of wells which had only been blocked, washed identically and substrate solution added.  
2.19.2  Heparin-binding ELISA 
Coating was done overnight at 4 °C with 100 µl of 5 -10 ng/well heparin-BSA 
and treated-BSA complexes prepared in 50 mM Tris-HCl containing 12.7 mM EDTA 
buffer, pH 7.4.  Both were synthesised as described in Section 2.20. The experiment 
hereafter was conducted as described in the previous section except that PBS-5% (w/v) 
BSA was used as blocker solution and PBS-0.5% (w/v) BSA solution used as wash and 
antibody incubation buffer instead.   
2.19.3  Myc-capture gremlin ELISA 
This sandwich ELISA targets the C-Myc tag on both expressed wildtype and 
gremlin proteins. An anti-Myc 9E10 antibody (Abcam, UK) prepared 1:500 in 50 mM 
Tris-HCl containing 12.7 mM EDTA buffer, pH 7.4, is used as coating antibody. 
Everything else was carried out as described in Section 2.19.1.   
2.19.4 Myc-capture GREM1/BMP-4 double sandwich ELISA 
The Myc-capture GREM1/BMP-4 double sandwich ELISA was conducted on 
crude wildtype and selected mutant gremlin-Myc cell culture supernatants to assess their 
BMP-4 binding capabilities. This ELISA was a development of the Myc-capture gremlin 
ELISA described in the previous section in which both gremlin bound to BMP-4 were 
sandwiched by the Myc antibody-capture layer and the detecting primary antibody, 
indeed. In this double sandwich ELISA, BMP-4 added was incubated overnight at 4 °C 
prior to detecting with a monoclonal biotinylated BMP-4 detecting primary antibody 
(R&D Systems, USA) prepared at 4 µg/ml as described in Section 2.19.1.  
2.20  Synthesis of heparin-BSA conjugate 
A reducing-end coupled heparin-BSA complex was synthesised as described by 
Najjam and co-workers (1997). Porcine intestinal mucosa heparin (grade 1-A) and BSA 
(99% pure grade) were both purchased from Sigma-Aldrich, UK. Heparin, 1.5 g, 
dissolved in 1 ml deionised water was dialysed against three changes of 1.5 L of 1 M 
NaCl and then two further changes of the same volume in deionised water using cellulose 
dialysis tubing, 23 mm x 15 mm, (Sigma-Aldrich, UK). Changes were made at 2 h 
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intervals except the last change in deionised water which was carried out overnight at 4 
°C. The dialysed material was then freeze-dried for 48 – 72 h using a freeze-dryer 
(Lyovac GT 2, Lebold-Heraeus, Germany). Freeze-dried heparin (680 mg) and 34 mg 
BSA were dissolved in 5 ml 0.2 M potassium phosphate buffer, pH 8, after which 25 mg 
sodium cyanoborohydride (Sigma-Aldrich, UK) was added, cautiously. The reaction 
mixture was then incubated in a 37 °C water bath for 48 h. Using gel filtration, the 
reducing-end coupled heparin-BSA conjugate was separated from free heparin and BSA 
in the mixture. Sepharose CL 4B beads with a bead diameter of 45 - 165 µm (Pharmacia 
Biotech, UK), were packed slowly to a column height of 84 cm over 24 - 48 h, in a 1 x 
100 cm column (Pharmacia Biotech, UK). Once packed, the column was then washed 
with 3 – 5 bed volumes of 0.25 M ammonium bicarbonate, pH 8.  The flow rate was also 
adjusted to 9 ml/h during the washes. Gel filtration was conducted throughout at 4 °C. 
Coupling mixture, 5 ml, was loaded onto the column and the first 84 fractions, 1.5 ml in 
volume, were collected with the first 20 ml eluate discarded. The protein contents in the 
remaining fractions were estimated using the bicinchoninic assay (BCA) reagent kit 
(Pierce, Europe) in 96 well microtiter plates following the manufacturer’s protocol. 
Standards, 0 - 15 ng amounts of BSA per 20 µl prepared in 0.25 M ammonium 
bicarbonate buffer, pH 8 were included. Absorbance readings at 595 nm were measured 
using the same plate reader described in Section 2.19.1.  
From the protein content profile, leading peak fractions in which the heparin-
BSA conjugate was expected to elute, were analysed on non-reducing 10% 
polyacrylamide gels. Separate gels were then stained for heparin with 0.08% (w/v) Azure 
A and for BSA with 0.25% (w/v) Coomassie blue R250, respectively. Both stains were 
purchased from Sigma-Aldrich, USA. Protocols for these GAG and protein staining 
methods were as published previously by Rider (1997) and Laemli (1970), respectively. 
Fractions containing the heparin-BSA conjugate as indicated by the presence of the 
excluded complex together with low amount of free BSA and moderate amounts of free 
heparin, were pooled and freeze-dried for 48 h. This was then resuspended in 50 mM 
Tris-HCl containing 12.7 mM EDTA buffer, pH 7.4 and its protein content was measured 
against a BSA standard curve in the same buffer as shown in Figure 2.3. The stock 
solution was then reconstituted in this same buffer at 75 ng/µl. Aliquots were then stored 
at -20 °C. A mock-BSA conjugate was previously prepared in our laboratory, in which 
free BSA had been processed using the same method described above. This served as a 





Figure 2.3: BSA standard curve.   
BSA amounts were prepared in 0.25 M ammonium bicarbonate buffer, pH 8 or in 50 
mM Tris-HCl/12.7 mM EDTA buffer, pH 7.4 to determine the protein content of gel 
filtration eluates and for the reconstitution of purified heparin-BSA complex, 
respectively. This was achieved using the bicinchoninic assay (BCA) reagent kit. Each 
point on the curve represents the average of triplicate absorbance readings at 595 nm and 
error bars represent the SEM.   
2.21  Heparin affinity chromatography  
Heparin affinity chromatography of expressed gremlin-Myc culture supernatants 
was carried out at an analytical scale. AF-heparin beads, 200 µl, (HC650M, Tosoh 
Bioscience, Japan) were equilibrated as recommended by the manufacturer in two 
changes of 1 ml PBS-1M NaCl at room temperature for 10 min and then once in 1 ml 
PBS at room temperature for 20 - 30 min. Equilibrated beads were then loaded into a 0 - 
20 µl bevelled filter tip (Starlab Ltd, UK) and a 1 ml syringe barrel (Becton Dickinson 
S.A., Spain) was tightly connected to serve as a reservoir. The loading volume of crude 
gremlin-Myc culture supernatants ranged between 1 – 2 ml depending on the levels of 
gremlin-Myc immunoreactivity each possessed. All applied crude culture supernatants 
were prepared 1:1 in PBS-0.2% (w/v) BSA. The run was conducted at a flow rate of 12 
- 14 ml/h using a pump (Minipuls3, Gilson, UK) and 1 ml eluates were manually 
collected in 1.5 ml microcentrifuge tubes. After loading, the column was washed with a 
minimum of 5 ml PBS-0.2% (w/v) BSA. This was followed by a step NaCl elution 
gradient ranging from 0.2 – 1.0 M NaCl buffers in PBS. Immediately after the run, 125 
µl sample from each eluate was diluted in 25 ml deionised water for conductivity 
measurements. Conductivity readings were measured using a conductivity meter (model 



























generated by similar dilution of known NaCl in PBS buffers, was used to calculate the 
corresponding NaCl concentrations of the eluates. The gradient fractions were dialysed 
against two changes in 0.5 – 1 L PBS; the first overnight at 4 °C and the second for 1 h 
at 4 °C, using dialysis tubing cellulose membrane with 10 mm average flat width (Sigma-
Aldrich, UK). After dialysis, the dialysed samples were squeezed into 1.5 ml 
microcentrifuge tubes and immunoassay of all fraction samples was conducted using the 
Myc-capture gremlin ELISA as described in the Section 2.19.3. 
 
 
Figure 2.4: Conductivity standard curve.  
The standard curve shows the conductivity at shown NaCl concentrations after diluting 
1/200. The line equation is given as y = 0.5697x; where, y is the conductivity value 
measured and x is the NaCl concentration to be determined. 0.18 M NaCl indicates PBS 
molarity. 0 M NaCl indicates molarity of deionised water.  
2.22 Ion-exchange chromatography  
Ion-exchange chromatography of expressed gremlin-Myc culture supernatants 
was conducted as described by Stabile et al. (2007) on sulfopropyl (SP)-Sepharose bead 
columns (Sigma-Aldrich, USA) carrying the side chain -CH2CH2CH2SO3
-. The same 
experimental set-up as described for heparin affinity chromatography was also employed 
in these experiments. In a typical experiment, 400 µl SP-Sepharose beads were 
equilibrated in two changes of 1 ml 50 mM MES (Sigma-Aldrich, USA) solution 
prepared in deionised water buffered to pH 6.5 with 1M NaOH solution (50 mM MES-
NaOH buffer, pH 6.5). The beads were equilibrated at room temperature for 10 min each. 




























mM MES-NaOH buffer, pH 7.5 which also served as wash buffer for the column and as 
elution buffer when prepared with NaCl.  
2.23  SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
Gel electrophoresis was conducted on 15% (w/v) polyacrylamide gels using a 
similar method described by Laemli (1970). This was performed using the Bio-Rad Mini-
Protean III mini-gel system (Bio-Rad, USA).  Resolving gels (15% w/v) consisted of 1.7 
ml deionised water, 3.75 ml bis-acrylamide (30% (w/v)), 1.9 ml resolving buffer 1.5 M 
(1.88 M Tris-base, pH 8.8), 75 µl sodium dodecyl sulphate (SDS; 10% (w/v)), 75 µl 
ammonium persulphate (APS; 10% (w/v)) and 3 µl N,N,N,N-tetramethylethylene-
diamine (TEMED). The stacking gel consisted of 1.45 ml deionised water, 475 µl bis-
acrylamide (30% (w/v)), 625 µl stacking buffer 0.5 M (0.625 M Tris-base, pH 6.8), 
15.75µl APS 10% (w/v) and 3.75µl TEMED. All chemicals were purchased from Sigma-
Aldrich, UK. Where appropriate, experimental samples were prepared under reducing 
and non-reducing conditions in 2x SDS sample buffer with/without 2-mercapto-ethanol, 
respectively. The 2x SDS sample buffer was prepared by diluting in deionised water, a 
5x SDS sample buffer stock constituting, 0.8 ml glycerol (100% v/v), 1.6 ml SDS (10% 
w/v), 1 ml stacking buffer pH 6.8, 4 ml deionised water, 0.2 ml bromophenol blue (5% 
w/v) with/without 0.4 ml 2-mercapto-ethanol. Samples were denatured by boiling for 5 
min. The polymerised gel was placed in an electrophoresis tank accordingly and then 
submerged in running buffer, pH 8.3 containing, 0.025 M Tris-base, 0.19 M glycine and 
10 ml SDS (10% w/v). Samples (15 - 20 µl) were then loaded into gel wells alongside 5 
µl SeeBlue Plus2 pre-stained standard (Invitrogen, UK). Gel electrophoresis was 
conducted at 200 V until suitable migration of bands down the gel.  
2.24  Silver staining of polyacrylamide gels 
Silver staining was conducted following ion-exchange chromatography of 
expressed wildtype gremlin-Myc (refer to Section 2.22) and SDS-polyacrylamide gel 
electrophoresis of fraction eluates as described in the previous section. This was carried 
out using the ProteoSilver silver stain kit (Sigma-Aldrich, USA) following the 
manufacturer’s protocol. An image of the gel was obtained using an hp scanjet 8200 
scanner.   
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2.25  Western blotting and development of blots 
Western blotting was conducted according to the method of Sambrook and co-
workers (1989). A polyacrylamide gel sandwich constituting two sponges (Bio-Rad, 
USA), two Whatman papers (Whatman, UK), a polyacrylamide gel and a nitrocellulose 
membrane (pore size: 0.45µm; Amersham BioSciences, UK) was assembled.  
Electroblotting was conducted using the Bio-Rad Mini Trans-Blot system (Bio-Rad, UK) 
with the Bio-Rad Mini-Protean III gel tank alongside an ice pack. The blotting buffer pH 
7.9 (0.025 M Tris-base, 0.19 M glycine, 1 ml SDS (10% w/v) and 200 ml methanol (20% 
(v/v)) was ran at 100 V. After 1 h blotting, the membrane was washed for 10 min in Tris 
buffered saline (TBS), pH 7.6 (0.02 M Tris-base and 1.37 M NaCl) and then blocked for 
1 h in TBS-5% (w/v) dried skimmed milk powder (Marvel, UK), which had been 
centrifuged at 4472 x g for 10 min using a 50 ml centrifuge tube (Orange Scientific, 
Belgium) and the supernatant decanted into another sterile 50 ml centrifuge tube. Both 
primary and secondary antibodies were prepared in blocking solution to the required 
concentration. The membrane was incubated overnight at 4 °C with the primary antibody 
after which it was washed twice in TBS-0.05% (v/v) Tween20 and once in TBS over 15 
min at room temperature with gentle shaking. The same sequence of washes was repeated 
after incubation of the membrane with the HRP-conjugated secondary antibody at room 
temperature for 1 h. The membrane was then incubated with the substrate, SuperSignal 
West Pico chemiluminescent substrate (Pierce, UK) following the supplier’s protocol. 
The blot was exposed immediately to a Kodak biomax film (Kodak, UK) for 1 min in a 
darkroom. The exposed film was developed using an automatic film processor (Photon 
Imaging System, UK). 
2.26 Gremlin-Myc immunoprecipitation (IP)  
IP experiments of expressed wildtype gremlin-Myc and its mutants in crude 
CHO-S cell culture supernatants were carried out using rabbit polyclonal anti-C-Myc 
agarose affinity beads (Sigma-Aldrich, USA). Equilibration the beads and IP 
experiments were conducted as in the supplier’s protocol. Typically, 50 - 150 µl agarose 
anti-C-Myc beads were equilibrated in two changes of PBS-1M NaCl, pH 7.4 for 10 min 
each, at room temperature under gentle rotation in 2 ml Eppendorf tubes. Between each 
equilibration step, the beads were centrifuged at 68 x g for 60 s and stood at room 
temperature for 2 – 3 min before discarding the supernatant. Next, 1 - 2 ml gremlin-Myc 
culture supernatant was loaded onto the equilibrated beads and incubated overnight at 4 
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°C with gentle rotation. In the case of crude MGR3 culture supernatant, a prolonged bead 
binding step was performed over 48 h at 4 °C with gentle rotation. The gremlin-Myc-
bead complexes were then centrifuged at 68 x g for 60 s and the resulting supernatant 
collected and prepared in reducing 5x SDS sample buffer for Western blotting. Pelleted 
bead complexes were then washed five times in 1 ml PBS and when appropriate with 1 
ml PBS-0.05% (v/v) Tween20, for 5 min each at room temperature with gentle rotation 
followed by a spin as specified above. Reducing SDS sample buffer 2x (50 µl ), (refer to 
Section 2.23) was then added to the pelleted bead complexes, which were stood at room 
temperature for 1 – 2 min and then boiled for 1 min to elute bound gremlin-Myc from 
the bead complexes. The boiled bead complexes were centrifuged as specified above and 
supernatants collected for Western blotting (refer to previous section). Western Blotting 
was performed using 0.4 – 0.8 µg/ml goat polyclonal gremlin primary antibody and 
1:2500 diluted HRP-conjugated rabbit polyclonal anti-goat IgG secondary antibody. 
2.27 IP of BMP-4 on gremlin-Myc-bead complexes  
Anti-Myc beads were loaded with gremlin-Myc, as described in the previous 
section. The bead complexes were then incubated overnight with 500 ng BMP-4 prepared 
in 1 ml PBS-0.1% (w/v) BSA. After bead binding, the IP experiment was conducted as 
described in the previous section after the initial bead binding step. Centrifugation and 
boiling of beads were also conducted as specified in the previous section.  
2.28 Murine C2C12 myoblastic cells: supply and maintenance 
A frozen vial of murine C2C12 myoblastic cells, strain C3H, was kindly provided 
by Dr. John Beechamp, Royal Holloway, University of London. The cells had been 
originally purchased from the American Type Culture Collection (ATCC), USA at low 
passage number. All reagents used for their maintenance unless stated otherwise were 
purchased from Gibco Life Technologies, USA. 
For growth, differentiation and freezing of C2C12 cells, different medium was prepared 
as follows: 
 DMEM-10%FBS growth medium: Dulbecco’s Modified Eagle Medium 
(DMEM; modified with high glucose, GlutaMAX-I, sodium pyruvate and phenol 
red) containing sterile 10% (v/v) fetal bovine serum (FBS).  
 
 DMEM-5% horse serum differentiation medium: DMEM containing 5% (v/v) 




 Freezing medium: 0.5 - 1 ml aliquots of C2C12 cell suspension at cell density 1.0 
x 106 cells/ml containing 10% (v/v) dimethyl sulfoxide (DMSO; Sigma-Aldrich, 
USA). 
Stocks of 100% FBS and horse serum were heat inactivated at 56 °C for 30 min and 
then filtered-sterilised. Aliquots were stored at -20 °C. C2C12 cell suspensions prepared 
in freezing medium were aliquoted into 1.8 ml cryo-vials (Nunc, Denmark). These were 
then frozen overnight to -80 °C at a freezing rate of -1 °C/min by inserting them into an 
extruded polystyrene block. Next day, the frozen vials were transferred into liquid 
nitrogen for long term storage.  
To sub-culture the cells, a liquid nitrogen frozen vial of C2C12 cells was thawed in 
a 37 °C water bath and then transferred to a 50 ml centrifuge tube (Corning Incorporation, 
USA) containing 10 ml pre-warmed growth medium. The cell suspension was 
centrifuged at 250 x g for 5 min and the cell pellet was resuspended in 15 ml fresh pre-
warmed growth medium. This was then plated into a tissue culture flask with 75 square 
cm surface area (T75; Corning incorporation, USA). The flask was cultured in 
humidified atmosphere at 37 °C and 5% CO2 for 2 - 3 days until cells were 70% 
confluent. The cells were then passaged by discarding the spent growth medium and 
washing the adherent cell layer twice in sterile PBS. Cells were then trypsinized by 
applying 800 µl trypsin [prepared by a 1:10 dilution of its 10X stock solution (Gibco Life 
Technologies, USA) in sterile PBS] and standing at room temperature for 3 – 5 min until 
rounding of cells was apparent under the microscope. Pre-warmed growth medium (10 
ml) was then added to quench the trypsinization process. The cell suspension was 
transferred into a 50 ml sterile centrifuge tube and centrifuged at 250 x g for 5 min. The 
cell pellet was resuspended in 5 - 10 ml pre-warmed growth medium and a cell count 
was performed by diluting a sample of cell suspension 2.5:1 in 1% (w/v) nigrosin stain 
prepared in deionised water. After counting, cells were split and plated into new T75 
flasks at 6 - 8 x 104 cells/ml. All sterile tissue culture plasticware was purchased from 
Corning Incorporation, USA. 
2.29 BMP-SMAD1/5/8 phosphorylation assay in C2C12 cell cultures  
In this functional assay, both BMPs -4 and -7 were expected to induce SMAD1/5/8 
phosphorylation in C2C12 myoblastic cells (Kuo et al., 2010). In these assays, the cells 
were plated into wells of a 12 well tissue culture plate at 0.2 x 106 cells/ml cell density 
in pre-warmed differentiation medium (refer to previous section). The plate was cultured 
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overnight in humidified atmosphere at 37 °C and 5% (v/v) CO2 after which, the adhered 
cell layers were treated with varying amounts of BMPs -4 and -7. When appropriate, both 
BMPs -4 and -7 were pre-incubated with different amounts of purified gremlin-His at 
room temperature for 45 – 60 min with gentle rotation. Expressed gremlin-Myc proteins 
in crude culture supernatants were not used in this assay. Both BMPs with/without 
gremlin-His, were prepared at each required amount in pre-warmed differentiation 
medium to a total volume of 0.5 ml. For treatment, the spent medium, 0.5 ml, was 
replaced with the freshly prepared BMP and/or gremlin-His samples.  Treated cells were 
then incubated in humidified atmosphere at 37 °C and 5% (v/v) CO2 for 45 min, after 
which wells were washed twice in sterile PBS. Cell lysis and detachment from well 
surfaces were achieved by adding 200 µl boiling reducing 2x SDS sample buffer into 
each well and then scraping the well surfaces with sterile cell scrapers (Corning 
Incorporation, USA). The lysates were immediately boiled for 5 min, centrifuged at 
12816 x g for 1 min and the supernatants collected for Western blotting. Polyacrylamide 
gel electrophoresis and Western blotting were then conducted as described previously in 
Sections 2.23 and 2.25, respectively except that TBS-5% (w/v) BSA was used as blocker 
and antibody preparation buffer. Typically, when probing the same nitrocellulose 
membrane, phospho-SMAD1/5/8 immuno-detection was conducted first before stripping 
and re-probing for total SMAD1/5/8 immuno-detection. Both primary antibodies used in 
this functional assay are listed below and were detected using the same 1:2500 diluted 
HRP-conjugated goat polyclonal anti-rabbit IgG secondary antibody (Dako, Denmark). 
 Phospho-SMAD1(Ser463/465)/SMAD5(Ser463/465)/SMAD8(Ser426/Ser428)) 
rabbit polyclonal antibody (p-SMAD1/5/8 primary antibody, Cell Signaling 
Technology, USA; working dilution 1:1000).  
 
 SMAD 1/5/8 N-18 (raised against peptide mapping at the N-terminus of human 
SMAD 1) goat polyclonal antibody (SMAD1/5/8 primary antibody, Santa Cruz 
Biotechnology Incorporation, USA; working dilution 1:500). 
2.30 Luciferase reporter assay in C2C12 cell cultures 
2.30.1 Preparation of the 12XSBE-Oc-Luc+-pGL3 construct  
The SMAD1/5/8-specific signalling reporter construct, 12XSBE-Oc-Luc+-pGL3 
(refer to Figure 2.2 for the backbone map) was provided by Dr. Zhao Ming, University 
of Texas Health Science Center, Texas, USA. The insert had been subcloned into the 
pGL3 expression vector constituted of 12 copies of SMAD1 binding element (12XSBE) 
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in front of an osteocalcin (Oc) basal promoter that was also cloned in front of the P. 
pyralis firefly luciferase gene (luc+). These specific modifications would enable cellular 
expression of the luciferase enzyme as a direct response to BMP-SMAD1/5/8 signalling 
(Zhao et al., 2003; Sudo et al., 2004).  
This sequence-verified reporter construct was supplied as a spotting on a marked 
filter paper. This was extracted by soaking the trimmed filter paper in 100 µl elution 
buffer (recipe in Section 2.13.2) in a sterile 1.5 ml Eppendorf tube and stood at room 
temperature for 20 min. Its DNA concentration was then quantitated by NanoDrop 
measurement (refer to Section 2.4). DNA construct (4.8 ng) was then transformed into 
100 µl DH5α competent cells and bacterial colonies were grown on ampicillin-selective 
LB agar plates as described previously in Section 2.12. This was followed by Maxi prep 
purification during which glycerol stocks of the starter culture were also prepared 
accordingly (refer to Sections 2.11 and 2.13.2). The air-dried purified reporter construct 
was resuspended in 300 µl of the same elution buffer above, and stored at -20 °C.           
2.30.2        Transient transfections of C2C12 cells 
Transient transfections of the 12XSBE-Oc-Luc+-pGL3 reporter construct into 
sub-cultured C2C12 cells used either Lipofectamine 2000 or Fugene transfection 
reagents both purchased from Invitrogen Life Technologies, USA and Promega 
Corporation, USA, respectively. The Opti-MEM medium used by both transfection 
protocols was purchased from the former supplier. Transfections were carried out 
according to the manufacturer’s protocol. To achieve the same transfection efficiency 
per plate well, cells were transfected in a single tissue culture flask after which they were 
split into wells of a 24-well tissue culture plate for separate treatments (refer to Section 
2.28). 
2.30.2.1 Lipofectamine 2000 transfection method 
Initially, sub-cultured C2C12 cells were plated into in a T25 tissue culture flask 
at 2 x 105 cells/ml containing 5 ml pre-warmed growth medium (refer to Section 2.28) 
and incubated overnight in humidified atmosphere at 37 °C and 5% (v/v) CO2.  When 
above 90% confluency, the cells were washed once in sterile PBS and fresh pre-warmed 
growth medium replenished. The transfection reagent and reporter DNA construct were 





Lipofectamine 2000 transfection reagent   28 µl 
Pre-warmed Opti-MEM medium    250 µl 
 
12XSBE-Oc-Luc+-pGL3 construct     6 µg 
Pre-warmed Opti-MEM medium    250 µl 
 
Both preparations were mixed together and incubated at room temperature for 10 
min for the formation of DNA-lipid complexes. After incubation, the DNA-lipid 
preparation was added to cells in the T25 flask with fresh growth medium. Cells were 
then incubated overnight in the conditions described above after which, the transfected 
cells were passaged as in Section 2.28.  Cells were plated into wells of a 24-well tissue 
culture plate at 0.7 – 2.0 x 105 cells/well for overnight incubation.  
2.30.2.2 Fugene 6 transfection protocol 
Transient transfections using the Fugene 6 transfection reagent were carried out 
with few changes to the Lipofectamine 2000 transfection method described in the 
previous section. Firstly, transfections were conducted when cells were 70% confluent.  
Secondly, the lipid-DNA complexes were prepared as follows: 
 
Pre-warmed Opti-MEM medium  450 µl       
Fugene 6 transfection reagent   18 µl       
 
These were incubated prior to use at room temperature for 5 min 
 
12XSBE-Oc-Luc+-pGL3 construct  9 µg 
(Added to the above preparation) 
 
Incubate at room temperature for 20 min as above 
 
After incubations, the DNA-lipid preparations were added to the 70% confluent 
cells in a T25 flask each containing 5 ml fresh growth medium. The cells were then 
incubated for 4 h in humidified atmosphere at 37 °C and 5% (v/v) CO2 prior to passaging 
and splitting into wells of 24-well tissue culture plates at 0.7 – 2 x 105 cells/well. The 
cells were adhered to the well surfaces during incubation for 16 h.  
2.30.3 BMP-4 and gremlin treatments of C2C12 cell cultures 
C2C12 cells transiently transfected in 24-well tissue culture plates were washed 
once in sterile PBS. Varying concentrations of BMP-4 in 0.5 ml fresh pre-warmed 
growth medium were loaded into the wells. In inhibition experiments with gremlin, the 
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same final volume was maintained and a fixed concentration of BMP-4 was used. This 
was then pre-incubated with either varying volumes of concentrated gremlin-Myc 
preparations or varying concentrations of purified gremlin-His. Pre-incubations of BMP-
4 and gremlin were carried out at room temperature for 45 – 60 min with gentle rotation 
after which the samples were applied to the wells. The treated cells were then incubated 
for 24 h in humidified atmosphere at 37 °C and 5% (v/v) CO2. 
2.30.4 Measurement of luciferase activity 
After BMP-4/gremlin treatments described in the previous section, the treated 
C2C12 cells were washed twice in sterile PBS. Cells were then lysed by adding 0.2 
ml/well cell culture lysis reagent, CCLR (25 mM Tris-phosphate (pH 7.8), 2 mM 
dithiothreitol (DTT); 2 mM 1,2-diaminocyclohexane-N,N,N´,N´-tetraacetic acid 
(DCTA), 10% (v/v) glycerol, 1% (v/v) Triton X-100) prepared in deionised water from 
its 5x stock solution. This was provided with the Luciferase Assay System purchased 
from Promega Corporation, USA. The plate wells were then scraped and cell lysates were 
transferred into 1.5 ml sterile microcentrifuge tubes and centrifuged at 12816 x g for 30 
s. Supernatants of cell lysates were then collected into sterile 1.5 ml microcentrifuge 
tubes and luciferase activity was measured immediately after.  
The expressed P. pyralis firefly luciferase enzyme that is present in cell lysates 
catalyses the oxidation of luciferin to oxyluciferin ion through a single electron transition 
using ATP•Mg2+ cation and molecular oxygen as co-substrates.  In this transfer of 
chemical energy, photons of light are emitted as oxyluciferin produced in the excited 
state returns to the ground state (Kricka, 1988). In the conventional luciferase assay, the 
intensity of light emitted decreases rapidly over a few seconds. However by 
incorporating coenzyme A (CoA), the kinetics are significantly improved allowing 
greater enzymatic turnover that results ultimately in sustained light intensity that is nearly 
constant for at least 1 min (Fraga et al., 2005). 
Measurement of secreted luciferase activity was carried out in a 96 well plate 
(Nunc Incorporation, Denmark) by adding 100 µl/well of luciferase assay reagent 
luciferin substrate (Promega Corporation, USA) to 30 µl cell lysate supernatants. The 
plate was read immediately in a GloMax 96 microplate luminometer (Promega 
Corporation, USA). Readings were made over an integration time of 10 s with 2 s delay 
in order to obtain readings from a flat portion of the signal curve.  
Initially, the linear range of light detection for the luminometer was determined 
as advised by the manufacturer by plotting a standard curve of relative light unit (RLU) 
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against known doses of purified luciferase enzyme. This QuantiLum recombinant firefly 
luciferase enzyme was also purchased from Promega Corporation, USA and was 
prepared in CCLR lysis buffer supplemented with 1 mg/ml BSA. The standard curve 













































Q u a n t i lu m  r e c o m b in a n t  lu c ife ra s e  ( m o le s )
 
Figure 2.5: Standardizing the Luciferase Assay System.   
Varying amounts of the standard purified enzyme, firefly Quantilum recombinant 
luciferase were prepared in cell culture lysis reagent supplemented with 1 mg/ml BSA. 
30 µl samples were added into wells of a 96 well plate followed by 100 µl/well of 
luciferin substrate. GloMax 96 microplate luminometer set to 10 s integration time with 
2 s delay before and between two read cycles. The first of each paired measurement has 
been plotted.    
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Chapter 3: Cloning of wildtype and mutant GREM1-Myc 
constructs 
3.1 Introduction 
Earlier in this thesis, the prediction of the heparin binding site on gremlin and 
other CAN family members was discussed extensively (refer to Chapter 1). Briefly, at 
the beginning of this study, only the high resolution NMR structure of sclerostin had 
been resolved experimentally by Veverka et al. (2009). In this sclerostin structure, a 
distinct heparin/HS binding site was identified experimentally which raised interest into 
the heparin/HS binding properties of other CAN family members. Based on this 
sclerostin structure, Rider and Mulloy (2010) were able to generate predicted homology 
models for other CAN family members including gremlin. In docking calculations with 
short chain heparin oligosaccharides, they were then able to map a predicted heparin 
binding site on some of these CAN family members; except for DAN and Cerberus which 
were predicted not to bind to heparin/HS. Unfortunately, without accompanying 
supportive experimental evidence, these predictions are uncertain.  
This current study of gremlin would serve as an experimental verification of the 
predictions made by Rider and Mulloy (2010). Present within the primary sequence of 
gremlin are three interspersed basic clusters constituting largely of arginine and lysine 
residues, which they predicted formed its putative heparin binding site. Using strategic 
site-directed mutagenesis, work in this chapter will seek to clone and express various C-
Myc-tagged mutant gremlin proteins incorporating specific substitutions within these 
basic clusters. Equally, a C-Myc-tagged wildtype gremlin protein will be cloned and 
expressed as a more suitable alternative to the only commercially available His-tagged 
gremlin protein. The potential risk of the polyhistidine tag acting as an artefactual heparin 
binding site in gremlin mutants was considered. The goal of this site-directed 
mutagenesis was to express gremlin-Myc mutants with reduced heparin/HS binding 
capabilities. The BMP antagonist activities of such mutants could then be assessed so as 
to investigate the importance of heparin/HS in gremlin activity. An outline of the specific 
objectives met in this chapter is as follows;   
 To design suitable mutants of gremlin within the predicted contact basic clusters 
in wildtype gremlin.  
 
 To clone both wildtype and mutant GREM1 inserts incorporating all targeted 
substitutions.   
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 To subclone all GREM1 inserts into a suitable C-Myc tagging expression vector 
hence generate targeted sequence-verified GREM1-Myc constructs. 
 
 To transfect the sequence-verified GREM-Myc constructs into CHO-S cells.  
3.2 Cloning of the wildtype GREM1 insert 
The initiation of translation involves a scanning mechanism by which small 40 S 
ribosomal subunits bind initially at or near the 5’ terminus of an mRNA, migrating 
linearly and stopping when the first AUG codon is reached. At this point, 60 S ribosomal 
subunits are recruited and peptide bond formation is initiated. Studies by Kozak and 
Shatkin (1978) and Kozak (1980) provided the first experimental evidence in support of 
this hypothesis. This mechanism is relevant as it brings into perspective the possible 
regulatory effects 5’-noncoding sequences may exert on translation. Kozak (1984) 
showed that the sequence context influences the ability of the AUG codon to be 
recognised as initiator codon by eukaryotic ribosomes. By introducing point mutations 
around the translation start site of a clone preproinsulin gene (Kozak, 1984) and by 
compiling the 5’-noncoding sequences from 699 vertebrate mRNAs (Kozak, 1987), an 
optimal sequence for the initiation of translaton was revealed. This was termed as the 
Kozak consensus sequence forming the recognition sequence GCCRCCAUGG, where a 
purine base, R, at -3 is particularly highly conserved amongst vertebrates (refer to Figure 
3.1), (Kozak, 1984 & 1987). The purines at -3 and +4 positions were shown to have 
dominant effects as substituting any or both with a pyrimidine base resulted in 
translational inefficiency and dramatic reduction in translation-dependent protein 
expression (refer to Figure 3.1), (Kozak, 1986 & 2002). Moreover, translation proceeds 
efficiently as long as both of these purines conform thus restating their essential nature 
(Kozak, 2002). Thus, the Kozak consensus sequence will promote a high yield of 
translation-dependent protein expression.  
In most cloning studies that aim to achieve an optimal yield of a specific 
eukaryotic protein, it is now common practice that its genomic sequence in the 
translational start site is made to conform to the Kozak motif. This can be done by 
conforming either entirely or in part at least at the -3 and +4 positions. Given that the aim 
of this current study was to obtain high yields of several C-Myc-tagged gremlin proteins 
in mammalian cell cultures, an assessment of the genomic sequence in the translational 




Figure 3.1: Base substitutions incorporated into the 5’- and 3’-ends of all cloned 
murine GREM1 inserts cloned. 
At the 5’ end, a NotI restriction endonuclease (RE) site was introduced followed by a 
sequence optimized at the -2, -1 and +4 positions to resemble the Kozak consensus 
sequence. At the 3’ end, the introduced XhoI RE site replaced the putative stop codon 
(asterisk). Introduced bases within GREM1 sequence are emboldened and at RE sites, 
are underlined. Alignment of base nucleotides at -3 and +4 positions of the Kozak 
consensus sequence are indicated by the vertical broken lines. Respective polypeptide 
residues (abbreviated) are shown below each codon.  XXXX represents the coding 
sequence of the GREM1 gene. 
 
 
As shown in Figure 3.1, the genomic sequence around the ATG start codon of 
the murine GREM1 clone conforms largely to the Kozak consensus sequence at most 
notably, the -3 position. In a significant base change at +4, an adenine residue was 
replaced by a guanine residue that introduced a negatively charged aspartic amino acid 
residue (D) into the coding sequence (CDS) of the GREM1 gene in place of the polar 
asparagine residue (N).  However, this single polypeptide substitution took place within 
the signal peptide of gremlin predicted to be formed by the first 22-24 coded polypeptide 
residues (Topol et al., 2000a; Katoh and Katoh, 2004). Given that cleavage of the signal 
peptide occurs in the Golgi apparatus during post-translational modifications, it implies 
that this single base substitution in not present in the mature gremlin protein (Hsu et al., 
1998; Topol et al., 2000a). On another hand, despite having a less dominant effect on 
initiation of translation, both purine bases at the -1 and -2 positions were substituted by 
the pyrimidine base, cytosine in order to achieve in greater conformation to the Kozak 
consensus sequence.  The single base nucleotide mismatch observed at the -5 position 
was left unchanged as this GCC codon was shown to matter least in the initiation of 
translation (Kozak, 2002).   
Also as shown in Figure 3.1, the NotI and XhoI RE sites were introduced at both 
ends of all GREM1 inserts enabling sticky end ligation into the multiple cloning site 
(MCS) of the expression vector also possessing both RE sites. This feature was also 
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exploited as a diagnostic marker of successful transformation prior to selecting plasmid 
clones for sequencing. The N-terminally located NotI site (GCGGCCGC) was 
introduced directly upstream and in frame with the optimised Kozak sequence in the 5’ 
untranslated region (UTR) whilst the C-terminally located XhoI site (CTCGAG) 
substituted the putative TAA stop codon normally found at the end of the GREM1 open 
reading frame (ORF). 
Cloning of the GREM1 insert was expected to generate a band fragment, 560 bp 
in size, after purification and trimming by NotI/XhoI double digestion.  Experimentally, 
a band fragment of this size was obtained as illustrated in Figure 3.2A. Topol and co-
workers (1997) identified the GREM1 gene as drm, down-regulated in v-mos-
transformed cells possessing a 552 bp (184 amino acids) ORF and that was located on 
chromosome 15q13 - q154. This finding on drm, now synonymous to GREM1, was also 
confirmed elsewhere (Hsu et al., 1998; McMahon et al., 2000; Topol et al., 2000b). 
Given that the published GREM1 gene size incorporated neither extended Kozak 
sequences in the 5’-UTR nor NotI/XhoI RE sequences, the increase in size to 560 bp was 
expected in this study. 
A gradient PCR was required initially in order to determine an optimal annealing 
temperature to serve the general purpose of cloning. As shown in Figure 3.2B (upper 
panel), a strong amplification of the GREM1 insert (~ 0.6 kb) was observed between 60 
– 68 °C annealing temperature. As a result, an optimal annealing temperature of 60 °C 
was chosen for all subsequent types of PCR reactions employed in this study. Non-
specific bands at 4 and 6 kb were detected in all experimental PCR reactions that were 
too large to be primer dimers. This most likely indicated use of a high concentration of 
the DNA template. The results also demonstrated weak detection of GREM1 inserts in 
the negative control reactions, in which no DNA template had been added (Figure 3.2B, 
bottom panel). This was most likely due to contamination of the control PCR samples. 
When a standard PCR reaction was conducted in which the DNA template was diluted 
1000 fold and more negative control reactions were included in parallel as indicated in 
Figure 3.3, no non-specific bands and contaminations were observed in the experimental 










Figure 3.2: Cloning of the wildtype GREM1 insert.  
A) Schematic representation of the cloning and RE double digestion of the wildtype 
GREM1 insert (560 bp in size). Orange colour: NotI RE site, green colour: optimal 
Kozak sequence, XhoI RE site: brown colour, grey colour: unmodified coding 
sequences. B) Gradient PCR cloning of the wildtype GREM1 insert at increasing 
annealing temperatures (Temp). The insert is shown as ~0.6 kb bands in the top panel. 
The respective negative control reactions are shown in the bottom panel in which no 
GREM1 I.M.A.G.E. cDNA template (1.6 µg/µl) is added. Non-specific bands are also 





                          
Figure 3.3:  Standard PCR amplification of the wildtype GREM1 insert.  
Detection of a GREM1 insert, ~0.6 kb, by standard PCR amplification using 1.6 ng/µl 
(1000 fold diluted). Several negative control reactions are included as indicated. 
3.3 Design of site-directed mutagenesis within the GREM1 insert 
In addition to constructing a C-Myc-tagged wildtype GREM1 construct, this 
study also aimed at constructing several C-Myc-tagged mutant GREM1 constructs 
possessing targeted substitutions in the predicted putative heparin/HS binding site of the 
wildtype. The heparin binding site on a homology model of gremlin based on the 
experimental structure of sclerostin was predicted as detailed in Chapter 1, Section 1.16. 
In gremlin, the alignment of basic surface patches that formed its heparin binding site 
were present within its primary sequence as three interspersed basic clusters that 
constituted largely of arginine and lysine residues. The full primary polypeptide sequence 
of the gremlin precursor highlighting these basic clusters is shown in Figure 3.4A. In this 
study, these basic clusters were termed basic clusters I, II and III as also indicated in 
Figure 3.4A. Basic cluster III forms the largest basic cluster and together with cluster II, 
are located on the third β-stranded finger loop of gremlin (refer Figures 1.13 and 3.4B). 
According to Rider and Mulloy (2010), these two formed the main site of interaction for 
heparin/HS binding. Cluster I is located just outside the first β-stranded loop closest to 
the wrist region (refer to Figures 1.13 and 3.4B).  
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Based on their collective docking calculations, Rider and Mulloy (2010), 
predicted heparin/HS binding for all CAN family members except DAN and Cerberus. 
As mentioned previously in Chapter 1, Section 1.16, both CAN members were observed 
to possess far fewer surface basic residues compared to their heparin binding homologues 
(refer to Figure 1.12). Another difference between heparin-binding CAN members and 
the non-heparin-binding DAN and Cerberus, was apparent after a primary sequence 
alignment of homologous regions possessing basic cluster residues. Remarkably, such 
an alignment made against the precursor gremlin primary sequence revealed that both 
DAN and Cerberus lacked the three basic clusters identified earlier (Figure 3.4B).  
Observations that both DAN and Cerberus lacked the basic contact clusters in 
gremlin were highly relevant for this current study. This enabled strategic substitutions 
to be made within the contact basic clusters in gremlin.  Alanine-scanning mutagenesis 
is a typical strategy used to identify key residues for protein function, by systematic 
alanine substitution of predicted functional residues (Morrison and Weiss, 2001). 
Alanine residues are often deemed suitable as they are non-bulky and nonpolar however, 
because of their small side chain sizes, their use in tandem can result in loss of size 
conservation in the resulting mutant protein (Morrison and Weiss, 2001). Such loss of 
size conservation may ultimately alter the tertiary structure of the protein hence 
damaging it. Moreover, substituting these basic residues on the surface of the protein 
with fairly hydrophobic alanine residues may in itself alter the orientation of tertiary 
structure. Therefore, in order to retain the cysteine partners within the wildtype gremlin-
Myc and its mutants in appropriate orientations and spacing so that the correct disulfide 
bridges are formed, size conservation was important. As such, the identification of 
largely neutral clusters in both DAN and Cerberus homologous to the basic contact 
clusters in gremlin was highly relevant as this could be used preferably with lesser risk 
in misfolding and loss of size conservation (refer to Figure 3.4B). Table 3.1 summarizes 
the designed changes made to the wildtype GREM1 ORF at its contact basic clusters in 

























































































































































































































































As a general rule, a strategy of minimising the number of base nucleotide changes 
was always chosen in order to achieve efficient mutagenesis. As shown in Table 3.1, 
some or all polypeptide sequences of basic clusters I and II, KR (90 – 91) and KPKK 
(145 – 148), would be replaced with their homologous sequences, HW and MPAQ, on 
Cerberus and DAN, respectively (Table 3.1).  
Basic cluster III was subdivided further into clusters IIIa (KKKR, 166 - 169) and 
IIIb (RVKQCR, 172 – 177), (Table 3.1). It followed that two different substitutions were 
designed in the former. In the first, residues 167 – 169 of cluster IIIa would be substituted 
with the homologous polypeptide sequence, IKV, from Cerberus generating the cluster 
KIKV. The basic residue (K-168) would be left unchanged given that it is not amongst 
the predicted basic contact residues in gremlin (refer to Figure 3.4). In a second design, 
the same substituting homologous sequence from Cerberus was modified to LNV, to 
yield the sequence KLNV, instead. In this sequence, both KL residues would introduce 
a HindIII restriction site with recognition sequence AAG CTT (refer to Table 3.1) that 
together with both Not1 and Xho1 RE sites, will serve as diagnostic markers to provide 
an early indication of successful mutagenesis. In this case, K-168 residue was substituted 
despite the above observation. Its substitution with a neutral asparagine residue (N) was 
selected, as this is a polar residue with a neutral side chain whose incorporation would 
require the least number of base nucleotide substitution within this basic cluster (refer to 
Table 3.1).  
The designed polypeptide sequence, LVEQCL, would substitute for the basic 
cluster IIIb polypeptide sequence, RVKQCR (172 – 177). This was made to resemble 
the homologous polypeptide sequence, LVEECQCK and LVEKILHCS, in Cerberus and 
DAN, respectively (refer to Figure 3.4B and Table 3.1). The substitution of R-177 with 
a nonpolar leucine residue possessing a neutral side chain, was again for reasons of 
minimal base nucleotide substitution (refer to Table 3.1).  
3.4 PCR-based methods used for site-directed mutagenesis 
In order to clone specific GREM1 mutant inserts possessing basic contact residue 
substitutions, different PCR cloning methods were employed. A brief description of these 
PCR cloning methods will be provided. 
  In standard PCR, the ability of oligodeoxyribonucleotide (oligo) primers to bind 
tightly onto their complementary sequences on the target gene allows mismatch 
nucleotides to be incorporated into the cloned DNA fragment. It is this ability which 
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enabled the incorporation of both terminal NotI and XhoI RE sites together with 
optimized Kozak sequence within the GREM1 nucleotide sequence, as illustrated earlier 
in Figure 3.2A. However, a major drawback of standard PCR itself is that oligo primers 
longer than 110 nucleotides are difficult to produce (Wosnick et al., 1987). These result 
in standard PCR being able to introduce mismatch nucleotides at the initial sites 
complementary between the target gene and the pair of oligo primers. Internal changes 
to target gene beyond these sites are not possible in a single reaction. Given that several 
designed substitutions in the gremlin basic clusters were internally located, alternative 
PCR-based methods were required. In this study, both overlap extension (OE) PCR and 
one-step OE (OOE) PCR, were employed, which both enable internal mutations to be 
incorporated anywhere along the length of the target gene (Higuchi et al.,  1988; Ho et 
al., 1989; Ke and Madison, 1997, Urban et al., 1997).  
As illustrated in Figure 3.5, OE PCR requires several rounds of PCR to generate 
intermediate DNA fragments that have ends overlapping each other. These are generated 
using one or several pairs of complementary mutagenic internal oligo primers together 
with standard PCR pair of non-complementary outer oligo primers. In a subsequent 
“fusion” reaction, the overlapping intermediate DNA fragments, are mixed at equimolar 
ratios and standard PCR conducted using only the outer oligo primers. As a result, the 
full target insert is generated.   
On the other hand, in a OOE PCR reaction, as illustrated in Figure 3.6, all 
appropriate pairs of complementary internal mutagenic and standard PCR outer oligo 
primers are added together. Both OOE PCR and OE PCR proceed via the same 
mechanism, although the former does not require the physical processing and purification 
of intermediate DNA fragments generated. As a result, OOE PCR is a more rapid and 
less laborious alternative to OE PCR. In the published protocol by Urban and co-workers 
(1997), reduced concentrations of internal mutagenic primers were used that ensured they 
were fully consumed during the early cycles. Thus, only the newly formed template and 
outer oligo primers were left behind during the late cycles for further extension of the 
full length target gene (refer to Figure 3.6). In this current study however, the 

































































































































































































































































































































































































































































































































































































































          
 
Figure 3.6: Schematic diagram of the one-step overlap extension PCR (OOE PCR). 
This method essentially involves a single standard PCR reaction in which two or more 
complementary pairs of internal mutagenic primers (b and c and their respective reverse 
primers b’ and c’) are used together with a non-complementary pair of outer oligo 
primers (universal/a and dx) to clone a mutant GREM1 insert. Symbols and annotations 
are described in the legend of the previous figure.  
3.5 Application of PCR-based methods in cloning of mutant GREM1 inserts 
In addition to the wildtype GREM1 insert, a total of seven different mutant 
GREM1 constructs were cloned by applying the different PCR-based methods described 
in the previous section. These included: mutant gremlin (MGR)1, MGR2, MGR1+2, 
MGR3, MGR4, MGR4 and MGR6, all numbered in the order they were expressed except 
for MGR1+2. These names were also applied to their respective expressed proteins. The 
MGR1+2 insert was not successfully expressed in this study but incorporated both MGRs 
1 and 2 mutations. As shown in Table 3.2, only both MGRs1 and 2 inserts possessed 
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individual mutations of basic clusters II and III, respectively. The remaining inserts each 
possessed combined mutations of either basic clusters I or III together with the basic 
cluster II mutations.   
 
 
Mutant GREM1 inserts 
cloned 
 




























I + II 
 
Table 3.2: List of all GREM1 mutant inserts cloned.  
The table provides a list of all mutant GREM1 inserts cloned together with the respective 
targeted contact basic cluster they were each made to possess.   
 
 
During cloning of GREM1 inserts, the same universal forward oligo primer was 
always employed (Figures 3.5 and 3.6).  This incorporated, at all their 5’ termini, both 
NotI RE site in frame with the optimized Kozak sequence (refer to Figures 3.1 and 3.2A). 
The outer reverse oligo primer that could be made either non-mutagenic or mutagenic, 
always incorporated a XhoI RE site at the C-terminal ends of the GREM1 inserts (refer 
to Figures 3.1 and 3.2A). The application of standard PCR, OE and OOE PCR methods 
in cloning GREM1 inserts are summarised in Tables 3.3 – 3.5 respectively.  
By standard PCR, the wildtype, MGRs 2 – 5 and MGR1+2 inserts were generated 
using the universal forward oligo primer paired with either a non-mutagenic (d1) or 
mutagenic (d2-5) reverse oligo primers (Table 3.3). The mutant inserts, MGRs 1+2, 5 and 
6 were generated by OE PCR and in addition, MGRs 1, 1+2 and 6 were generated by 
OOE PCR. In both of these methods, one or two pairs of complementary mutagenic 
internal oligo primers, annotated b and c (refer to Tables 3.4 and 3.5, Figures 3.5 and 
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3.6), were used together with a pair of complementary outer oligo primers listed in Table 
3.3.  
  By both standard and OOE PCR methods, a wildtype or mutant GREM1 insert, 
560 bp in size, was typically generated as shown previously in Figure 3.2. On the other 
hand, the DNA intermediates generated when cloning the MGRs 1+2, 5 and 6 inserts by 
OE PCR method, were as shown in Figure 3.7.  These were generated prior to the final 
fusion reaction that yielded the full mutant inserts, ~0.6 kb in size.  
Note that all bands produced correspond in size to their anticipated lengths. In 
cloning of the MGR1+2 insert, two intermediate GREM1 DNA fragments, ~ 440 bp and 
~ 120 bp, were generated using a sequence-verified wildtype GREM1-Myc construct as 
template (Figure 3.7A).The larger DNA was generated using the outer forward universal 
oligo primer and a reverse mutagenic oligo primer, c’, which mutagenized the basic 
cluster II (refer to Figure 3.5 and Table 3.4). The ~ 120 bp DNA fragment was generated 
possessing mutations in basic cluster III by the non-complementary pair of mutagenic 
oligo primers, c and d2 (refer to Table 3.4). The same result was also achieved during 
similar cloning of the MGR5 insert (Figure 3.7A). In this case, the same combination of 
oligo primers was also utilised except that the d5 reverse mutagenic outer oligo primer 
was used instead of the d2 reverse oligo primer (refer to Table 3.4).  
In cloning the MGR6 insert, three intermediate DNA fragments were generated 
of approximate sizes 280 bp, 160 bp and 120 bp as shown in Figure 3.7B. Using the same 
template as above, the fragments were generated using three non-complementary pairs 
of oligo primers that included the universal forward and b’ , b and c’, and, c and d1, 
respectively. The internal oligo primers used here were mutagenic which resulted in the 
combined mutagenesis of both basic clusters I and II only (refer to Figure 3.5 and Table 
3.4). When using a sequence-verified MGR1 DNA plasmid as template instead, already 
possessing in it targeted mutations to basic cluster II, two intermediate DNA fragments 
of equal size, 280 bp, were generated (Figure 3.7C). This required use of one less non-
complementary pair of oligo primers that included, the universal forward with b’ and b 












[Corresponding polypeptide sequence] 
                             








































































































Table 3.3: List of primers and GREM1 mutant inserts cloned by standard PCR method.  
Provided are the sequences of oligo primers used for site-directed mutagenesis by standard PCR 
method. The templates used in this method are also provided.  The NotI, HindIII and XhoI RE 
sites and optimal Kozak sequence are highlighted in purple, brown, blue and green colours, 
respectively. The polypeptide sequences of the base nucleotide sequences provided are enclosed 
in brackets.  The substituted wildtype basic clusters are underlined in the polypeptide sequences. 
Optimal template concentrations for wildtype GREM1-Myc (wtGREM1myc) and GREM1 
I.M.A.G.E. cDNA templates = 1.6ng/µl, MGR1-Myc template = 380ng/µl and 10µM working 














[Corresponding polypeptide sequence] 
                             


































































































Table 3.4: List of primers and GREM1 mutant inserts cloned by OE PCR-based method.  
Provided are the sequences of oligo primers used for site-directed mutagenesis by OE PCR 
method. The templates that enabled application of this method are also provided.  Refer to the 





Figure 3.7: Intermediate DNA fragments of GREM1 mutant inserts generated using OE 
PCR. 
 A) Cloning of MGR1+2 and MGR5 mutant inserts using the wildtype GREM1 DNA plasmid as 
template. In both cases, two intermediate DNA fragments, 440 bp and 120 bp in size were 
generated in experimental lanes (Lanes 1 and 2). B) MGR6 cloning using the wildtype GREM1 
DNA plasmid as template generated three intermediate DNA fragments, 280 bp, 160 bp and 120 
bp, in the experimental lanes (Lanes 1, 2 and 3). C) MGR6 cloning using the MGR1-Myc DNA 
plasmid as template generated two intermediate DNA fragments of equal size, 280 bp in 
experimental lanes (Lanes 1 and 2). All control reactions (Lanes 1c, 2c and 3c) did not have the 
templates added to them, and some contamination is observed. Note that the indicated band sizes 
























[Corresponding polypeptide sequence] 
                             























































































     
Table 3.5: List of primers and GREM1 mutant inserts cloned by OOE PCR method.  
Provided are the sequences of oligo primers used for site-directed mutagenesis by OOE PCR 
method. The templates that enabled application of this method are also provided.  Colour 
highlights and both template and oligo primer concentrations are provided in the legend of Table 













3.6 Subcloning the GREM1 inserts into the pCMV-Tag5A expression vector 
3.6.1 The pCMV-Tag5A expression vector 
The next stage of the cloning process involved subcloning previously constructed 
wildtype and its mutant GREM1 inserts into a pCMV-Tag5A mammalian expression 
vector via sticky-end ligation at the NotI and XhoI RE cleavage sites they all incorporate 
(Figure 3.8). This subcloning strategy ensured that MCS of the expression vector 
remained in frame with its C-Myc sequence and stop codon (refer to Figure 3.8). As such, 
this would enable C-terminal tagging of all subcloned GREM1 inserts with a Myc 
sequence.  The three different MCS frames of this expression vector were described 
previously in Chapter 2, Section 2.9.1. In addition to possessing an adaptable MCS, this 
expression vector also possessed essential features as shown in Figure 3.8.   
A cytomegalovirus (CMV) immediate-early enhancer containing promoter, 
pCMV promoter, found directly upstream of the MCS, drives strong expression of the 
subcloned GREM1 gene in CHO-S expression systems (Stinski and Isomura, 2008). A 
Simian virus 40 (SV40) early promoter controls expression of both neomycin and 
kanamycin resistance genes that in this study, conferred kanamycin resistance to all 
positive integrative transformants (Gazdar et al., 2002; Liu et al., 2013). Another 
promoter, the blasticidin promoter, directly upstream the SV40 promoter, drives strong 
expression of blasticidin deaminase gene that confers resistance to blasticidin. 
Blasticidin is a nucleoside antibiotic which inhibits protein synthesis in both prokaryotes 
and eukaryotes (Kimura et al., 1994; Mamoun et al., 1999; Goyard and Beverley, 2000). 
Although this feature was not exploited in this study, this promoter would have offered 
another screening option post-transfection for the isolation of positive integrative 
transfectants in blasticidin selective medium.  
The expression vector also carried two origins of replication (ori), pUC ori and 
f1 ori, at which sites replication was initiated during the transformation of DH5α and 
TOP10 competent cells. The pUC ori enables high copy number replication of GREM1-
Myc single-stranded DNA (ssDNA) constructs while the f1 ori acts similarly however in 
the reverse orientation to the pUC ori. Given that both ssDNA constructs are 
complementary, it meant that only double-stranded GREM1-Myc constructs were 
always generated for eukaryotic expression systems (Dotto and Horiuchi, 1981; Dotto et 
al., 1981; Dente et al., 1983).  
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Two polyadenylation (pA) signals, SV40 pA and the Herpes simplex virus 
thymidine kinase (TK) pA, were also present in the expression vector. These both trigger 
the termination of transcription by RNA polymerase II resulting in cleavage of the 
GREM1 pre-mRNA (Huang and Workman, 2013; MacDonald and McMahon, 2010).  
 
Figure 3.8: Plasmid map of the pCMV-Tag5A expression vector.  
The pCMV-Tag5A vector possesses a multiple cloning site (MCS, light blue colour) 
which is in frame with a Myc sequence (dark blue colour) that in turn is in frame with a 
stop codon at its C-terminal end (red colour). Subcloning of GREM1 inserts into the 
MCS (light blue colour) occurs at their mutual NotI and XhoI RE cleavage sites. Other 
features of the vector include; P CMV: cytomegalovirus promoter, SV40 pA: Simian 
virus 40 polyadenylation signal, f1 ori: f1 origin, P bla: blasticidin promoter, P SV40: 
SV40 promoter, neo/kan: neomycin/kanamycin resistance gene, TK pA: thymidine 
kinase pA, pUC ori: pUC origin of replication. Coloured arrows indicate direction of 
transcription.  
3.6.2 Preparing the pCMV-Tag5A expression vector 
Alkaline phosphatases are non-specific phosphomonoesterases that catalyse the 
hydrolysis of a wide variety of phosphate monoesters and small organic molecules such 
as DNA and RNA (Nilsen et al., 2001; de Backer et al., 2002). By dephosphorylating 
the ends of an empty linearized expression vector prior to ligation, vector-vector re-
ligation would be prevented. This stated benefit of SAP treatment however has remained 
questionable mainly due to the non-specificity of the enzyme itself. As such, at the initial 
phase of this current study, the empty expression vector was linearized by NotI and XhoI 
double digestion and then treated with/without thermolabile shrimp alkaline phosphatase 
(SAP) in parallel.   
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As shown in Figure 3.9, the SAP-treated vector migrated only slightly further 
down the gel with approximately the same size, between 4 - 5 kb, as the untreated vector. 
Given that SAP treatments had no marked adverse effects on both transformations and 
transient transfections, the SAP-treated vector was used hereafter.  
       
Figure 3.9: Thermolabile SAP treatment of the pCMV-Tag5A expression vector.  
Bands of approximately the same size and intensity were detected following -/+ SAP 
treatment of an empty pCMV-Tag5A vector after its double digestion with NotI/XhoI 
RE enzymes.  
3.7 Screening of bacterial transformants 
3.7.1 Preliminary screening by restriction endonuclease digestion  
To recapitulate, all GREM1 inserts possessed end-to-end NotI and XhoI RE 
cleavage sites and in addition, three inserts, MGRs 1+2, 2 and 3, also possessed a HindIII 
RE site within their basic cluster IIIa (refer to Sections 3.2 and 3.3). Together, these RE 
cleavage sites provided a rapid diagnostic tool for the preliminary screening of positive 
integrative transformants prior to sequencing. 
As shown in Figure 3.10A, NotI and XhoI double digestions in positive 
integrative transformants, reproducibly showed two bands, ~ 4 kb and ~ 0.6 kb, 
corresponding to the approximate sizes of the expression vector (4.3 kb) and all GREM1 
inserts (0.56 kb), respectively. In single digestions using either NotI or XhoI enzymes, a 
single band of ~ 5 kb is seen. In the uncut DNA plasmid, two bands are consistently seen 
of variable sizes. These diagnostic features were characteristic for all positive integrative 
transformants and indicated that a DNA fragment with the approximate size of the 
GREM1 insert had been subcloned successfully within MCS of the pCMV-Tag5A 
expression vector. It also indicated that no random mutations had occurred at both 
targeted RE sites. Only sequencing could reveal conclusive evidence of successful 





Figure 3.10: Preliminary screening by restriction endonuclease (RE) digestion. 
Purified DNA construct from positive integrative transformants were both single and 
double digested with A) NotI and XhoI RE enzymes. This diagnostic test was applicable 
to all GREM1 constructs (B) NotI and HindIII RE enzymes. This test was only applicable 
to MGR2 (shown) and MGR3 constructs both incorporating HindIII RE sites at the C-
terminal end of their GREM1 inserts close to the XhoI RE site. 
 
 
In positive integrative transformants expected to possess the additional HindIII 
RE site, similar results to those described using NotI/XhoI RE, were obtained after 
NotI/HindIII double digestions (Figure 3.10B). This was not surprising as the HindIII 
site was located close to the XhoI site at the C-terminal end of the GREM1 insert. 
Nonetheless, this alternative NotI/HindIII diagnostic approach was more informative as 
it indicated successful incorporation of the HindIII site within of basic cluster IIIa of 
these GREM1 mutant inserts. As shown in Figure 3.10B, this alternative screening 
approach was made even more informative when conducted alongside a similar double 
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digestion of the wildtype GREM1-Myc plasmid that lacks a HindIII cleavage site. Of the 
three candidate GREM1 inserts only the MGR1+2 constructs consistently failed to 
demonstrate two bands typical of such double digestion as mentioned above. Therefore 
only the MGRs 2 and 3-Myc constructs were sequenced (refer to Figure 3.11).  
As it carried the largest number of mutations, it was always expected that the 
MGR1+2 construct would be the most difficult to clone gremlin mutant. Despite using 
different PCR cloning strategies, altering the ligation ratios, and the amounts of ligated 
DNA transformed into both DH5α and TOP10 competent cells, the same outcome was 
consistently obtained. Consequently, cloning of the MGR1+2-Myc construct was aborted 
and the other six out of seven mutant GREM1-Myc constructs were sequenced. 
3.7.2 Sequencing of GREM1-Myc constructs 
As shown in Figure 3.11, sequence analyses was performed on six out of seven 
GREM1-Myc mutant constructs after preliminary screening mentioned in the previous 
section. Part of the wildtype GREM1-Myc sequence is also included. As revealed, all 
designed substitutions within wildtype basic clusters I – III were successfully completed 
in the MGRs 1 – 6 mutant GREM1-Myc constructs (refer to Sections 3.3 and Figure 
3.11). In MGR1, substitution of 3/3 contact basic residues within basic cluster II was 
achieved. In MGR2, substitution of 5/5 contact basic residues including one non-contact 
lysine residue was achieved within basic cluster III. MGRs 3 - 5 all carried the same 
substitutions in the MGR1 substitution combined with partial substitutions of basic 
cluster III (refer to Figure 3.11). In combination, MGR3 possessed the same substitutions 
as those within the basic cluster IIIa of MGR2 whereas MGR4 possessed 1 out of 2 (1/2) 
substitutions of the same basic cluster including one substitutions of a non-contact lysine 
residue. Furthermore, MGR5 in addition to MGR1 substitutions, possessed the same 3/3 
substitutions of contact basic residues within the basic cluster IIIb. On the other hand, 
MGR6 possessed combined MGR1 substitutions together with 2/2 substitutions of 
contact basic residues in basic cluster I (refer to Figure 3.11).  
Moreover, all incorporated RE sites and optimized Kozak sequence were also 
verified (not highlighted in Figure 3.11). More importantly, the C-terminal Myc sequence 
followed by the stop codon were correctly incorporated in both wildtype and mutant 
GREM1 constructs.  This confirmed that only C-Myc-tagged gremlin proteins would be 




  Listed in Table 3.6 are the total yields of these GREM1-Myc constructs as 
obtained after extraction from positive integrative transformants and Maxi prep 
purification. Also provided are the underlying PCR-based methods that were used 
initially for the cloning of their GREM1 inserts. Altogether, these results demonstrate 
that using different PCR-based methods to that of wildtype GREM1-Myc construct did 
not affected the total yields of its mutant constructs. No direct analyses were made in this 
study comparing their efficiencies. 
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Table 3.6: Effects of using different PCR-based strategies on the DNA yields of all 
GREM1-Myc constructs.  
DNA yields as obtained after extraction and Maxi prep purification of both wildtype and 
mutant GREM1-Myc constructs from a single positive integrative transformant for each. 
















All aims set at the start of these cloning studies were achieved as described in this 
chapter. Initially, a C-Myc-tagged wildtype GREM1-Myc construct was cloned as an 
alternative to the commercially purified His-tagged wildtype gremlin. This was achieved 
primarily by subcloning the wildtype GREM1 insert into the MCS of the pCMV-Tag5A 
expression vector which was then transformed in competent DH5α E. coli cells. 
Following its sequence verification, the Maxi prep purified wildtype GREM1-Myc 
construct was then transiently transfected in the CHO-S eukaryotic cell line. The 
expressed wildtype gremlin-Myc protein was then harvested in crude cell culture 
supernatants for immunoassay (next chapter).   
The wildtype GREM1 insert was cloned from an I.M.A.G.E. clone of murine 
gremlin using standard PCR. Like all mutant GREM1 inserts cloned, it possessed a NotI 
RE cleavage site in frame with an optimized Kozak sequence at its N-terminal end and a 
XhoI RE cleavage site at the C-terminal end which replaced the putative stop codon. By 
substituting this putative stop codon by this mutual XhoI RE site, C-terminal tagging of 
the GREM1 insert with the Myc sequence in the expression vector was made possible. 
A typical GREM1 insert, migrated on 1% (w/v) agarose gels as a PCR band fragment, 
approximately 0.6 kb in size. Both RE cleavage sites were introduced to facilitate 
subcloning of the GREM1 insert into the MCS of the pCMV-Tag5A expression vector 
that also possess them. The optimized Kozak sequence that substituted genomic 
sequences around the translation start codon has been shown to increase strongly, 
translation efficiency, thus enabling optimal yield in terms of eukaryotic levels of protein 
expression (Kozak, 1984 & 1987). Given that these findings have been extensively 
verified in several studies, no further direct investigations into the Kozak consensus were 
made in this current study. 
By conforming to the Kozak consensus sequence, a single amino acid substitution 
was made at the N-terminal region of all GREM1 inserts immediately after the 
methionine start amino acid residue. This was caused by a single base nucleotide change 
in the GREM1 genomic sequence so as to conform to the +4 position of the Kozak 
consensus sequence. Findings by Kozak in 1986 and 2002 showed that the purine bases 
at the -3 and +4 positions within the Kozak consensus sequence have the most dominant 
effect in promoting proper initiation of translation. It was observed that only a guanine 
base at the +4 position carried this dominant effect on the initiation of translation unlike 
the -3 position where either purine bases were suitable candidates. By conforming to 
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these findings, the adenine base found at the +4 position in the genomic sequence of the 
GREM1 gene was substituted by a guanine base. This in turn caused a single amino acid 
substitution of an asparagine residue (N) to an aspartate residue (D) immediately after 
the methionine translation start amino acid residue. Fortunately, this polypeptide 
substitution occurred in the predicted signal peptide region which encompasses the first 
22 - 24 polypeptide residues in polypeptide sequence of gremlin precursor protein (Katoh 
and Katoh, 2004; Topol et al., 2000a). Cleavage of the signal peptide is reported to occur 
during post-translational modifications in the Golgi apparatus (Hsu et al., 1998; Topol 
et al., 2000a). Therefore, it was highly unlikely that this single polypeptide substitution 
would cause change to the tertiary structure of mature wildtype and mutant gremlin 
proteins.   
Having successfully cloned the wildtype GREM1-Myc construct, the next aim 
achieved was generating mutant GREM1-Myc constructs possessing specific mutations 
within the three predicted basic clusters that form the heparin binding site on the 
wildtype. These mutants would serve as an experimental verification to the predictions 
made by Rider and Mulloy (2010) on the heparin binding site on homology models of 
CAN family members. These homology models were based on the high resolution NMR 
structure of sclerostin resolved by Veverka et al. (2009). Within the gremlin primary 
sequence, three basic clusters annotated as basic clusters I – III, were identified and 
constituted largely of arginine and lysine contact residues. In this study, the experimental 
verification of these predictions were achieved using site-directed mutagenesis. Here, 
both basic contact and non-contact residues within the basic clusters in gremlin were 
strategically substituted with mostly, polar and nonpolar residues from homologous 
regions of DAN and Cerberus. This was designed based on the predictions made by Rider 
and Mulloy (2010), that DAN and Cerberus would not bind to heparin. By adopting such 
strategic approach to site-directed mutagenesis, the hope was to express several mutant 
gremlin-Myc proteins possessing reduced binding for heparin/HS yet still conserved in 
size compared to the wildtype. Also, this approach increased the likelihood that the 
gremlin-Myc mutants would remain functionally active as judged by their ability to 
inhibit BMP signalling activities, in vitro.  
  In this study, seven GREM1 inserts, MGRs 1+2, 1 – 6, were cloned and six out 
of seven sequence-verified GREM1-Myc constructs, MGRs 1 – 6, were successfully 
obtained for expression in CHO-S cell culture. MGR1 and MGR2, both carried 
individual substitutions of basic clusters II and III, respectively. The remaining 
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constructs were hybrid constructs of MGR1 possessing its substitutions itself combined 
with substitutions of basic cluster IIIa (MGRs 3 and 4), IIIb (MGR5) and I (MGR6). The 
incorporation of MGR1 substitutions in all these mutant GREM1-Myc constructs was 
based on results obtained at earlier MGRs 1 and 2 cloning cycles, expressions and 
assessment of their heparin binding capabilities. These results are discussed in the next 
chapter.  
In this next round of hybrid mutant constructions, the substitutions within the 
basic cluster III were carried out in part; either in combination with basic clusters IIIa or 
IIIb. These were designed as it was expected that cloning of the MGR1+2-Myc construct 
possessing both full basic cluster substitutions would be difficult.  
Oligonucleotide-based site-directed mutagenesis involved use of three different 
PCR-based methods that included, standard, overlap extension (OE) and one-step 
overlap extension (OOE) PCRs (Mullis et al., 1986; Higuchi et al., 1988; Urban et al., 
1997). In this current work, the diverse alternative cloning routes that these PCR-based 
methods provided, achieved the same GREM1 inserts. OE and OOE PCRs were both 
effective in tackling difficult to clone inserts such as MGR1+2 and MGR6. MGR6 was 
a difficult to clone insert, because both targeted contact residues in basic clusters I and II 
were internal and also far apart from each other. Their complementary sites could not be 
reached by the short-length outer mutagenic oligo primers. In this work, sufficient DNA 
yields of purified GREM1-Myc mutant constructs were obtained irrespective of the 
underlying PCR-based methods used at initial stages of the process. This indicated that 
all three methods are effective. It is important to stress that this work did not seek to 
directly compare between these PCR-based methods. As such, no investigation was made 
into their efficiencies.   
In this study, no direct comparison was made into transformation and transfection 
efficiency between SAP-treated and -untreated empty pCMV-Tag5A expression vector. 
However, it is possible to at least comment on its apparent effects in these processes. No 
marked difference in the number of single colony transformants was apparent in parallel 
transformations of DH5α cells with both wildtype GREM1- pCMV-Tag5A+/-SAP 
constructs. Moreover, no marked difference in gremlin-Myc immunoreactivity was 
detected in crude CHO-S culture supernatants using Myc-capture gremlin ELISAs 
following parallel transfections with the above constructs (as will be discussed in Chapter 
4). Therefore, this study takes a neutral standpoint on the beneficial use of SAP in 
molecular cloning.   
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In the previous chapter, the cloning of six C-Myc-tagged mutant gremlin 
constructs, MGRs 1 – 6, alongside the C-Myc-tagged wildtype was discussed. Both 
MGRs 1 and 2 incorporated individual basic residue substitutions of basic clusters II 
and III, respectively. MGRs 3 – 6 were hybrid mutants of MGR1, all incorporating the 
MGR1 substitutions combined with partial substitutions of either basic clusters I or III. 
The expression of these gremlin-Myc proteins in CHO-S cells and their analysis will be 
discussed in this chapter. The aim was to generate functional gremlin-Myc mutants 
which possessed significantly reduced heparin binding activity.  
The hypothesis tested herein is that postulating the existence of a specific 
heparin binding site on gremlin which consists largely of arginine and lysine residues. 
An outline of the specific objectives met in this chapter is listed as follows: 
 
 To confirm expression of gremlin-Myc proteins in crude CHO-S cell culture 
supernatants. 
 
 To compare the heparin binding capabilities of expressed gremlin-Myc against 
purified gremlin-His.  
 
 To assess the heparin binding capabilities of expressed gremlin-Myc mutants 
against that of wildtype gremlin-Myc.  
 
 To identify gremlin-Myc mutants with weakest heparin binding affinity for use 
alongside the wildtype in functional studies next. 
 
 To investigate whether binding of all expressed gremlin-Myc proteins to 
heparin is specific.    
 
4.2 Gremlin detection in crude gremlin-Myc culture supernatants 
 
Initially detection of gremlin-Myc immunoreactivity in the expressed CHO-S 
cell culture supernatants was attempted using a Myc-capture gremlin ELISA (refer to 
Section 2.19.3). In this immunoassay, expressed gremlin proteins are captured via their 
C-terminal Myc tag on the surfaces of the wells of a 96-well plate coated with the 9E10 
Myc capture antibody. A polyclonal biotinylated gremlin detecting antibody and 
streptavidin-conjugated alkaline phosphatase enzyme complete the sandwich. As such 
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this immunoassay confirms the co-expression of both gremlin and the C-Myc epitopes 
within the same protein.  
In results as shown in Figure 4.1, gremlin-Myc immunoreactivity was detected 
at varying levels amongst the different crude gremlin-Myc culture supernatants. 
Wildtype gremlin-Myc and MGRs 4 – 6 displayed the highest gremlin-Myc 
immunoreactivities, with the gremlin-Myc immunoreactivity in MGR1 also high.  Both 
MGRs 2 and 3 demonstrated very weak gremlin-Myc immunoreactivities although 
these were significantly higher than the background immunoreactivity generated by the 
EGFP crude culture supernatant. These very weak gremlin-Myc immunoreactivities of 
both MGRs 2 and 3 may have reflected underlying damage to their gremlin epitopes 
during their cloning, thus, though they might have been expressed at high levels, being 
misfolded rendered their gremlin epitopes inaccessible to the gremlin antibody. 
Another possible explanation could have been that both these mutant GREM1-Myc 
constructs are not particularly well expressed by the CHO-S cells themselves.  
In Figure 4.2, the semi-quantitative nature of the Myc-capture gremlin ELISA 
was displayed using crude wildtype and MGRs 3, 5 and 6 culture supernatants. By 
comparing the slopes, both crude wildtype and MGR5 culture supernatants 
demonstrated the highest and approximately equal gremlin-Myc immunoreactivities. 
Compared to these, gremlin-Myc immunoreactivities generated in crude MGRs 3 and 6 
were approximately several tens of fold lower and half fold lower, respectively (refer to 
Figure 4.2). These results partly correlated with those shown in Figure 4.1 in that both 
wildtype and MGR5 exhibited highest gremlin-Myc immunoreactivity followed by 
MGR6 and then MGR3. The marked difference in gremlin-Myc immunoreactivities 
between MGR6 and both wildtype and MGR5 was not so apparent due to saturation 
and flattening of the absorbance readings between 2 – 2.5 units (refer to Figure 4.1). 
This had been done in order to enable detection of gremlin-Myc immunoreactivity in 
crude MGRs 2 and 3 culture supernatants as all were immunoassayed on the same 96-
well plate. 
Given that the aim of this study was to compare the heparin-binding properties 
of the gremlin-Myc mutants to that of the wildtype, and later to compare their 
functional activity, it was essential to equalise their gremlin-Myc immunoreactivities 
beforehand. As shown in Figure 4.3, this was achieved by a dilution of their crude 
culture supernatants, on a trial and error basis, using the Myc-capture gremlin ELISA. 
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Equalisations were made against the least immunoreactive culture supernatant of either 
MGR2 or MGR3.  
 
       
 
Figure 4.1: Myc-capture gremlin ELISA of crude gremlin-Myc CHO-S culture 
supernatants.  
Gremlin-Myc immunoreactivity was detected in the crude CHO-S cell culture 
supernatants of expressed gremlin-Myc proteins and EGFP protein, serving as a 
negative control. The latter served as a negative control generating the background 
immunoreactivity in the assay. 100 µl/well crude supernatants were captured using 2 
µg/ml 9E10 anti-Myc capture antibody and detected using a polyclonal biotinylated 
murine gremlin antibody at 0.8 µg/ml. Error bars represent SEM of quadruplicate 
absorbance readings (n=4). One-way ANOVA followed by Bonferroni post hoc test 
were carried out. Statistical difference compared to the mean background 











Figure 4.2: Dose response curves of expressed gremlin-Myc proteins.  
The dose response curves of expressed gremlin-Myc proteins in crude CHO-S culture 
supernatants were generated using the Myc-capture gremlin ELISA as described in the 
legend of the previous figure. The indicated volumes of crude supernatants were made 
to 100µl with PBS-0.05% (w/v) BSA buffer prior to loading into each well. Error bars 
represent SEM of quadruplicate absorbance readings (n=4). WT: wildtype gremlin-





Figure 4.3: Equalising gremlin-Myc immunoreactivity using the Myc-capture 
gremlin ELISA.  
The gremlin-Myc immunoreactivity in the crude gremlin-Myc culture supernatants 
were equalised by trial-and-error on a dilution basis in PBS buffer. Equalisations were 
made against low gremlin-Myc expressing culture supernatants MGR2 (A) and MGR3 
(B). Dilutions ratios in panel A: 1/100 WT-Myc (wildtype gremlin-Myc), 1/80 MGR1, 
1/2 MGR2, and in panel B: 1/40 WT-Myc, 1/2 MGR3, 1/30 MGR4, 1/50 MGR5, 1/15 
MGR6. The assay was conducted using 100 µl/well diluted samples as described in the 
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Gremlin detection in most of the crude culture supernatants was also achieved 
by Western blotting using a polyclonal murine gremlin antibody. As shown in Figure 
4.4, both Myc- and His-tagged wildtype gremlin bands shared a similar molecular 
weight (MW) of 25 kDa that was in line with published findings (Maciel et al., 2008; 
Sudo et al., 2004; Topol et al., 2000a). The purified His-tagged wildtype gremlin 
protein showed two bands which differed from the expressed crude wildtype gremlin 
which consistently showed a single band (left panel, Figure 4.4). This may indicate that 
both gremlin proteins may be of different isoforms, possibly of different glycosylated 
forms. Strong gremlin detection was achieved for MGRs 1, 4, 5 and 6, but only faintly 
for MGR3. No gremlin detection was achieved for MGR2 (left panel, Figure 4.4). The 
gremlin-Myc proteins shown in separate panels in Figure 4.4 were expressed in 
different batches of crude culture supernatants both containing protease inhibitors. In 
the left panel, wildtype gremlin detection was weak whereas in the right panel, strong 
detection was achieved. It was not possible to reproduce the latter result in repeat 
experiments with the same batch of crude wildtype gremlin-Myc culture supernatant. 
Instead, in these repeat experiments, weak wildtype gremlin detection in crude culture 
supernatants was more consistent. As expected, no gremlin detection was achieved in 
the crude EGFP culture supernatants used as negative control thus establishing that the 
25 kDa band is confined to crude supernatants of cultures where gremlin is anticipated 
(refer to Figure 4.4).  
Unexpectedly, a band, 50 kDa in size, was also detected in all crude culture 
supernatants including the EGFP negative control (Figure 4.4). Western blot detection 
of this 50 kDa band was consistently achieved when using the goat polyclonal gremlin 
primary antibody only. Immunoblots of the same culture supernatants using only the 
HRP-conjugated anti-goat IgG secondary antibody in absence of the gremlin primary 
antibody failed to detect this 50 kDa band. This eliminated the possibility of antibody 
heavy chain cross-reactivity as the cause. Instead, this unknown 50 kDa protein seemed 
to demonstrate specific binding towards the same goat polyclonal gremlin antibody also 
employed in the Myc-capture gremlin ELISA. The fact that the EGFP-induced 
immunoreactivity in the Myc-capture ELISA was significantly lower than the gremlin-
Myc-induced immunoreactivities indicated that this 50 kDa band present in all crude 
culture supernatants does not interfere with gremlin binding to the Myc antibody (refer 
to Figures 4.1).  Nevertheless, it became important to verify this observation in separate 







Figure 4.4: Western blot detection of gremlin in crude CHO-S culture 
supernatants. 
Gremlin detection shown at 25 kDa was achieved using a polyclonal murine gremlin 
primary antibody at 0.8 µg/ml. EGFP culture supernatant served as negative control. A 
50 kDa non-specific band was detected in all culture supernatants including the 
negative control. Asterisks denote positive controls of purified His-tagged gremlin 
protein.   
 
4.3 Investigating the Myc and heparin binding properties of the 50 kDa protein 
 
The source of the 50 kDa protein was investigated in fresh growth medium of 
CHO expression medium supplemented with L-glutamine, in conditioned medium from 
untransfected CHO-S cells and in both crude EGFP and wildtype culture supernatants. 
This was achieved by Western blotting as described in the previous section. As shown 
in Figure 4.5A, strong 50 kDa protein was only detected in culture media which had 
been exposed to the CHO-S cells. These included both crude EGFP and wildtype 
gremlin-Myc culture supernatants and conditioned medium from untransfected cells. Its 
detection in the latter was a significant finding as it demonstrated that the 50 kDa 
protein was constitutively secreted by the CHO-S cells and cannot be a product of the 
transfection. Detection of this unknown protein was not achieved in the fresh CHO 
expression medium prior to exposure to the cells. Although fresh CHO expression 
medium is supplied commercially as a serum-free and protein-free medium, it was 
important to eliminate this as a potential source of the 50 kDa protein. In these results, 
weak gremlin detection was achieved in crude wildtype gremlin-Myc culture 
supernatant thus supporting observations made in the previous section. 
Next, the Myc and heparin binding properties of the 50 kDa protein were 
investigated using immunoprecipitation (IP) experiments of the crude wildtype 
gremlin-Myc culture supernatant on anti-Myc agarose and AF heparin HC650M beads, 
respectively. Western blotting of boiled bead supernatants using the goat polyclonal 
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gremlin primary antibody was then carried out next. As shown in Figure 4.5B, the 50 
kDa band was not detected in the boiled bead supernatant (Track 2) following IP on 
anti-Myc beads. Only strong detection of gremlin at 25 kDa and weaker detection of a 
non-specific band at 60 kDa, were detected in this track. In this experiment, detection 
of the 50 kDa band was achieved only in the crude culture supernatant as expected and 
in the supernatant collected immediately after the bead binding step (Track 1, Figure 
4.5B). Altogether, this demonstrated that the 50 kDa protein does not bind to the anti-
Myc beads and most probably the 9E10 anti-Myc capture antibody used in ELISA.  
The same results were also achieved following incubation with the heparin 
beads as shown in Figure 4.5C. Here, much stronger gremlin detection was achieved in 
the boiled bead supernatants (Track 2). Stronger detection of both 50 kDa and 60 kDa 
bands were achieved only after longer exposure of the film. Again, detection of the 50 
kDa band was achieved only in the initial crude culture supernatant and in the 
supernatant collected immediately after the bead binding step (Track 1, Figure 4.5C). 
These results therefore established that the 50 kDa protein does not bind to heparin 
beads whereas the 25 kDa gremlin protein does therefore, the 50 kDa protein is an 
endogenous protein secreted by the CHO-S cells themselves and recognised by the goat 
polyclonal primary antibody. On another hand, the fact that the 60 kDa band was 
detected in boiled bead supernatants from both IP experiments, made it more likely that 






Figure 4.5: Investigating the source, Myc and heparin binding of the unknown 50 
kDa protein detected in CHO-S culture supernatants.   
A) Western blotting of fresh CHO growth medium and supernatants of CHO-S cell 
suspensions from untransfected (conditioned CHO medium) and both WT GREM1-
Myc- and EGFP-transfected cells. Immunoprecipitation of wildtype (WT) GREM1-
Myc crude culture supernatant on: B) rabbit polyclonal agarose anti-Myc beads and C) 
AF heparin HC650M beads. Gremlin was detected at 25 kDa as described in the legend 
of Figure 4.4.  
 
4.4 Partial purification of wildtype gremlin-Myc 
 
Partial purification of wildtype gremlin-Myc protein in its crude culture 
supernatant was achieved using ion-exchange chromatography on an SP-Sepharose 
column. Both pass-through and dialysed peak fractions were then analysed by silver 
staining on a 15% polyacrylamide gel. To investigate the long term stability of the 
partially-purified wildtype gremlin-Myc together with that of the 50 kDa protein, 
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Western blotting was carried out on the same samples which had been stored for over 
two weeks at -20 °C.  
The wildtype gremlin-Myc elution profile on SP-Sepharose is shown in Figure 
4.6A. In these analyses, the peak wildtype gremlin-Myc immunoreactivity eluted at ~ 
0.45 M NaCl although gremlin-Myc immunoreactivity was distributed across three 
surrounding fractions (fractions at 19, 21 and 22 ml elution volumes, Figure 4.6A) that 
eluted at ~ 0.35, ~ 0.6 and ~ 0.65 M NaCl, respectively.  The low gremlin-Myc 
immunoreactivity observed in the first immunoassayed fraction (fraction at 10 ml 
elution volume, Figure 4.6A) represented that in a 10 ml pooled pass-through fraction 
(refer to Figure 4.6A).    
Results shown in Figure 4.6B were obtained by silver staining of the collected 
pooled pass-through fraction, fractions surrounding the main peak fraction alongside a 
sample of the crude wildtype gremlin-Myc culture supernatant. Stronger detection and 
a higher number of protein bands were detected in the crude wildtype gremlin-Myc 
culture supernatant (Track 9, Figure 4.6B) compared to any other fraction sample. This 
demonstrated that the collected peak fractions (Tracks 3 – 8, Figure 4.6B) including the 
pooled pass-through fraction (Track 2, Figure 4.6B) were at least more purified than the 
crude wildtype gremlin-Myc culture supernatant. It was difficult to identify the 25 kDa 
gremlin protein band in both the crude culture supernatant itself and in the peak 
fractions. In peak fractions, there were several bands present in the 25 kDa region as 
shown in Tracks 4 and 5 but none in Tracks 6 and 7 (refer to Figure 4.6B). The crude 
wildtype gremlin-Myc culture supernatant also displays several bands in this MW 
region. Nevertheless, the silver staining clearly indicates that large amounts of 
interacting proteins present in the crude culture supernatants can be removed.  
Interestingly, a fairly strong band in the 50 kDa region was detected in only the 
pooled pass-through fractions and the crude culture supernatant itself (Tracks 2 and 9, 
Figure 4.6B, respectively). This was a significant finding as it indicated that the 
unknown 50 kDa protein characterised in the previous section, does not bind to the SP-
Sepharose column, thus eluting in the pass-through fraction. This was confirmed by 
Western blotting detection of a 50 kDa band in the same pooled-peak fraction which 
had been stored at -20 °C for over two weeks as shown in Track 2, Figure 4.6C.  
When the peak fractions were stored for over two weeks at -20 °C and 
immunoassayed under similar conditions, gremlin detection was only achieved in one 
out of four peak fractions (Track 6, Figure 4.6D). Intriguingly, gremlin detection was 
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not achieved in the peak fraction (Track 5, Figure 4.6D) which had possessed the peak 
gremlin-Myc immunoreactivity in the elution profile shown in Figure 4.6A. These 
results indicate that partially purified wildtype gremlin-Myc protein is not stable on 
storage. In addition to the damaging effect of freezing and thawing on this partially 
purified protein, it is also likely that loss of its activity over storage may be caused by it 





Figure 4.6: Partial purification of wildtype gremlin-Myc using SP-Sepharose and 
its stability. 
 A) Wildtype (WT) gremlin-Myc elution profile generated by Myc-capture gremlin 
ELISA of fraction samples collected following ion-exchange chromatography on an 
SP-Sepharose column. Dotted points along the WT gremlin-Myc elution profile 
represent mean of quadruplicate absorbance readings. The dots were larger than the 
error bars of SEM. B) Silver staining of a 15% (w/v) polyacrylamide gel. Western blot 
detection of the 50 kDa unknown protein (C) and WT gremlin-Myc protein (D), in 
fraction samples collected from the same SP-Sepharose column above and crude WT 
gremlin-Myc CHO-S culture supernatant which had been stored over two weeks at – 








4.5 Synthesis of the heparin-BSA conjugate  
 
As described in detail in Chapter 2, Section 2.20, a synthesised heparin-BSA 
conjugate was used as coating layer in a heparin-binding ELISA as described by 
Najjam et al. (1997). The separation of the heparin-BSA conjugate from uncoupled 
heparin and BSA involved use of gel filtration on a Sepharose CL 4B column. The 
protein elution profile shown in Figure 4.7 was obtained by determining the protein 
content in the eluate fractions. The fully conjugated heparin-BSA complex having the 
largest size was expected to lead the front end of the elution peak comprising fractions 
3 to approximately fraction 17 (Figure 4.7). The major protein content peak fractions, 
18 – 45, were expected to contain a relatively higher proportion of unconjugated BSA, 
partially conjugated heparin-BSA and probably also unconjugated heparin.  
Shown in Figure 4.8 are the results obtained after Azure A and Coomassie blue 
R250 staining of peak fraction samples ranging from fractions 6 – 45. These stained for 
heparin (upper panels, Figure 4.8) and BSA (lower panels, Figure 4.8), respectively. 
With Azure A staining, the heparin-BSA complex, which was excluded from the gels 
due to its large size was detected in peak fractions 6 – 42 whereas with Coomassie 
staining, this was only detected in peak fractions 9 – 39 (upper and lower panels 
respectively, Figure 4.8). In these peak fractions containing the excluded heparin-BSA 
complex, free heparin was not detected in peak fraction 6 whereas low to moderate 
amounts were detected in peak fractions 9 – 15. Moreover, high amounts of 
unconjugated heparin were detected in fractions 18 – 42 (upper panels, Figure 4.8). On 
the other hand, unconjugated BSA was not detected in peak fractions 6 – 12 and was 
only present in very low and relatively higher amounts in fractions 15 – 18 and 
remaining peak fractions excepts fractions 36 and 42, respectively (lower panel, Figure 
4.8).  
For efficient coating of 96-well plates during the heparin-binding ELISA, it was 
important that only a very low amount of unconjugated BSA was present alongside the 
heparin-BSA complex in the pooled peak fraction sample. This was because a large 
amount of unconjugated BSA might occupy protein binding sites in the wells instead of 
the conjugate. On the contrary, a large amount of unconjugated heparin in the same 
pooled peak fraction sample would be less problematic, as this binds poorly and could 
be washed out easily from the wells. On this basis, only peak fractions 7 – 15 which 
possessed in them very low amounts of unconjugated BSA and moderately high 
amount of unconjugated heparin were pooled together. This pooled peak fraction 
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sample was then freeze-dried and reconstituted as described previously in Chapter 2, 
Section 2.20. Of note, a mock-treated BSA conjugate used in this study had been 
synthesised previously in our laboratory by a similar procedure for heparin-BSA 





Figure 4.7: Gel filtration profile of heparin and BSA conjugates. 
 Size exclusion gel filtration on a Sepharose CL 4B column was carried out to separate 
synthesised heparin-BSA conjugates from uncoupled purified free heparin and BSA. 
The elution profile was generated by measuring the protein content in eluted fraction 
samples. The fraction designated as‘1’ starts half-way into the void volume. Horizontal 









Figure 4.8: Detection of conjugated heparin-BSA complexes. 
Fraction numbers are those of eluate fractions provided in Figure 4.7. These peak 
fractions were stained on non-reducing 10% (w/v) polyacrylamide gels with 0.08% 
(w/v) Azure A and 0.25% (w/v) Coomassie blue R250 for both free, partially and fully 
conjugated heparin (panels A and B) and BSA (panels C and D), respectively. Fully 
conjugated heparin-BSA is annotated as excluded complex. Known amounts of 
purified free heparin and BSA were included as positive controls (5 ng and 10 ng).  
 
 
4.6 Assessing the heparin binding capability of expressed His- and Myc-tagged 
wildtype gremlin proteins using the heparin-binding ELISA 
 
Initially, the heparin-binding ELISA was used in order to investigate whether 
the wildtype gremlin-Myc protein expressed in this study shared similar heparin 
binding capability to the purified His-tagged gremlin protein.  
As shown in the Figure 4.9, when captured on a heparin-BSA layer, both 
purified His-tagged gremlin and the crude wildtype gremlin-Myc culture supernatant 
generated gremlin-Myc immunoreactivities which increased in a dose-dependent 
manner (solid curves, panels A and B, Figure 4.9). These immunoreactivities were 
significantly higher than those generated on mock-treated BSA capture layer (broken 
curves, panels A and B, Figure 4.9). Next, the inhibition curves of both gremlin 
proteins were compared. This involved the pre-incubations of a fixed dose of gremlin-
His (2.5 ng) and fixed volume of crude gremlin-Myc culture supernatant (50 µl) with 
increasing concentrations of soluble unfractionated heparin prior to addition to the 
wells. As shown in Figure 4.9, both gremlin proteins displayed similar inhibition curves 
with the same IC50 value of approximately 10 µg/ml (solid curves, panels C and D, 
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Figure 4.9). In all these experiments, the specific binding of both gremlin proteins to 
heparin was demonstrated by comparative detection of markedly weaker gremlin-Myc 
immunoreactivities hence flattened curves from wells coated with mock-BSA (broken 
curves, Figure 4.9). Since this binding to the conjugate is displaceable with soluble 
unfractionated heparin, the binding is confirmed to depend on the heparin chains within 
the conjugate. This also demonstrated that the synthesis of heparin-BSA described in 
the previous section was successful. Collectively, these results demonstrated that both 
the wildtype gremlin-Myc protein expressed in this study and purified His-tagged 
gremlin bind to heparin with the same affinity.  
Chiodelli and co-workers (2011) demonstrated high affinity binding of purified 
His-tagged wildtype gremlin to heparin on immobilised SPR bionsensor chips. A Kd 
value of 20 nM was provided for this interaction (Chiodelli et al., 2011). As such, 
considering that both His- and Myc-tagged wildtype gremlin proteins displayed similar 
heparin binding affinities in the heparin-binding ELISA, it assumes that the expressed 
wildtype gremlin-Myc protein also shares the same published Kd value. More 
importantly, these results demonstrate for the first time that the binding of gremlin to 










Figure 4.9: The heparin binding properties of expressed gremlin-Myc and 
purified gremlin-His wildtype proteins.  
A and B) Dose response curves generated using the heparin-binding ELISA. C and D) 
Heparin-binding ELISA at fixed dose (2.5 ng/well) gremlin-His and fixed volume (50 
µl/well) gremlin-Myc pre-incubated with increasing concentrations of soluble 
unfractionated heparin. The solid curves with filled symbols and broken curves with 
open symbols represent gremlin-Myc (A and C) and gremlin-His (B and D) 
immunoreactivities in wells captured with 10 ng heparin-BSA and 10 ng mock-treated 
BSA per well, respectively. All samples were prepared to a final volume of 100µl in 
PBS-0.05%(w/v)BSA prior to loading into wells. Gremlin detection achieved using the 
polyclonal biotinylated murine gremlin antibody at 0.8 µg/ml. Dots on curves are 
representative of quadruplicate absorbance readings (n=4). The symbols sizes were 
larger than error bars of SEM.  
 
 
4.7 Assessing the heparin binding activity of expressed wildtype and mutant 
gremlin-Myc proteins using the heparin-binding ELISA 
 
Having demonstrated that expressed crude wildtype gremlin-Myc shared similar 
heparin binding affinity as its His-tagged counterpart, its heparin binding affinity was 
then compared to those of its expressed crude mutants using the heparin-binding 
ELISA. As covered in the previous chapter, the gremlin-Myc mutants, MGRs 1 – 6, 
possessed specific mutations that would results in them possessing potentially reduced 
heparin binding capabilities compared to the wildtype. As earlier introduced in Chapter 
1, Section 1.13, the binding interaction of most cytokine proteins with heparin/HS are 
believed to be largely coulombic and superficial (Esko and Selleck, 2002). Varying the 
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ionic strength at a constant pH, which disrupts ionic interactions, is a common method 
employed to measure surrogately the binding affinity between two ionically interacting 
proteins. In the heparin-binding ELISA, this was achieved by varying the NaCl 
concentration in PBS buffer in which the crude gremlin-Myc culture supernatants were 
prepared prior to loading into the heparin-BSA complex-coated plate wells.  
First, before conducting the above experiments, it was essential to investigate 
whether the binding interaction of the heparin-BSA capture layer to the well surfaces 
was not in itself susceptible to changes in ionic strength.  
As shown in Figure 4.10, high levels of wildtype gremlin-Myc 
immunoreactivity was generated in heparin-BSA coated wells which had been washed 
after overnight incubation with PBS containing either 0.7 or 1 M NaCl immediately 
followed with PBS alone (blue columns). These matched the level of wildtype gremlin-
Myc immunoreactivity generated in similarly coated wells washed with PBS alone 
(0.18 M NaCl) which served as positive control (black column above red column, 
Figure 4.10). As expected in the negative control of wells coated with mock-BSA 
capture layer and washed with PBS alone, significantly lower gremlin-Myc 
immunoreactivity was generated compared to that in the positive control (red column, 
Figure 4.10). As such, these results demonstrated that washing the heparin-BSA 
capture layer at high NaCl salt concentrations of up to 1 M, had negligible effect on its 
binding to the well surfaces hence on the immunoassay itself. On the other hand, when 
crude wildtype gremlin-Myc culture supernatants which had been prepared at either 0.7 
M or 1 M NaCl at first were added into heparin-BSA coated wells which had been 
washed in PBS alone, the high gremlin-Myc immunoreactivity that was generated in 
the positive control above was significantly reduced (black columns below blue 
columns, Figure 4.10). This strongly demonstrated that wildtype gremlin-Myc binding 
to heparin is inhibited at high ionic strength thus suggesting that their binding 
interaction is mainly coulombic.  




      
 
Figure 4.10: Effect of high NaCl concentrations on the heparin-BSA capture layer.  
Heparin-binding ELISA of crude wildtype gremlin-Myc culture supernatant capturing 
on 5 ng/well heparin- and mock-treated BSA using the same detection antibody as 
stated in the legend of Figure 4.9. The blue columns at 0.7 and 1 M NaCl represent 
gremlin-Myc immunoreactivities generated by washing directly heparin-BSA coated 
wells, several times with PBS-0.7 M NaCl and PBS-1 M NaCl buffers followed by 
PBS washes (0.18 M NaCl) prior to blocking and loading of the crude gremlin-Myc 
culture supernatant. The black columns below the blue columns represent gremlin-Myc 
immunoreactivity generated by heparin-BSA coated wells washed in PBS alone and 
blocked before loading 100 µl/well gremlin-Myc samples of the wildtype prepared at 
0.7 and 1 M NaCl. The black and red columns at 0.18 M NaCl represent gremlin-Myc 
immunoreactivities generated by wells coated with heparin-BSA and mock-treated 
BSA, respectively, in which 100 µl/well crude gremlin-Myc culture supernatant was 
added (normal assay). Error bars represent SEM of quadruplicate absorbance readings.  
 
Having established that the heparin-binding ELISA is suitable for use at high 
NaCl concentrations, the heparin binding affinities of the gremlin-Myc mutants could 
then be compared to that of the wildtype. The mutant gremlin-Myc culture supernatants 
were investigated alongside the wildtype, which served as the positive control, by 
preparing them at increasing NaCl concentrations ranging from 0.18 – 1 M. The 
preparations were then incubated in heparin-BSA-coated wells which had been washed 
and blocked at PBS concentration (0.18 M NaCl).  The crude gremlin-Myc culture 
supernatants with equalised gremlin-Myc immunoreactivities were applied as described 
previously using the Myc-capture gremlin ELISA (refer to Section 4.2).  
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As shown in Figure 4.11, a shift in all mutant gremlin-Myc inhibition curves 
(broken curves) to the left of the wildtype gremlin-Myc inhibition curve (solid curves) 
was observed. By comparing the average IC50 values over at least four repeat 
experiments, the order of relative binding affinity of gremlin-Myc proteins to heparin 
on the heparin-BSA complex, from strongest to weakest, was obtained as follows:  
[WT GREM1-Myc] > [MGR2] = [MGR3] = [MGR6]> [MGR1] = [MGR4]> [MGR5] 
By all demonstrating lower IC50 values to that of wildtype, the gremlin-Myc 
mutants demonstrated weaker ionic binding to heparin. However, significant binding of 
both wildtype and mutant gremlin-Myc proteins to the heparin-BSA capture layer was 
observed at physiological NaCl concentration of 0.18 M.  
For most parts, this binding order of heparin affinity derived using the heparin-
binding ELISA was not as anticipated. For example, MGRs 3 and 6 demonstrated 
stronger ionic binding to heparin than MGR1 as shown in the binding order. Both 
MGRs 3 and 6 were hybrid mutants which incorporated the MGR1 substitutions of 
basic cluster II combined with partial substitutions in basic clusters III and I, 
respectively (refer to Chapter 3, Section 3.5). As such, it was expected that, these 
MGR1 hybrid mutants together with MGRs 4 and 5, would possess weaker ionic 
binding to heparin than MGR1, at least.  In these inhibition ELISAs, use of diluted 
gremlin-Myc immunoreactivities may have affected the shape of the inhibition curves 
which in turn may have affected the average IC50 values, as such. Given the relevance 
of this work, it was therefore essential to verify these findings using another method 







































Figure 4.11: NaCl inhibition curves of wildtype versus mutant gremlin-Myc proteins 
generated using the heparin-binding ELISA.  
The expressed gremlin-Myc proteins at stated NaCl concentrations were prepared by diluting 
their crude culture supernatants in PBS buffers with high NaCl concentrations as required but 
maintaining the same pH 7.4. Dilution ratios were adjusted for each crude gremlin-Myc culture 
supernatant so as to equalise their gremlin-Myc immunoreactivities throughout. 100µl/well 
prepared samples were captured on 5 ng/well heparin-BSA and detected using the polyclonal 
biotinylated murine gremlin primary antibody at 0.8 µg/ml. After gremlin incubation, the NaCl 
concentration was returned to isotonic (0.18 M NaCl) by washing in PBS prior to loading the 
primary antibody. The gremlin-Myc immunoreactivities were normalised against those 
generated at 0.18 M NaCl. Each point on curves represent the average of quadruplicate 
absorbance readings (n=4). 100% represents the mean absorbance value at 0.18 M NaCl 
divided by itself and multiplied by 100, for each gremlin protein. Symbols were larger than 















4.8 Heparin affinity chromatography  
 
4.8.1 Assessment of the Myc-capture gremlin ELISA for heparin affinity 
chromatographic analyses 
 
Heparin affinity chromatography (refer to Chapter 2, Section 2.21) was 
employed next, in order to verify the previous findings of the reduced heparin affinity 
of the mutants. Heparin affinity chromatography is the most widely used method to 
study affinity of the ionic basis of protein binding to polysaccharides. This method also 
eliminates the need to equalise the gremlin-Myc immunoreactivities by dilution of the 
gremlin-Myc culture supernatants prior to being compared.  
Eluate fractions collected during heparin affinity chromatography will be 
immunoassayed using the Myc-capture gremlin ELISA. Therefore, it was important to 
test whether this ELISA would be affected by the elevated NaCl concentrations 
anticipated in the key eluate fractions. This would establish whether the use of high 
NaCl-containing eluates in the Myc-capture gremlin ELISA was appropriate. Of note, 
in this control experiment, coated wells incubated with wildtype gremlin-Myc samples 
prepared at elevated NaCl concentrations were returned to physiological conditions by 
washing in PBS buffer prior to loading with the biotinylated gremlin primary antibody. 
As shown in Figure 4.12, a progressive increase in levels of wildtype gremlin-Myc 
immunoreactivity was observed between 0.11 – 0.2 NaCl which peaked at 0.2 M NaCl. 
This was then followed by a progressive decrease in immunoreactivity between 0.2 – 
0.6 M NaCl. These findings demonstrated that NaCl concentrations ˃ 0.2 M NaCl 
interfere with Myc capture of wildtype gremlin-Myc in this ELISA. Peak gremlin-Myc 
immunoreactivity was demonstrated only around physiological NaCl concentration. 
Given that the binding interaction between the Myc antibody to the Myc epitope on 
gremlin is not expected to be largely coulombic, a reduction in immunoreactivity may 
be caused by the antibody adopting a less favourable conformation at high ionic 
strength. Altogether, this experiment demonstrated that reducing the NaCl 
concentration in gradient fractions down to 0.18 – 0.2 M NaCl was required after 
heparin affinity chromatographic runs before ELISA could be reliably performed.  
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Figure 4.12: Effects of varying the ionic strength on the Myc-capture gremlin 
ELISA.  
Myc-capture gremlin ELISA of wildtype gremlin-Myc culture supernatant; refer to 
legend of Figure 4.1 for detection antibody used. The gremlin-Myc samples applied 
(100 µl/well) were prepared at the NaCl concentrations indicated by diluting in the 
crude gremlin-Myc culture supernatant in the appropriate NaCl in PBS stock solution. 
Each point on the curve represents the average of quadruplicate absorbance readings 
(n=4). Error bars represent SEM.  
 
 
Dialysis presented itself as a useful method for reducing the NaCl concentration 
in the gradient fractions without associated loss of gremlin-Myc immunoreactivity. In a 
further control experiment, possible loss of wildtype gremlin-Myc immunoreactivity 
following dialysis of the crude culture supernatant was investigated.  Results, not 
shown, revealed only negligible loss in gremlin-Myc immunoreactivity following 
dialysis of the wildtype culture supernatant. Dialysis was, therefore, used preferably 
over dilution as standard method of reducing the NaCl concentration in gradient 
fractions after heparin binding chromatography.  
 
4.8.2 Heparin affinity chromatography of wildtype gremlin-Myc protein 
Heparin affinity chromatography was conducted using the crude wildtype 
gremlin-Myc culture supernatant, with/without the presence of protease inhibitors, in 
order to define its elution profile. At first, this was conducted on either the HiTrap 
heparin-Sepharose column or the AF heparin HC650M column. The important 
difference between them is that the former makes use of a larger bed volume compared 
to the latter performed at much smaller scale. In the HiTrap heparin-Sepharose column, 
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heparin from porcine intestinal mucosa is coupled to carboxylate groups of Sepharose 
on agarose matrix whereas in AF heparin HC650M beads, heparin of same origin, is 
coupled to non-functionalized bead resins instead. The specific coupling mechanisms 
used are not disclosed by the manufacturers.   
As shown in Figures 4.13A and 4.14A, single elution peak profiles with 
corresponding peak wildtype gremlin-Myc immunoreactivity eluting at 0.7 M and 0.8 
M NaCl, respectively were generated on both heparin columns.  These were 
consistently generated from aliquots of the wildtype culture supernatant with no 
protease inhibitors that had been passed through only 2 – 3 freeze-thaw cycles and 
stored frozen only for about 1 - 2 weeks. Beyond these conditions, after more 
prolonged storage or multiple freeze-thaw cycles, double elution peak profiles were 
generated on both heparin columns instead, as showed in Figures 4.13B and 4.14B. On 
the HiTrap heparin-Sepharose column, the first and second wildtype gremlin-Myc 
elution peaks were observed at 0.55 M NaCl and 1 M NaCl (Figure 4.13B) and on the 
AF heparin HC650M column, these were observed between 0.2 – 0.4 M NaCl and 
between 0.6 – 0.8 M NaCl (Figure 4.14B).  
As demonstrated in Figure 4.14C, when the peak fractions in Figure 4.14B were 
pooled and re-run separately on AF heparin, each pooled peak fraction generated a 
single peak elution profile. In both single elution profiles, the individual wildtype 
gremlin-Myc elution peaks were consistent with those on the parent elution profile 
shown previously in Figure 4.14B. These findings suggested that at first the CHO-S 
cells secrete a single unstable wildtype gremlin-Myc protein which after long-term 
storage with multiple freeze-thaw cycles in the absence of protease inhibitors, 
segregates into two forms both immunoreactive. Such segregation could occur mostly 
via proteolytic degradation by endogenous proteases or by aggregation. These 




Figure 4.13: Wildtype gremlin-Myc elution profiles generated using HiTrap 
heparin-Sepharose columns.  
Heparin affinity chromatography on HiTrap heparin-Sepharose columns was conducted 
using crude wildtype gremlin-Myc culture supernatant samples from the same batch 
freeze-thawed and/or stored: A) 2 - 3 cycles and/or stored frozen only for about 1 – 2 
weeks and B) over 3 cycles and/or prolonged storage. Eluted fraction samples (100 
µl/well) were assayed using the Myc-capture gremlin ELISA; refer to legend of Figure 
4.1 for detection antibody used. Pass-through fractions (1-4), wash fractions (5-9) and 
gradient fractions (10-22) dialysed prior to assay. Each point on the curve represents the 
average of quadruplicate absorbance readings (n=4). Error bars represent SEM. NaCl 






Figure 4.14: Wildtype gremlin-Myc elution profiles generated using AF heparin 
HC650M bead columns.  
Heparin affinity chromatography on packed AF heparin HC650M bead columns was 
conducted using of crude wildtype gremlin-Myc culture supernatant samples from the 
same batch freeze-thawed and/or stored: A) 2 - 3 cycles and/or stored frozen only for 
about 1 – 2 weeks and B) over 3 cycles and/or prolonged storage. The peak fractions in 
panel B, were pooled separately and run each on a separate AF heparin HC650M 
column, which generated two elution profiles (C). The separate elution profiles in panel 
C were highlighted in red and light blue colours. Eluted fraction samples (100 µl/well) 
were assayed using the Myc-capture gremlin ELISA and all gradient fractions were 
dialysed to 0.18M NaCl in PBS buffer prior to assay; refer to the legend of Figure 4.1 
for detection antibody used. Each point on the curve represents the average of 
quadruplicate absorbance readings (n=4). Error bars represent SEM. Pass-through 
fractions (Panel A: 1 - 3; Panel B:1 - 4; Panel C: 1 - 2  ), wash fractions (Panel A: 4 - 8, 
Panel B: 5 - 9; Panel C: 3 - 7 ) and gradient fractions (Panel A: 9 - 17; Panel B: 10 - 27; 
Panel C: 8 - 16). NaCl concentrations were measured from conductivities of eluates. 
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When the similar experiments were repeated this time using the crude wildtype 
culture supernatant containing protease inhibitors the results as shown in Figure 4.15 
were obtained. Consistent with previous observations, a single elution peak profile with 
peak gremlin-Myc elution at ~ 0.8 M NaCl, was produced using 1 – 2 weeks old frozen 
aliquots of the wildtype supernatant which had been freeze-thawed 2 – 3 times (Figure 
4.15A). Interestingly, in the presence of protease inhibitors, the same single peak 
elution profile was generated despite using frozen aliquots which had been exposed to 
conditions beyond those stated above (Figure 4.15B). However, it was observed that 
wildtype gremlin-Myc immunoreactivity in these peak gradient fractions was markedly 
lower than that normally generated in the fresher aliquot samples in Figure 4.15A. The 
reduced wildtype gremlin-Myc immunoreactivity was also accompanied by a decrease 
in the peak wildtype gremlin-Myc elution from ~ 0.8 M NaCl to ~ 0.6 M NaCl (refer 
to Figures 4.15 A and B, respectively). It is possible the harsh conditions would have 
adversely affected the structural integrity of the wildtype gremlin-Myc protein and its 
Myc epitope or caused its aggregation. Altogether, these results indicated that the 
transition from a single to double peak wildtype gremlin-Myc elution profile as was 
observed earlier can be prevented by the addition of protease inhibitors to this crude 
wildtype culture supernatant immediately after its harvesting. This suggested that by 
inhibiting the activities of endogenous proteases secreted by the CHO-S cells 
themselves, progressive proteolytic degradation of wildtype gremlin-Myc was 
inhibited. It is for this reason that protease inhibitors were also added to all mutant 




Figure 4.15: Determining the true elution profile of expressed wildtype gremlin-
Myc protein.  
Heparin affinity chromatography on AF heparin HC650M bead columns was 
conducted using crude wildtype gremlin-Myc culture supernatant samples from a batch 
to which protease inhibitor cocktail had been added immediately after its harvesting. 
Shown are elution profiles of samples freeze-thawed through A) a single cycle and B) 
multiple cycles. Eluted fraction samples (100 µl/well) were assayed using the Myc-
capture gremlin ELISA; refer to legend of Figure 4.1 for detection antibody used. Each 
point on the curve represents the average of quadruplicate absorbance readings (n=4). 
Error bars represent SEM. Pass-through fractions (Panels A and B: 1 - 2), wash 
fractions (Panel A: 3 - 6, Panel B: 3 - 7) and gradient fractions (Panel A: 7 - 15; Panel 







4.8.3 The heparin affinity chromatography of mutant gremlin-Myc 
proteins 
The elution of profiles of MGRs 1 – 6 were compared against that of the 
wildtype in order to verify the previous findings obtained using the heparin-binding 
ELISA (refer to Section 4.7).  
All mutant gremlin-Myc elution peaks shifted left from that of the wildtype 
gremlin-Myc elution peak at 0.8 M NaCl (Figure 4.16). These shifts have also been 
summarised in Table 4.1. This demonstrated that reduced binding to heparin had been 
achieved by targeted site-directed mutagenesis of the three basic clusters predicted to 
form the putative heparin/HS binding site on wildtype gremlin. By comparing the 
average elution peaks over three repeat experiments, the order of relative binding 
affinity of the gremlin-Myc proteins to heparin, from strongest to weakest, was as 
follows:  
    Wildtype GREM1-Myc > MGR1 > MGR2 = MGR4 = MGR5 ≈ MGR6 > MGR3 
This binding order of the mutant gremlin-Myc proteins differs markedly from 
that observed using the heparin-binding ELISA (refer to Section 4.7). Here, MGR1 had 
the highest average elution peak amongst the mutants eluting at 0.5 M NaCl whereas 
MGR3 had the lowest average elution peak eluting at 0.33 M NaCl (Figure 4.16). 
MGRs 2, 4, 5 and 6 shared similar elution peak on average, eluting between 0.40 – 0.42 
M NaCl (Figure 4.16). Unlike the heparin-binding ELISA, these findings were more 
consistent with the predicted contact basic residue subsititutions incorporated in each 
gremlin-Myc mutant. All MGR1 hybrid mutants, MGRs 3 – 6, which possessed the 
MGR1 substitutions of basic cluster II combined with partial substitutions in either 
basic cluster I or III, showed weaker binding affinities to heparin compared to that of 
the parent MGR1 mutant alone (also refer to Chapter 3, Section 3.5). On this note, 
selection of candidate gremlin-Myc mutants possesing the lowest heparin binding 
affinity for work in the next phase of this study, was made based on this heparin 
affinity chromatographic data. Therefore, MGRs 3, 5 and 6 were selected for further 
analyses later. By demonstrating experimentally that all gremlin-Myc mutants 
possessed reduced heparin binding capabilities, mapping predictions made by Rider 
and Mulloy (2010) using a sclerostin-based homology model of gremlin, were verified. 
Therefore, mapping of the heparin binding site on gremlin has been successfully 






Figure 4.16: Heparin affinity chromatography of mutant gremlin-Myc proteins 
versus wildtype.  
The gremlin-Myc elution profiles shown were generated on packed AF heparin 
HC650M bead columns by applying crude culture supernatants of wildtype and mutant 
gremlin-Myc proteins containing protease inhibitors followed by assay of eluates (peak 
fractions dialysed) using the Myc-capture gremlin ELISA. Refer to legend of Figure 
4.1 for detection antibody used for ELISA. The first filled square on all the elution 
profiles represents the mean of quadruplicate absorbance readings of all pass-through 
and wash fractions. Vertical broken lines indicate the elution peak of wildtype gremlin-





4.9 SP-Sepharose ion-exchange chromatography of gremlin-Myc proteins 
Next, ion-exchange chromatography of the expressed gremlin-Myc proteins was 
carried out on SP-Sepharose columns possessing -CH2CH2CH2SO3
- side chains. This 
was done to investigate whether binding of gremlin-Myc proteins to heparin involved a 
specificity beyond simple coulombic interactions. This was conducted in a similar 
manner to heparin affinity chromatography described previously using the bevelled tip 
columns (refer to Chapter 2, Section 2.22).  
As shown in Figure 4.17, wildtype gremlin-Myc eluted at 0.43 M NaCl on 
average compared to 0.8 M NaCl average peak elution from the AF heparin HC650M 
column observed in the previous section. On the SP-Sepharose column, both mutant 
gremlin-Myc elution peaks also shifted to the left of that of the wildtype as seen 
previously in their heparin affinity chromatography. However, these shifts were much 
more subtle than those observed using heparin columns (refer to Table 4.1).  On basis 
of their average peak elutions over two repeat experiments, the order of relative binding 
affinity to SP-Sepharose, from strongest to weakest, was as follows:  
  WT ≈ MGR1 ≈ MGR4 > MGR2 ≈ MGR5 ≈ MGR6 > MGR3 
 
On SP-Sepharose columns, both MGRs 1 and 4 shared similar average elution 
peaks with the wildtype eluting at 0.40 – 0.43 M NaCl. MGRs 2, 5 and 6 shared similar 
average elution peaks, all eluting at 0.33 M NaCl. MGR3 showed the weakest binding 
to the column eluting at 0.21 M NaCl on average. As can be seen, both the wildtype 
and mutant gremlin-Myc proteins eluted at lower NaCl concentrations from SP-
Sepharose columns compared to their elution from the AF heparin HC650M column. 
Altogether, the weaker binding of these gremlin-Myc proteins to SP-Sepharose 
columns strongly indicated that their binding to heparin is more specific. Together, 
findings using both chromatographic methods demonstrate that the substituted 
positively charged arginine and lysine residues within predicted basic clusters 










Gremlin-Myc mutant Wildtype to mutant shift 
for heparin affinity (M) 
Wildtype to mutant shift 
for ion exchange (M) 
MGR1 0.38 0 
MGR2 0.39 0.12 
MGR3 0.48 0.22 
MGR4 0.39 0.02 
MGR5 0.39 0.14 
MGR6 0.40 0.10 
 
Table 4.1: Elution NaCl molarity shifts for heparin and ion-exchange 
chromatography. 
The NaCl molarities shown represent the difference in average elution peaks of mutant 
gremlin-Myc proteins from that of the wildtype as determined from their elution 
profiles generated after heparin and ion-exchange chromatography on AF heparin and 





Figure 4.17: SP-Sepharose ion-exchange chromatography of mutant gremlin-Myc 
proteins versus wildtype.  
The gremlin-Myc elution profiles shown were generated on SP-Sepharose columns by 
applying crude culture supernatants of wildtype gremlin-Myc and its mutant containing 
protease inhibitors followed by assay of eluates using the Myc-capture gremlin ELISA. 











Overall, the studies in this chapter aimed at assessing the heparin binding 
activities of wildtype and mutant gremlin-Myc proteins that were cloned and expressed 
in the previous chapter using site-directed mutagenesis. Given that such site-directed 
mutagenesis was based on heparin binding site mapping predictions made by Rider and 
Mulloy (2010), this study would also serve as an experimental verification of their 
predictions. All the specific objectives outlined in the introduction of this chapter were 
met in the study.  
Gremlin-Myc detection in all expressed crude gremlin-Myc CHO-S cell culture 
supernatants was achieved using the Myc-capture gremlin ELISA in which their C-Myc 
epitope was targeted by using a 9E10 Myc capture antibody. In these crude culture 
supernatants, varying levels of gremlin-Myc immunoreactivity were observed; most 
notably, both MGRs 2 and 3 crude culture supernatants possessed the least gremlin-
Myc immunoreactivities of all. By this immunoassay, it was possible to deduce 
conclusively that the gremlin-Myc immunoreactivities generated, was a product of the 
action of a single protein possessing both gremlin and the Myc epitopes. Using 
wildtype, MGRs 3, 5 and 6, the gremlin-Myc proteins, assessed further in the next 
chapter, increase in gremlin-Myc immunoreactivity correlated with increase in loading 
volumes of their crude culture supernatants. The wildtype and MGR5-induced slopes of 
gremlin-immunoreactivity were steepest and more or less equivalent, whereas that of 
MGR6 was about half as steep, thus indicating lower gremlin-Myc immunoreactivity of 
MGR6 compared to both the wildtype and MGR5. The correlation was less apparent 
for MGR3, as it possessed the least gremlin-Myc immunoreactivity. Altogether, this 
demonstrated the semi-quantitative nature of the Myc-capture gremlin ELISA which 
together with Western blotting, were used to estimate the yields of these gremlin-Myc 
proteins as discussed further in the next chapter.  
The gremlin immunoreactive band, 25 kDa in size, was detected in the crude 
gremlin-Myc culture supernatants by Western blotting using the same non-biotinylated 
gremlin detection antibody used in the Myc-capture gremlin ELISA. On one occasion, 
strong detection was achieved for MGRs 1, 4, 5 and 6 whereas only weak detection was 
achieved for MGR3 and no detection at all for MGR2. Both weak and strong detection 
of wildtype gremlin-Myc was achieved using two different batches of its crude culture 
supernatants. In repeat experiments, weak detections of the wildtype, MGRs 3 and 6 
were more consistent even with the presence of protease inhibitors in their crude 
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culture supernatants during harvesting. On some attempts, MGR5 detection was also 
weak. According to the Myc-capture gremlin ELISA, weak detection of both MGRs 2 
and 3 was also the case, thus it may be concluded that their crude culture supernatants 
possessed the lowest gremlin-Myc immunoreactivities. It is possible that a major 
gremlin epitope could have been damaged during their constructions, or that the CHO-
S cells themselves could not overexpress both constructs particularly well. On the other 
hand, weak detections of wildtype and other highly expressed gremlin-Myc mutants 
may have indicated progressive loss in their activity over prolonged storage and/or 
repeated freeze-thaw cycles. Nonetheless, detection of a 25 kDa band that matched the 
size of the purified gremlin-His protein, demonstrated that mutant gremlin proteins 
with conserved sizes to the wildtype has been successfully cloned and expressed. This 
observed MW of gremlin was observed previously by Topol et al. (2000a) and Sudo et 
al. (2004) in its glycosylated form. Findings in this current study that the commercially 
purified gremlin-His was consistently detected as two bands, in contrast to the single 
wildtype gremlin-Myc band, all in the 25 kDa region, indicates gremlin proteins of 
different isoforms, most likely of different glycosylated forms. 
Gremlin detection in all crude culture supernatants including that of the EGFP 
negative control was accompanied by the detection of a 50 kDa band of an unknown 
protein. This seemed to bind specifically to the polyclonal gremlin detection antibody 
used, as use of the secondary antibody alone failed to detect it. It was identified that 
this unknown protein is an endogenous product of the CHO-S cells themselves, as it 
was absent in fresh CHO growth medium not exposed to the cells and present in CHO 
conditioned medium from both transfected and untransfected cells. It was also 
investigated whether this unknown 50 kDa protein could bind specifically to either 
Myc antibody or to heparin. IP experiments of crude wildtype gremlin supernatant on 
either polyclonal anti-Myc agarose beads or AF heparin HC650M beads demonstrated 
that this unknown protein does not bind to either the Myc antibodies or heparin beads 
and, therefore, does not interfere with this study. It is important to note that such 
artefact secretion by mammalian cells is not atypical. Topol et al. (2000a) also 
observed a 50 kDa band in Western blotting detection of gremlin overexpressed in 
COS-7 mammalian cells in spite of using a polyclonal gremlin detection antibody from 
rabbit instead of goat origins. In this current study, partial purification of wildtype 
gremlin-Myc from its crude culture supernatant containing other endogenous proteins, 
including the 50 kDa protein, was achieved by ion-exchange chromatography on an SP-
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Sepharose column. This assessment was based on silver staining and Western blotting 
of the pass-through and peak gradient fractions alongside the crude wildtype. In the 
former, partial purification was indicated by the relatively lower amounts of proteins in 
these fraction eluates compared to those in the crude wildtype gremlin-Myc sample. In 
the latter, the 50 kDa protein was detected only in the pooled pass-through fraction 
eluate in which gremlin protein was absent. This, together with dialysed wildtype 
gremlin-Myc peak fractions had been stored frozen over two weeks prior to 
immunoassay using Western blotting. In most peak fraction eluates, including the 
major peak eluate, the gremlin immunoreactive band was not detected. This suggested 
that in the absence of a protein carrier, partially purified wildtype gremlin-Myc protein 
is unstable relative to the 50 kDa protein.  
Next, a heparin-BSA conjugate complex was prepared in this study as described 
previously by Najjam et al. (1997) for use as capture layer in the heparin-binding 
ELISA. Using the ELISA, it was observed that both Myc- and His-tagged wildtype 
gremlin proteins shared the same heparin binding properties. This was demonstrated by 
both sharing similar dose response curves and soluble unfractionated heparin inhibition 
curves. In the latter, both proteins exhibited the same IC50 value of 10 µg/ml. Chiodelli 
et al. (2011) using SPR experiments demonstrated strong binding of His-tagged 
wildtype gremlin to immobilised heparin on biosensor chips quoting a Kd value of 20 
nM. Given that both Myc- and His-tagged gremlin proteins shared similar IC50 values, 
it would be fair to conclude that Myc-tagged gremlin, expressed in this study, would 
also bind to heparin with similar affinity. This was also an interesting finding as it 
demonstrated for the first time that neither Myc nor His tags interfere with heparin 
binding of wildtype gremlin. This however does not challenge the earlier raised 
concern on the use of this long (10X) polybasic His tag in binding studies with heparin. 
Findings by Lacy and Sanderson (2002) demonstrated that presence of a 6XHis tag on 
the recombinant Sp17 protein, expressed on acrosome-reacted sperm, dramatically 
increased binding of the protein to HS on cell surfaces of myeloma ARP-1 cells by 
about 7-fold compared to a 2-fold increase in that of the untagged protein. Moreover, a 
marked increase in 6XHis-Sp17-induced HS-mediated ARP-1 cell-cell adhesion was 
observed relative to that induced by the untagged Sp17 protein. The significant 
decreases in cell surface-bound Sp17 and Sp17-induced cell aggregation in 
heparitinase-treated ARP-1 cells demonstrate that these are HS-mediated effects. In a 
different study by Alfano et al. (2007), heparin binding of recombinant soluble His-
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tagged GDNF family receptor α 1 (GFRα1)-Fc but not of Sf9-expressed FLAG-tagged-
GFRα1 was demonstrated using the heparin-binding ELISA. Because binding of both 
GFRα1 and Fc to heparin are unlikely, it is possible that the polybasic His tag sequence 
may have introduced an artefactual heparin-binding site.  
Next, reduced binding to heparin was demonstrated in all gremlin-Myc mutants, 
MGRs 1 – 6, using both the heparin-binding ELISA and heparin affinity 
chromatography. In the former, all their inhibition curves were displaced below that of 
the wildtype hence their lower IC50 values. In the latter, marked shifts in their elution 
peaks left to that of the wildtype hence their lower major peak-eluting NaCl molarity, 
were observed. Although marked reduction in heparin binding was exhibited by the 
gremlin-Myc mutants, complete depletion of their heparin binding was not achieved. 
This was as shown by their capabilities to bind both heparin-BSA and the AF heparin 
HC650M column at 0.18 M NaCl and pH of 7.4. This rather indicated that complete 
depletion of heparin binding of wildtype gremlin may require the total combined 
substitutions of all its predicted contact basic clusters I – III. This thinking is supported 
by findings that most gremlin-Myc mutants possessing combined substitutions of basic 
clusters demonstrated more reduced binding to heparin than mutants with substitutions 
of a single basic cluster.  For example, on the AF heparin column, MGR1 hybrid 
mutants, MGRs 3 – 6, all demonstrated lower elution peaks than that of MGR1 itself. 
These hybrid mutants all incorporated the MGR1 substitutions of basic cluster II 
combined with partial substitutions of either basic cluster I or III (refer to Chapter 3, 
Section 3.5). Nonetheless, the aim of cloning and expressing gremlin-Myc mutants 
possessing reduced binding to heparin was achieved in this study. Also, given that site-
directed mutagenesis was based on mapping predictions made by Rider and Mulloy 
(2010), these findings also served as an experimental validation to their findings. 
Ultimately, mapping of the putative heparin/HS binding site of wildtype gremlin was 
achieved in this study. 
Given that all six gremlin-Myc mutants expressed in this study demonstrated 
reduced binding to heparin, it was, therefore, important to select a few that possessed 
the weakest binding affinity to heparin. These candidate gremlin-Myc mutants could 
then be used alongside the wildtype when assessing further its functional activity as 
will be covered in the next chapter. In this study, this was made difficult, as the 
inhibition heparin-binding ELISA and heparin affinity chromatography gave different 
order of their relative binding affinities. As discussed earlier, it is believed that one 
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cause might be the large dilutions of the crude gremlin-Myc culture supernatants 
effectuated in order to equalise their gremlin-Myc immunoreactivities prior to being 
compared on the inhibition heparin-binding ELISA. Such large dilutions of gremlin-
Myc immunoreactivity may have changed the shape of their inhibition curves thus also 
altering their IC50 values. The heparin affinity chromatography circumvented the need 
of dilutions prior to using the crude culture supernatants and also enabled high loading 
to be made onto the heparin column for lowly expressed mutants such as MGRs 2 and 
3. Moreover, the order of heparin binding affinity obtained in this method was more 
consistent with the incorporated substitutions in each gremlin-Myc. Using the heparin-
binding ELISA, binding of gremlin-Myc to the heparin-BSA capture layer was 
demonstrated to be inhibited by increase in ionic strength, which demonstrated that 
their binding interaction is mainly coulombic. Therefore, it was expected that the 
degree of gremlin-Myc mutants binding to heparin would correlate with the number of 
contact arginine and lysine residues which were substituted during site-directed 
mutagenesis. As was exemplified above, the findings by heparin affinity 
chromatography that all MGR1 hybrid mutants, MGRs 3 – 6, possessed lower affinity 
to heparin than MGR1 itself, was consistent with their incorporated substitutions. On 
this basis, MGRs 3, 5 and 6 were selected as those gremlin-Myc mutants possessing the 
least binding to heparin.   
Lastly, all gremlin-Myc mutants including the wildtype demonstrated weaker 
binding to SP-Sepharose columns, which served as a simple cationic exchanger in ion-
exchange chromatography. Although the same shift patterns in elution peaks as those 
observed using heparin affinity chromatography were also observed in these 
experiments, these were comparatively much more subtle. As such, these findings 
strongly suggest that binding of gremlin to heparin is more specific than binding to SP-
Sepharose matrices. Together, these verified the hypothesis that gremlin harbours a 











CHAPTER 5: Investigating the BMP antagonist activity of 
wildtype gremlin-Myc against its mutants 
5.1  Introduction 
In the previous chapter, experimental evidence was produced in favour of a 
proposed specific heparin binding site on gremlin. It was also demonstrated that 
gremlin binds to heparin mainly via ionic interactions. Therefore, this leads to the 
further hypothesis that gremlin binding to heparin/HS occurs at a specific binding site 
on gremlin that is physically distinct and independent of its BMP binding site. This 
raises the important question on whether the low heparin binding gremlin-Myc mutants 
retain BMP binding.  
To fully verify this new hypothesis, the BMP binding capabilities of wildtype 
gremlin-Myc alongside the three lowest heparin-binding mutants, MGRs 3, 5 and 6, 
will be studied. These will be investigated using both immunoprecipitation experiments 
and a novel Myc-capture GREM1/BMP-4 double sandwich ELISA. This will also be 
tested in functional assays established in C2C12 myoblastic cell cultures that in 
addition, will determine whether or not these expressed gremlin-Myc proteins, are 
functionally active. This will be indicated by their activities in antagonising BMP 
signalling. In the case of the mutants this will be interesting given their reduced affinity 
to heparin. In this chapter a further hypothesis that heparin potentiates gremlin binding 
interaction with its BMP ligands will also be tested using the double sandwich ELISA.    
An outline of the specific objectives to be met in this chapter is as follows; 
 To assess the BMPs -4/-7 binding capabilities of expressed wildtype gremlin-
Myc and its mutant proteins by establishing suitable immunoassays. 
 
 To investigate the effect of heparin on gremlin-Myc interaction with BMPs -4/-
7 in immunoassay. 
 
 To establish reliable cellular assays in C2C12 myoblastic cell cultures in order 











5.2 Assessing the BMP-4 binding capability of wildtype gremlin-Myc and its 
mutants by immunoprecipitation (IP) 
 
5.2.1 IP of gremlin-Myc proteins on anti-C-Myc agarose beads  
In order to assess biochemically whether the mutagenized Myc-tagged gremlin 
proteins maintain their natural abilities to bind directly to their BMP ligands, a series of 
co-IP experiments were carried out. Initially, IP experiments were conducted on rabbit 
polyclonal anti-C-Myc beads using only the crude culture supernatants of wildtype 
gremlin-Myc and its low heparin-binding mutants, MGRs 3, 5 and 6. This was done in 
order to achieve satisfactory loading and recovery of each of these gremlin-Myc 




Figure 5.1: Immunoprecipitation (IP) of expressed gremlin-Myc proteins.  
IP experiments were conducted using optimized loadings of crude CHO-S culture 
supernatants of WT gremlin-Myc (1 ml) and its low heparin binding mutants, MGR3 
(2ml), MGR5 (1 ml) and MGR6 (1.5ml) on polyclonal rabbit anti-C-Myc agarose 
beads (50 – 100 µl). Gremlin detection as a 25 kDa band was achieved by Western 
blotting using a polyclonal gremlin detection antibody. Non-specific bands were also 
observed at 50 and 60 kDa.   
 
 
By loading the anti-C-Myc beads with different volumes of crude gremlin-Myc 
culture supernatants, satisfactory recovery of each expressed gremlin-Myc protein was 
achieved (Figure 5.1). The satisfactory loading volumes of crude gremlin-Myc culture 
supernatants required in this work, correlated directly with the levels of gremlin-Myc 
immunoreactivity detected earlier using the Myc-capture gremlin ELISA (refer to 
Figure 4.2, Chapter 4). Wildtype and MGR5 crude culture supernatants (1 ml) 
possessed the highest gremlin-Myc immunoreactivity and therefore the least loading 
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volumes of 1 ml. Crude MGR6 culture supernatant possessed the next highest gremlin-
Myc immunoreactivity hence the second least loading volume of 1.5 ml. Crude MGR3 
culture supernatant possessed the least gremlin-Myc immunoreactivity requiring the 
highest loading volume of 2 ml. In addition, a prolonged incubation period of 48 h of 
this last culture supernatant with the anti-C-Myc beads was required compared to only 
24 h for all others. As shown in Figure 5.1 (Tracks 1), detection of the 25 kDa gremlin 
band in each crude supernatant was attempted prior to loading onto the beads. Strong 
gremlin detection was achieved for MGR5 only, weak detection for the wildtype and 
no detection for both MGR3 and MGR6. Previously, strong detection was achieved for 
all except MGR3 (refer Figure 4.4, Chapter 4). The reason for these different outcomes 
was not investigated further, as a gremlin band was detected for all these gremlin-Myc 
proteins in their boiled bead supernatants (Figure 5.1, Track 3) which was absent or 
only weakly detected in supernatants collected immediately after bead binding (Figure 
5.1, Tracks 2). This indicated successful binding and recovery of gremlin-Myc proteins 
from anti-C-Myc beads thus confirming that they indeed possess a Myc tag.      
 In these results, a 50 kDa band was detected in both crude gremlin-Myc culture 
supernatants and in supernatants collected immediately after bead binding (Figure 5.1, 
Tracks 1 and 2, respectively). This was not detected in all boiled bead supernatants 
(Figure 5.1, Tracks 3). These were in line with previous observations which had 
previously found and assessed this non-specific band as being incapable of binding to 
both anti-C-Myc and AF heparin HC650M beads (refer to Figure 4.5, Chapter 4).  
Also, another non-specific band, 60 kDa, was consistently detected in all boiled 
bead supernatants (Figure 5.1, Tracks 3). Initially, this was thought to be heavy chain 
cross-reactivity between escaped fragments of the rabbit polyclonal anti-Myc beads and 
the rabbit anti-goat HRP-conjugated secondary antibody. However, boiling 
uncomplexed beads alone and probing only with this secondary antibody did not detect 
the 60 kDa band. A similar result was observed when the boiled supernatant of 
gremlin-Myc-bound bead complex was probed using only this secondary antibody. As 
such, the source of this non-specific band is not clearly understood.     
 
5.2.2  IP of purified BMP-4 on gremlin-Myc-bead complexes 
Next, IP experiments were conducted in which purified BMP-4 was loaded onto the 
gremlin-Myc-bead complex under conditions stated in the previous section. In these 
experiments, BMP-4 recovery in boiled bead supernatants was assessed using Western 
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blotting by probing blots of the same samples with both polyclonal BMP-4 and gremlin 
primary antibodies. The aim of these experiments was to determine the optimal 
conditions for BMP-4 binding onto the bead complex using wildtype gremlin-Myc 
first, prior to the testing of its mutants. In this work, 10 ng purified BMP-4 prepared in 
PBS-1% (w/v) BSA was incubated with the wildtype gremlin-Myc-bead complex 




Figure 5.2: IP experiment of BMP-4 on wildtype gremlin-Myc-bead complex. 
500ng/ml BMP-4 (10 ng/20µl loaded on gel) was immunoprecipitated on wildtype 
gremlin-Myc-bead bound complex formed as described in the previous figure legend. 
Gremlin detection (left panel) and BMP-4 detection (middle and right panels), both at 
25 kDa, were achieved by Western blotting using polyclonal gremlin and BMP-4 
detection antibodies, respectively.  Non-specific bands detected at 50 and 60 kDa are 
detected across the gels.  
 
As shown in Figure 5.2, optimal BMP-4 binding to the wildtype gremlin-Myc-bead 
complex occurred on prolonged incubation of 16 h at 4 °C compared to a shorter 
incubation of 2 h at room temperature. Together, both conditions, demonstrated the 
BMP-4 binding capability of expressed wildtype gremlin-Myc.  As shown, a BMP-4 
band, at the anticipated molecular weight of 25 kDa was detected in the initial 
preparation prior to bead binding, and also in boiled bead supernatants (Figure 5.2, 
Tracks 3, middle and right panels). The same band of weaker band intensity compared 
to the initial BMP-4 detection was observed in supernatants collected immediately after 
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bead binding (Figure 5.2, Tracks 2). This represented the excess unbound BMP-4 after 
bead binding. In the same boiled bead supernatant, a gremlin band of the correct 
molecular weight was also detected (Figure 5.2, Track 3, left panel). This demonstrated 
effective loading of beads prior to further immunoprecipitating with BMP-4 in both 
experiments. In this gel, a very faint gremlin band was detected in the crude wildtype 
gremlin-Myc culture supernatant (Figure 5.2, Track 2) which was not visible in the 
supernatant collected after gremlin-Myc bead binding. Stronger detection of BMP-4 
bands in boiled bead supernatants collected after 16 h BMP-4 bead binding at 4 °C 
compared to those detected at 2 h at room temperature, confirmed optimal conditions 
for maximum loading of BMP-4 onto gremlin-Myc-bound beads (refer to Figure 5.2, 
Tracks 3, middle and right panels).  
As was found and discussed in the previous section, a 60 kDa non-specific band 
was detected in all boiled supernatants in spite using two different probing antibodies 
(Figure 5.2, Tracks 3). In this case, the band was even detected in the supernatant 
collected after the BMP-4-gremlin bead binding step when probing with the polyclonal 
BMP-4 primary antibody (Figure 5.2, Tracks 2, middle and right panels). This 
confirmed that this band was not specific to gremlin detection using the polyclonal 
gremlin antibody as is the case with the 50 kDa non-specific band. As expected, the 50 
kDa non-specific band was detected in the crude wildtype gremlin-Myc supernatant 
and only in the supernatant collected after the gremlin bead binding step as it does not 
bind to anti-C-Myc beads (Figure 5.2, labelled track and Track 1, respectively, left 
panel).  
Under the same conditions, similar investigations were carried out using the low 






Figure 5.3: IP of BMP-4 on mutant gremlin-Myc-bead complexes. 
This experiment was conducted in a similar manner to that described in the legend of 
Figure 5.2. The gremlin-Myc-bead-bound complexes were prepared with loading 
volumes stated in the legend of Figure 5.1.  Gremlin detection (left panel) and BMP-4 
detection (right panel), are both shown at 25 kDa. The non-specific bands at 50 and 60 
kDa are also detected.  
 
 
The results shown in the left and right panels of Figure 5.3 represented blots 
probed with polyclonal gremlin and BMP-4 primary antibodies, respectively. Samples 
were collected following loading of 10 ng BMP-4 onto bead complexes of MGRs 3, 5 
and -6 mutants including EGFP as the negative control. Strong detection of a BMP-4 
band, 25 kDa in size, in the boiled bead supernatants of both MGR5 and MGR6 but 
weaker in that of MGR3 indicated the BMP-4 binding activities of these gremlin 
mutants (Figure 5.3, Tracks 3, right panel). This was further supported by only very 
faint detection of a BMP-4 band in the boiled bead supernatant of the EGFP serving as 
a negative control (Figure 5.3, Track 3, right panel).  
Strong, weak and no gremlin detection in the boiled bead supernatants of MGRs 
5, 6 and 3, the same in which BMP-4 detection was achieved, were also observed, 
respectively (Figure 5.3, left panel, Tracks 3). This was consistent in all repeat 
experiments and it is not clearly understood why loading of BMP-4 caused weaker 
gremlin detection in boiled bead supernatants compared to those detected initially in 
their IP alone (refer Figure 5.1, Tracks 3). A likely explanation could have been gradual 
loss of gremlin-Myc-bound beads themselves during the extensive wash cycles they 
were subjected to. Nonetheless, gremlin detection in the boiled bead supernatants of 
both MGRs 5 and 6, respectively, supported their possession of strong BMP-4 binding 
activity. MGR3, whose gremlin band could not be detected in the same boiled bead 
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supernatant in which weak BMP-4 detection was observed, seemed less likely to 
possess BMP-4 binding capability.   
As expected, the BMP-4 bands in all supernatants collected immediately after 
BMP-4 bead binding were less intense than those loaded initially onto the bead 
complex (Figure 5.3, right panel, Tracks 2 and labelled track, respectively). This 
represents the use of excess BMP-4 under these conditions. Again, both 50 and 60 kDa 
non-specific weak and strong bands were observed in all supernatants collected 
immediately after BMP-4 bead binding and in all boiled bead supernatants (Figure 5.3, 
Tracks 2 and 3, respectively).  
Successive attempts to reproduce these results were not entirely successful due 
to the detection of a relatively strong BMP-4 band in the boiled bead supernatant of the 
EGFP that served as negative control (Results not shown). The likely explanation is 
due to the ‘sticky’ nature of BMP-4 itself hence its non-specific binding to the agarose 
matrix most likely. This occurred despite its preparation in 2%(w/v) BSA-containing 
buffer and carrying out multiple wash cycles after each bead binding process (results 
not shown). As such, this limited the observation of specific interactions of BMP-4 
with these gremlin-Myc-bead complexes. As a result, the establishment of another 
protein binding assay was required in order to reliably assess the BMP-4 binding 
capabilities of both wildtype gremlin and its low heparin-binding mutants.  
 
5.3       Assessing the BMP-4 binding capability of wildtype gremlin-Myc and its    
mutants by ELISA 
 
5.3.1 Establishment of a novel Myc-capture GREM1/BMP-4 double sandwich    
ELISA 
Following failure to demonstrate consistent BMP-4 binding using anti-Myc beads, a 
novel Myc-capture GREM1/BMP-4 double sandwich ELISA was established. This 
immunoassay is an adaptation to the pre-established Myc-capture gremlin ELISA (refer 
to Chapter 2, Sections 2.19.3 and 2.19.4). It measures the binding of purified BMP-4 to 
Myc-captured gremlin, thus forming a double antigen sandwich layer. The introduction 
of a BMP-4 binding step required a change upstream to the detection system, replacing 
the polyclonal biotinylated gremlin detection antibody with a monoclonal biotinylated 
BMP-4 detection antibody.   
Initially, the functionality of this novel immunoassay was tested using crude culture 
supernatants of expressed EGFP and WT gremlin-Myc proteins. In the assay, 100 
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µl/well crude culture supernatants were first loaded into coated wells after which wells 
were washed. In a stepwise manner, 75 ng/well purified BMP-4, prepared in PBS-0.5% 
(w/v) BSA buffer, was then loaded prior to its detection upstream. In order to develop a 






Figure 5.4: Effect of the Myc capture antibody loading in the Myc-capture 
GREM1/BMP-4 double sandwich ELISA. 
Wells coated with 2 and 4 µg/ml 9E10 Myc capture antibody were incubated with 100 
µl/well wildtype gremlin-Myc (wtGREM1-Myc) in crude CHO-S culture supernatant 
(Black columns). Wells loaded instead with 100 µl crude EGFP CHO-S culture 
supernatant generated the background immunoreactivity (Shaded columns). 75 ng 
commercially purified BMP-4 was then added. For detection, a biotinylated 
monoclonal BMP-4 antibody at 2 µg/ml was added to wells. Error bars represent SEM 
of quadruplicate absorbance readings (n=4). 2-tailed paired-samples T-test conducted 
comparing EGFP versus wtGREM1-Myc within each paired group. * and ** represent 
p < 0.01 and p < 0.001, respectively.  
 
From the results shown in Figure 5.4, the wildtype gremlin-Myc bound BMP-4 
immunoreactivity (Figure 5.4, black columns) was significantly higher than that 
induced by EGFP (Figure 5.4, shaded columns) within each paired group captured at 
both 2 and 4 µg/ml capture antibody. The EGFP-induced BMP-4 immunoreactivity 
constituted the background immunoreactivity in this ELISA, as it did not contain any 
gremlin protein except perhaps that expressed endogenously by the CHO-S cells 
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themselves which would not be captured on the Myc capture layer being untagged. 
Moreover, a comparison between both group pairs showed that wildtype gremlin-Myc-
induced BMP-4 immunoreactivity at 4 µg/ml capture antibody was significantly higher 
than the same induced immunoreactivity at half its concentration. Despite observing a 
corresponding increase in background immunoreactivity, the higher Myc capture 
antibody concentration was chosen for all subsequent experiments using this ELISA.   
5.3.2 Assessing the BMP-4 binding capabilities of expressed gremlin-Myc 
proteins using the Myc-capture GREM1/BMP-4 double sandwich 
ELISA 
Next, the BMP-4 binding capabilities of the gremlin-Myc mutants, MGRs 3, 5 and 
6, were assessed using the established Myc-capture gremlin/BMP-4 double sandwich 
ELISA. In order to further improve its cost effectiveness, the effect of reducing the 
dose of BMP-4 in this immunoassay was investigated using both wildtype gremlin-Myc 
and its low heparin mutants. 
 
 
Figure 5.5: Effects of BMP-4 loading in the Myc-capture GREM1/BMP-4 double 
sandwich ELISA.  
Wells coated with 4 µg/ml 9E10 Myc capture antibody were incubated with 100 
µl/well crude CHO-S culture supernatants containing either wildtype gremlin-Myc 
(WT GREM1-Myc) or the mutants, MGRs 3, 5 and 6 or EGFP.  Increasing amounts of 
BMP-4 per well prepared in PBS-0.05% (w/v) BSA were then loaded. Detection was 
carried out as described in the previous figure legend. Error bars represent SEM of 
quadruplicate absorbance readings (n=4). Kruskal-Wallis non-parametric one-way 
ANOVA followed by Bonferroni post hoc test were applied only within the group 
assayed at lowest BMP-4 amount in comparison to EGFP background 



























Overall, the results shown in Figure 5.5, demonstrated BMP-4 binding capability of 
both wildtype gremlin-Myc and MGR5. This was demonstrated by their significantly 
higher induced BMP-4 immunoreactivities compared to those generated by EGFP and 
MGRs 3 and 6 within each BMP-4 dose group tested (Figure 5.5, projecting black and 
shaded columns, respectively). Although a progressive dose-dependent increase in 
wildtype- and MGR5-induced BMP-4 immunoreactivities was observed, there was also 
a dose-dependent increase in EGFP background immunoreactivity. Thus, the signal-to-
background ratio remained fairly constant even with a three-fold increase in BMP-4 
amount from 25 ng to 75 ng. As a result, the dose of BMP-4 applied was maintained at 
25 ng in all other subsequent experiments that used this ELISA. 
In contrast to the wildtype and MGR5, both MGR3- and MGR6-induced BMP-4 
immunoreactivities remained similar to corresponding EGFP background 
immunoreactivities within each dose group (Figure 5.5). This may have reflected their 
genuine incapability of BMP-4 binding as a direct effect of their incorporated 
mutations. Alternatively, a trivial explanation is that their levels of expression in their 
respective crude supernatants may have fallen below the limit of detection of the 
double sandwich ELISA itself; a limit set perhaps above the levels of MGR6 
immunoreactivity in crude culture supernatants despite its strong expression.     
 
5.3.3 Effects of soluble heparin on wildtype gremlin-Myc binding interaction 
with BMP-4 in ELISA 
 
Recently, the high resolution three-dimensional crystal structure of PRDC, a close 
homologue of gremlin, has been elucidated by Nolan et al. (2013). Their analyses 
revealed a considerable regional overlap of both its BMP and heparin binding sites on 
the convex binding surface of the cystine-knot domain on the PRDC dimer. This by no 
means suggests that both binding sites are identical and, therefore, these should be 
thought of as being physically distinct. However, their regional proximity on the 
cystine-knot binding domain means that there is a considerable degree of allosteric 
competition between both sites in the presence of a binding ligand as argued by Nolan 
et al. (2013). This was confirmed in SPR measurements, when they showed that 
binding of PRDC to immobilised BMP-2 was inhibited by the addition of 
unfractionated heparin, ~25 kDa, and tinzaparin. Tinzaparin is a low molecular weight 
heparin, 5.5 – 7 kDa (Chiodelli et al., 2011). This inhibition occurred in an increasing 
dose-dependent manner within a tested range of 0.003 – 3 µM. This rather implies that 
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both heparin and BMP binding sites on PRDC are not fully independent from one 
another.  
In this current study, the Myc-capture GREM1/BMP-4 double sandwich ELISA 
was used to verify whether expressed wildtype gremlin-Myc behaved similarly to 
PRDC. In this case, Myc-captured wildtype gremlin-Myc was exposed to increasing 
concentrations of 0 – 20 µM unfractionated heparin prior to the loading of 25 ng/well 
BMP-4. In the experimental design, it was foreseen that the use of unfractionated 
heparin itself might confound the experiment, as it was envisaged that a single 
extended unfractionated heparin chain could provide several gremlin binding sites. This 
alone could potentially increase BMP-4 immunoreactivity resulting in multiple cross-
linked gremlin-BMP-4 complexes. Therefore in order to minimise such risk, a similar 

































         
 
 
Figure 5.6: Effects of soluble unfractionated heparin and tinzaparin on the 
binding interaction between wildtype gremlin-Myc and BMP-4.   
Top and bottom panels: two sets of results from two independent repeat experiments. 
The Myc-capture GREM1/BMP-4 double sandwich ELISA was conducted as 
described in the previous figure legend by coating wells with 4 µg/ml 9E10 Myc 
capture antibody and loading 100 µl/well crude wildtype gremlin-Myc 
(wtGREM1myc) or EGFP culture supernatant. Next varying concentrations of the 
heparins were added to respective wells and incubated for 45 min at room temperature 
prior to loading with 25 ng/well BMP-4. Error bars represent SEM of quadruplicate 
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In the results as shown Figure 5.6, the wildtype gremlin-Myc-induced BMP-4 
immunoreactivity remained fairly constant across the entire concentration range of 
intact heparin (Figure 5.6, upper solid lines) and tinzaparin (Figure 5.6, upper broken 
lines). The marked increase in wildtype gremlin-Myc-induced BMP-4 
immunoreactivity at 1 µM intact heparin was consistent over two independent repeat 
experiments (Figure 5.6, upper solid lines). This increase in BMP-4 immunoreactivity 
together with those observed at 5 and 10 µM (Figure 5.6, bottom panel, upper solid 
line) may indicate multiply cross-linked gremlin-BMP-4 complexes along an intact 
heparin chain, as suggested earlier. This was further supported by the constant levels of 
wildtype gremlin-Myc-induced BMP-4 immunoreactivity across the same 
concentration range of tinzaparin (Figure 5.6, upper broken line). Throughout this 
experiment, the wildtype gremlin-Myc-induced BMP-4 immunoreactivities were 
significantly higher than EGFP background immunoreactivities across the entire 
concentration range of both heparins (Figure 5.6, lower solid and/or broken lines).  
Unlike the binding competition observed by Nolan et al. (2013) between BMP-2 
and heparin on PRDC, addition of intact heparin and tinzaparin neither inhibited nor 
promoted gremlin-Myc interactions with BMP-4. As such, these results verified a 
hypothesis made in this study for the existence of physically distinct heparin/HS and 
BMP binding sites on gremlin which are independent of one another. In other words, 
these binding sites are located at different regions on gremlin and do not compete with 
each other upon binding to their ligands. 
 
5.4  SMAD1/5/8 phosphorylation assay in C2C12 cell cultures 
 
5.4.1. BMPs -4 and -7-induced SMAD1/5/8 phosphorylation 
C2C12 myoblastic cell cultures have been widely used for the establishment of 
functional cellular bio-assays to assess BMP activity (Mulloy and Rider, 2010). 
Addition of bone-inducing BMPs results in the intracellular phosphorylation of R-
SMADs proteins, SMAD1/5/8 and SMAD2/3, that in complex with co-SMAD, SMAD-
4, translocate into the nucleus causing transcriptional up-regulation of osteoblastic 
target gene markers such as alkaline phosphatase (Ali and Brazil, 2014). The end result 
is the BMP-induced transformation of C2C12 myoblastic muscle-type phenotype into 
an osteogenic phenotype (Urist, 1965; Higgins et al., 1970).  
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These intracellular molecular and signalling events, therefore, have led to three 
widely established methods of quantitating BMP activity: 1) measuring levels of 
expression of an osteogenic marker, such as alkaline phosphatase (Katagiri et al., 1994; 
Topol et al., 2000a). 2) Establishing a BMP-specific-luciferase secreted reporter gene 
assay in vitro (Zhao et al., 2003; Sudo et al., 2004; Alborzinia et al., 2013). 3) 
Measuring the SMAD1/5/8 phosphorylation that occurs early along the canonical 
signalling pathway (Kuo et al., 2010). In this latter assay, the stimulus-response lag 
time period is significantly shortened to only 45 – 60 min post-BMP treatment 
compared to 16 – 24 h post-BMP treatment in the other two methods. As such, the 
SMAD1/5/8 phosphorylation assay provides more flexible platform to investigate 
several cellular processes. In this current study, we aimed at adapting this method 
further by investigating the effect gremlin on BMP-dependent levels of phospho (p)-
SMAD1/5/8 activity.  
In our initial approach, the responsiveness of the assay to both BMPs -4 and -7, 
following stimulation of C2C12 myoblastic cells for 45 min at 37 °C, was assessed by 
generating BMP dose response curves.  The results obtained demonstrated that the 
assay was consistently responsive to both BMPs -4 and -7, as shown by the stronger 
detection of the 64 kDa p-SMAD1/5/8 protein bands in their presence (Figures 5.7A 
and 5.8A, top panels, respectively). However, both dose response curves, as determined 
by densitometry, failed to produce graded response in levels of p-SMAD1/5/8 activity 
with increasing amounts of the BMPs (Figures 5.7B and 5.8B, solid line curves).  In 
this experiment, and all other subsequent experiments in this functional assay, a loading 
control was included that involved parallel detection of nonphosphorylated or total (T)-
SMAD1/5/8 activity levels in the same experimental samples from which the p-
SMAD1/5/8 activity levels were detected.  In both cases, strong detection of T-
SMAD1/5/8 protein, 64 kDa, was also observed in the same experimental samples 
(Figure 5.7A and 5.8A, bottom panels). The levels of T-SMAD1/5/8 activity seemed to 
fluctuate somewhat over the range of BMPs -4/-7 doses, but nonetheless remained 
fairly constant (Figures 5.7B and 5.8B, broken line curves).   
Analysis of the BMP-4 dose response curve showed a sharp increase in levels of p-
SMAD1/5/8 activity from 0 - 10 ng BMP-4 which flattened between 10 – 40 ng BMP-4 
(Figure 5.7A, solid curve). Another sharp increase in levels of p-SMAD1/5/8 activity at 
50 ng BMP-4 was observed that then also flattened between 50 – 75 ng BMP-4. On the 
other hand, the BMP-7 dose response curve showed similar sharp increase in levels of 
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p-SMAD1/5/8 activity from 0 - 10 ng BMP-4, and remained at this latter level up to 75 
ng BMP-7.  These shapes in pattern of both dose response curves were consistent over 
several repeat experiments. Despite not observing satisfactory grading of the dose 
response curves over increasing doses of both BMPs, the marked difference between 
the background in the absence of the BMPs and BMPs -4/-7-induced levels of p-
SMAD1/5/8 activity observed, was consistent. This implied that a functional assay for 
assessing BMP activity had been successfully established in line with findings reported 
by Kuo et al. (2010). A graded dose response curve is prerequisite for inhibition studies 
which are needed to assay BMP antagonist activity. Although not the case in these 
results, the marked difference between the background and BMPs -4/-7-induced levels 
of p-SMAD1/5/8 activity meant that there was scope to attempt inhibition of BMP 
activity. 
    
 
  
Figure 5.7: BMP-4 dose response curve in the SMAD1/5/8 phosphorylation assay.  
Undifferentiated C2C12 cell cultures were treated for 45 min at 37 °C with increasing 
doses of purified BMP-4 protein. A) Western blot detection of p-SMAD1/5/8 at 64 kDa 
was achieved using a polyclonal p-SMAD1/5/8 primary antibody. T-SMAD1/5/8 
activity served as control to p-SMAD1/5/8 activity and was detected in parallel using a 
polyclonal T-SMAD1/5/8 primary antibody. B) Densitometric quantitation of 64 kDa 
bands detected in panel A, achieved using the IMAGE Studio Lite software. Results 




    
 
 
Figure 5.8: BMP-7 induced dose response curve in the SMAD1/5/8  
…..phosphorylation assay.  
The BMP-7 dose response curve was generated as described for BMP-4 in the previous 
figure legend. Results are representative of two independent repeat experiments.  
 
5.4.2. Effect of gremlin-His treatment on SMAD1/5/8 phosphorylation    
Next, in order to assess the effect of gremlin in the established SMAD1/5/8 
phosphorylation assay, it was important to show that gremlin alone does not induce p-
SMAD1/5/8 activity. As such, undifferentiated C2C12 cell cultures were treated 
initially with commercially purified gremlin-His at high doses of 0.2 µg and 1 µg.  
Detection of the 64 kDa p-SMAD1/5/8 protein bands was very faint at both doses of 
purified gremlin-His (Figure 5.9A, top panel). The p-SMAD1/5/8 levels of activity at 
0.2 and 1 µg gremlin-His were not significantly different from the background activity 
(Figure 5.9B, black columns). Strong detection of T-SMAD1/5/8 protein, 64 kDa, was 
also observed in the same experimental samples, as shown in Figure 5.9A, bottom gel. 
Altogether, these results demonstrated that gremlin-His treatment of undifferentiated 
C2C12 cell cultures does not initiate SMAD1/5/8 phosphorylation, a result in line with 
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the existing paradigm on its mechanism of action. Therefore, this enabled the 
investigation of its functional activity by significant inhibition of BMPs -4 and -7-




Figure 5.9: Effect of wildtype gremlin-His treatment alone on SMAD1/5/8 
phosphorylation.  
The BMP-independent effect of gremlin-His was assessed in the SMAD1/5/8 
phosphorylation assay.  Undifferentiated C2C12 cells were treated with either 0, 0.2 or 
1 µg of purified wildtype gremlin-His alone. Western blot detection of p- and T-
SMAD1/5/8 at 64 kDa (Panel A), and densitometric quantitation of 64 kDa bands 
(Panel B) were achieved as described in the legend of Figure 5.7. Error bars represent 
the SEM of duplicate readings from paired treatment groups (n=2).   
 
5.4.3 The effect of gremlin-His in the BMP-7-induced SMAD1/5/8 
phosphorylation  
Initial attempts at demonstrating functional activity of gremlin-His were carried out 
by the investigation of its effect on BMP-7-induced SMAD1/5/8 phosphorylation 
established previously (Figure 5.8). From the BMP-7 dose response curve, 30 ng BMP-
7 was chosen from the flattening portion of the curve. Reiterating, the aim in these 
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inhibition studies was to significantly inhibit BMP-induced p-SMAD1/5/8 levels of 
activity hence restoring activity levels equivalent to the background activity in 
untreated cells.  Because is it not known whether gremlin exists as a monomer or a 
dimer, for complete inhibition, the experiment was conducted using 15 ng and 30 ng 
gremlin-His so as to match the theoretical stoichiometric ratios of 1:1 or 2:1 for one 
gremlin dimer or two gremlin  monomers complexed to one BMP-7 dimer, 
respectively. In these experiments, gremlin-His was pre-incubated with BMP-7 at room 
temperature for 45 min with gentle rotation prior to addition to undifferentiated C2C12 




Figure 5.10: Effect of purified gremlin-His on BMP-7-induced SMAD1/5/8 
phosphorylation.  
The SMAD1/5/8 phosphorylation assay was carried out in undifferentiated C2C12 cells 
by addition of different amounts of purified gremlin-His pre-incubated with 30 ng 
purified BMP-7. Western blot detection of p- and T-SMAD1/5/8 at 64 kDa (Panel A) 
and densitometric quantitation of 64 kDa bands (Panel B) were carried out as described 
in the legend of Figure 5.7. Error bars represent the SEM of duplicate readings from 
paired treatment groups (n=2).   
 
As demonstrated in Figure 5.10, inhibition of BMP-7-induced p-SMAD1/5/8 
activity was not achieved at either 15 or 30 ng gremlin-His. In Figure 5.10A, top panel, 
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this was indicated by the persistent strong detection of p-SMAD1/5/8 protein bands, 64 
kDa, in the presence of both 15 and 30 ng gremlin-His. These band intensities were 
comparable to that generated by treating the cell cultures with 30 ng BMP-7 alone. 
Also, in untreated cell cultures, p-SMAD1/5/8 was detected but appeared less intense 
compared to those generated in treated cell cultures. In both treated and untreated cell 
cultures, the T-SMAD1/5/8 protein bands showed comparable band intensities (Figure 
5.10B, bottom panel). In terms of p-SMAD1/5/8 levels of activity, no decrease in this 
activity was observed in cell cultures treated with BMP-7 in the presence of gremlin-
His (Figure 5.10B, black columns). The higher than expected background activity 
observed in untreated cells probed for p-SMAD1/5/8 detection, may have been due to 
contamination of these lysates. This contamination did not seem to affect the levels of 
T-SMAD1/5/8 levels of activity in these samples which was very consistent across all 
samples altogether (Figure 5.10B, shaded columns).  
Given that these doses of gremlin-His did not affect BMP-7 activity, higher doses 
were then applied. This time, the same amount of BMP-7 was pre-incubated with 
gremlin-His at 30 ng, 60 ng and 150 ng prior to treating the undifferentiated cell 
cultures (Figure 5.11).   
In this case, the p-SMAD1/5/8 detection was by inspection, relatively weaker at 
both 60 and 150 ng gremlin-His compared to that generated in cell cultures treated with 
30 ng BMP-7 only (Figure 5.11A). A decrease in BMP-7-induced p-SMAD1/5/8 levels 
of activity at both 60 and 150 ng gremlin-His was confirmed by densitometric analyses, 
however this was not statistically significant (Figure 5.11B).  Moreover, the 
background detection in the untreated cell cultures was very faint, as would normally 
be expected (Figure 5.11A). The BMP-7-induced p-SMAD1/5/8 levels of activity in 
gremlin-treated cells remained significantly higher than the background activity in 
untreated cell cultures. The fact that similar levels of BMP-7 inhibition were achieved 
at 60 ng gremlin-His and at 150 ng gremlin-His, more than double the lower dose, 
strongly demonstrated the poor quantitative power of this functional assay.  
According to the existing dogma, gremlin is a natural antagonistic of the BMPs -2, -
4 and -7, as introduced earlier in this thesis (Chapter 1, Section 1.15). However, strong 
experimental evidence has been obtained to demonstrate that this is true for the BMPs -
2 and -4 but scarcely for BMP-7. For instance, Sudo et al. (2004) demonstrated the 
functional activity of PRDC alongside gremlin-His by their antagonism of these BMPs-
mediated signalling using a luciferase-secreted reporter assay. Here, gremlin 
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antagonism of BMPs -2/-4-SMAD1/5/8-induced luciferase expression was much 
stronger than that observed for BMP-7-induced signalling. Therefore BMP-4 was used 
in further studies of inhibition of SMAD1/5/8 signalling.  
            
 
 
Figure 5.11: Effect of higher doses of purified gremlin-His on BMP-7-induced 
SMAD1/5/8 phosphorylation. 
This experiment was carried out as described in the previous figure legend except that 
the doses of purified gremlin-His applied were increased as indicated. A) Western blot 
of p- SMAD1/5/8 (64 kDa). B) Densitometric quantitation of 64 kDa bands as detected 
in panel A. Error bars represent the SEM of duplicate readings from paired treatment 
groups (n=2).   
 
5.4.4. Effect of gremlin-His in the BMP-4-induced SMAD1/5/8 
phosphorylation  
When purified BMP-7 was substituted with purified BMP-4 and pre-incubated with 
gremlin-His, the same results were achieved; no significant inhibition of BMP-4 
induced p-SMAD1/5/8 activity was observed (Figure 5.12).  In this case, 25 ng and 50 
ng BMP-4 doses were chosen from its dose response curve established previously 
(Figure 5.7). Inhibition was achieved by pre-incubating purified BMP-4 with purified 




The p-SMAD1/5/8 protein bands, 64 kDa, detected in BMP-4/gremlin-His-treated 
cell lysates remained as strongly intense as that detected in BMP-4 only-treated cell 
lysates (Figure 5.12A). This was also observed in densitometric analyses of this band 
which showed no significant difference between both groups (Figure 5.12B).  The fact 
that the levels of p-SMAD1/5/8 activity in gremlin only-treated cell lysates were 
similar to the background activity in untreated cells, confirmed observations made 
earlier in Section 5.4.2. This experiment also demonstrated that gremlin-His on its own 




Figure 5.12: Effect of purified gremlin-His on BMP-4-induced SMAD1/5/8 
phosphorylation. 
This experiment was carried out as described in the legend of Figure 5.10 except that 
gremlin-His was pre-incubated with either 25 or 50 ng purified BMP-4 instead. A) 
Western blot of p-SMAD1/5/8 (64 kDa). B) Densitometric quantitation of 64 kDa 
bands as detected in panel A. Error bars represent the SEM of duplicate readings from 
paired treatment groups (n=2).   
 
The continued failure to demonstrate significant gremlin-His antagonism of BMP-
4-induced p-SMAD1/5/8 levels of activity meant that further work on this SMAD1/5/8 
phosphorylation assay was aborted. Such demonstration would have confirmed whether 
purified gremlin-His was functionally active providing quantitative insight into the 
effective dose of gremlin necessary for significant inhibition of both BMPs. This 
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information would have served as a useful reference for subsequent work of similar 
kind using the expressed gremlin-Myc proteins instead. Nevertheless, unsuccessful 
results despite using high amounts of gremlin-His of up 200 ng implied that expressed 
wildtype gremlin-Myc amounts greater than 200 ng would be required. With relatively 
low levels of its transient expression, it is likely that the expressed gremlin-Myc 
proteins would be insufficient in this functional assay. Thus the establishment of a 
more reliable quantitative and responsive functional assay was necessary. The lack of 
graded BMPs -4 and -7 dose response curves is believed to have been a fundamental 
problem in this assay and, therefore, must be avoided in the next functional assay. As 
such no attempts were made at testing our expressed gremlin-Myc proteins since these 
observations rather suggested that measuring the levels of p-SMAD1/5/8 activity in the 
BMP signalling pathway, does not yield a satisfactorily quantitative functional assay 
under the conditions used here; one requiring quite large amounts of gremlin to elicit a 
small response in p-SMAD1/5/8 activity. This remains a fundamentally limiting 
problem that must be taken into account when developing any robust functional assay.  
5.5. Investigating the functional activity of wildtype gremlin-Myc and its low 
heparin-binding mutants using a luciferase-secreted reporter assay 
  
5.5.1. Establishment of a luciferase-secreted reporter assay 
The BMP-SMAD1/5/8 specific luciferase-secreted reporter assay was one of three 
methods discussed earlier (Section 5.4.1), which can be applied to assess BMP-induced 
signalling along this axiomatic pathway. This reporter assay requires at least 16 – 24 h 
of incubation time period post-BMP treatment of cells before a strong measurable 
activity in SMAD1/5/8-induced luciferase expression can be detected. As such, this 
method is not especially suitable for investigating processes associated with fast 
recycling such as heparitinase treatment of cells in order to strip them of their cell 
surface HS. On the other hand, this method remains to date as the most sensitive, 
reliable and cost effective method to demonstrate functional activity in many proteins.  
In this study, the establishment of a BMP-4-SMAD1/5/8-specific luciferase-
secreted reporter assay was achieved using the 12XSBE-Oc-Luc+-pGL3 reporter gene 
construct. This reporter gene construct possesses a 12 repeat SMAD binding element 
(12XSBE) concatemer enhancer region that promotes high affinity binding of p-
SMAD1/5/8-SMAD4 complex. The reporter construct was cloned initially by Zhao et 
al. (2003) and was used in this study in order to mirror the approach by Sudo et al. 
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(2004), who used this reporter assay to demonstrate functional activity of BMPs -2, -4 
and -7 in P19 embryonic carcinoma cell cultures and their subsequent inhibition using 
both purified wildtype PRDC and gremlin-His. This current study aimed at establishing 
the same functional assay in undifferentiated C2C12 myoblastic cell cultures. By 
adding a suitable volume of luciferin-containing substrate to up-regulated luciferase-
containing lysates, the luciferase activity can be quantified, as a direct measure of 
BMP-induced SMAD1/5/8 activity upstream. 
As shown in Figure 5.13, a graded increase in luciferase activity was observed at 
BMP-4 concentrations ranging between 0 – 10 nM. The same smooth shape in pattern 
was consistently generated following two different transfection protocols; 
Lipofectamine 2000- and Fugene 6-based transfection protocols (Figures 5.13 A and B, 
respectively). Typically, transient transfection of undifferentiated C2C12 cell cultures 
was carried out in a single tissue culture flask in order to achieve the same transfection 
efficiency. The transfected cell cultures were then split into 24-well tissue culture plates 
and allowed to adhere prior to treating them with purified BMP-4 protein. When using 
the Lipofectamine 2000 protocol, a more than 90% confluency in the cell cultures was 
required prior to transfection, whereas only 70% confluency was required using the 
Fugene 6 protocol. Therefore, the Fugene 6 protocol offered a higher throughput 
experimental route than the Lipofectamine 2000 protocol and also, minimised the risk 
of achieving 100% cell confluency post-transfection. It is well established that at 100% 
confluency, undifferentiated cells undergo terminal differentiation which results to 
changes in intracellular signalling activities (Yoshida et al., 1998). 
As shown in Figure 5.13A, the BMP-4 dose response curve generated using the 
Lipofectamine 2000-based transfection protocol yielded higher luciferase activity 
compared to that generated using the Fugene 6-based transfection protocol (Figure 
5.13B). This observation may be due to the difference in transfection periods although 
differences in the mechanism of operation of both transfection reagents cannot be ruled 
out. Nonetheless, the signal-to-background signal ratio in both methods was highly 
satisfactory. In both cases, a linear responsive range was observed between 0 – 4 nM 
BMP-4 in the former and 0 – 5 nM BMP-4 in the latter (refer to Figures 5.13 A and B, 
respectively). Altogether, this is an important result as it overcomes the issue on 
consistent lack of graded BMPs -4/-7 dose response curves encountered in the 
SMAD1/5/8 phosphorylation assay discussed previously (refer to Section 5.4.1, Figures 
5.7B and 5.8B). Establishing consistent and graded BMP-4 dose response curves using 
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the luciferase reporter assay was a fundamental prerequisite to carrying out inhibition 
































Figure 5.13: BMP-4 dose response curves in the secreted-luciferase reporter assay.  
Undifferentiated C2C12 cell cultures were transiently transfected with 6 – 9 µg 
12XSBE-Oc-luc+-pGL3 reporter construct using the Lipofectamine 2000 (A) and 
Fugene 6 (B) transfection reagents. Cell cultures were subsequently treated with 
increasing concentrations of purified BMP-4, added exogenously. Luciferase activity 
was measured using the GloMax luminometer by addition of 100 µl substrate to 30 µl 
cell lysate. Error bars represent the SEM of duplicate relative light unit (RLU) values 





































5.5.2. Investigating the functional activity of wildtype gremlin-Myc and its 
mutants 
Having established graded BMP-4 dose response curves (refer to Figure 5.13), 
the functional activity of concentrated wildtype gremlin-Myc and its low-heparin 
binding mutant proteins were investigated. This was carried out using both 
Lipofectamine 2000- and Fugene 6-based transfection protocols, as described in the 
previous section. The commercially-purified wildtype gremlin-His protein was also 
used in order to verify the findings by Sudo et al. (2004).  
The results as shown in Figure 5.14, demonstrated that concentrated expressed 
wildtype gremlin-Myc together with MGRs 5 and 6 mutant proteins, were functionally 
active. This was indicated by significant inhibition of 3.6 and 5 nM BMP-4 induced 
luciferase activity (Figures 5.14 A and B, respectively). Significant inhibition of BMP-
4 activity was also observed at 25 nM purified gremlin-His protein in line with the 
findings by Sudo et al. (2004), (Figure 5.14B). Greater gremlin-His-mediated inhibition 
of BMP-4-induced luciferase activity was observed at 50 nM, demonstrating a 
concentration-dependent gremlin-mediated antagonism of BMP-4 activity. No 
significant inhibition of BMP-4 activity was achieved with concentrated MGR3 (Figure 
4B). 
Previously in this current study, the concentration of the expressed wildtype 
gremlin-Myc protein in crude culture supernatant was semi-quantified against purified 
gremlin-His using Western blotting at 50 ng/ml which approximates to about 2 nM 
(data not shown). Equally, by comparing the wildtype gremlin-Myc dose response 
curve to those of MGRs 3, 5 and 6 generated previously using the Myc-capture gremlin 
ELISA, their concentrations were estimated (refer to Figure 4.2, Chapter 4). These data 
had previously indicated that the slope of MGR5 immunoreactivity in crude culture 
supernatant was greater than or equalled that of wildtype gremlin-Myc, [MGR5] ≥ 2 
nM, whereas the slope of MGR6 immunoreactivity was approximately half that of the 
wildtype, [MGR6] ≅ 1 nM. That of MGR3 was at least 40-fold less than wildtype, 








Figure 5.14: Investigating the functional activities of expressed gremlin-Myc 
proteins. 
The experiments were conducted as described in the legend of Figure 5.14. 
Transfection of C2C12 myoblastic cell cultures were conducted using either (A) 
Lipofectamine 2000 or (B) Fugene 6 transfection reagents. Fixed BMP-4 doses of 3.6 
nM and 5 nM were chosen from BMP-4 dose response curves generated using the 
respective protocols (refer to Figure 5.13). The commercially-purified wildtype 
GREM1-His protein in panel B served as positive control. In this case, n = 3. Statistical 
analyses: Post hoc LSD followed Kruskal-Wallis non-parametric one-way ANOVA. 
Comparisons made against RLU value at 3.6 and 5 nM BMP-4. * indicates p<0.05; 
**indicates p< 0.01; *** indicates P<0.0001. Results are representative of at least two 
independent repeat experiments. 
 
 
In the results shown in Figures 5.14 A and B, significant BMP-4 inhibition at 
100 µl and 150 µl concentrated wildtype gremlin-Myc corresponded to functional 
activity at concentrations of 8 nM and 12 nM, respectively. Likewise, significant BMP-
4 inhibition at 150 µl concentrated MGR5 and 200 µl concentrated MGR6 
corresponded to functional activity at concentrations ≥ 12 nM and ≅ 8 nM, 
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respectively. Also concentrated MGR5-mediated inhibition of 3.6 nM BMP-4 activity 
was not significant at 8 nM (100 µl), the same concentration at which concentrated 
MGR6 showed significant inhibition of 5 nM BMP-4 activity (Figures 5.14 A and B). 
On this basis, MGR5 may be considered less functionally active than MGR6. In the 
case of MGR3, 200 µl concentrated MGR3 corresponded to only 0.4 nM which may 
have explained its functional inactivity (Figure 5.14B).  
The purified wildtype gremlin-His protein appeared to show stronger functional 
activity than the concentrated expressed wildtype gremlin-Myc protein (Figure 5.14B). 
This can be explained by the difference in the doses that were applied as it has been 
established that gremlin-mediated antagonism of BMP-4 varies in a concentration-
























The work described in this chapter was aimed at investigating BMP binding 
capability of expressed wildtype gremlin-Myc and its low-heparin binding mutants, 
MGRs 3, 5 and 6, and also at assessing their functional activity in vitro.  
Immunoprecipitation of BMP-4 on gremlin-Myc complexes of agarose anti-C-Myc 
beads indicated that wildtype gremlin-Myc together with MGRs 3, 5 and 6, were able 
to bind BMP-4. In this experiment, a marked difference in BMP-4 band intensity was 
observed in boiled bead complex supernatants of all gremlin-Myc proteins compared to 
that of the EGFP negative control. However in subsequent repeat experiments, this 
marked difference was less pronounced with even strong BMP-4 detection in EGFP 
boiled bead supernatants at times. The likely explanation is that purified BMP-4 protein 
is highly ‘sticky’ binding non-specifically to the beads. Reducing the loading amount of 
BMP-4 and introducing Tween20 detergent in washes did not reduce this non-specific 
binding. This greatly limited interpretation on the specific interaction between these 
gremlin-Myc proteins and BMP-4. The strong recovery of gremlin in boiled bead 
complex supernatants following loading of the anti-C-Myc beads with wildtype and 
mutant crude gremlin-Myc supernatants, demonstrates that gremlin-Myc proteins can 
be concentrated using anti-C-Myc beads.  For example, MGR3 is not detectable by 
Western blotting of its crude culture supernatant whereas strong detection is achieved 
in the boiled bead complex supernatant following its immunoprecipitation on anti-C-
Myc beads.  
In a novel Myc-capture GREM1/BMP-4 double sandwich ELISA, BMP-4 binding 
of wildtype gremlin-Myc and MGR5 mutant was reproducibly demonstrated using 
crude culture supernatants. In this assay, both MGRs 3 and 6 failed to capture 
significant BMP-4 immunoreactivity. Previously in this study, the amount of wildtype 
gremlin-Myc expressed in its crude culture supernatant was estimated by using both 
Western blotting and Myc-capture gremlin ELISA. Given that loadings of 0.125 
ng/well MGR3 and 2.5 ng/well MGR6 did not generate significant BMP-4 
immunoreactivity, it is possible that the limit of detection of the double sandwich 
ELISA was higher than 2.5 ng thus explaining the trend in results. On this basis, the 
BMP-4 binding activity of these mutants cannot be ruled out. On another hand, it is 
also possible that these observations may have genuinely reflected on the true BMP-4 
binding capabilities of both MGRs 3 and 6. Perhaps the specific mutations they each 
incorporate may have damaged a major BMP-binding epitope in them. Both mutants 
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share the same arginine and lysine substitutions in their basic cluster II, but differ in 
that MGR3 possesses combined substitutions in its entire basic cluster IIIa whereas 
MGR6 possesses combined substitutions in its basic cluster I. MGR5 which 
demonstrates BMP-4 binding, possesses combined substitutions in its basic clusters II 
and IIIb. Therefore, although all possess the basic cluster II substitutions, the different 
additional substitutions in both MGRs 3 and 6, may have caused modifications in the 
folding of the proteins. 
Using the same double sandwich ELISA, addition of both unfractionated heparin 
and the low molecular weight heparin, tinzaparin, both neither promoted nor inhibited 
the binding interaction of wildtype gremlin-Myc with BMP-4. The important 
information here was that addition of intact heparin did not result in the inhibition of 
wildtype gremlin-Myc-induced BMP-4 immunoreactivity. Therefore overall, this 
strongly supported an initial hypothesis of this study, for the existence of two 
physically isolated and independent heparin/HS and BMP binding sites on gremlin. 
These observations go further to reveal the type of subtle structural differences that can 
lead to different mechanisms of action between even closely related BMP antagonists, 
such as gremlin and PRDC. Previously, Nolan et al. (2013) demonstrated competitive 
binding between both binding sites to their ligands. This was believed to be the case 
because of the regional overlap between the binding sites that are both located on 
convex binding surface of the cystine-knot domain on a PRDC dimer.   
A Western blot detection of SMAD1/5/8 phosphorylation assay was established 
using both BMPs -4 and -7 in order to assess the functional activity of the expressed 
wildtype gremlin-Myc and its mutants, MGRs 3, 5 and 6. In this semi-quantitative 
assay, the levels of BMP-induced p-SMAD1/5/8 activity were measured at an early 
step of the canonical BMP-SMAD1/5/8 signalling pathway. Therefore, a rapid response 
was observed following treatment of undifferentiated C2C12 myoblastic cell cultures 
with different doses of these BMPs.  
This functional assay was consistently responsive to both BMPs -4 and -7 
treatments, but, however, it failed to produce BMPs -4 and -7 dose response curves. 
This was not ideal, as establishing a dose response curve is a prerequisite in inhibition 
studies to assay BMP antagonist activity. Irrespectively, the low background activity in 
untreated cell cultures was a consistent feature of the assay. This meant that only near 
complete inhibitions of BMP activity could be detected in this functional assay. This 
was attempted using high doses of purified gremlin-His protein at fixed doses of both 
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BMPs -4 and -7 chosen from their dose response curves. Unfortunately, such 
significant inhibition was not achieved. It is possible that the fixed BMPs -4 and -7 
doses chosen fell on non-responsive regions of the dose response curves where much 
higher doses of gremlin-His than those tested would be required. Nonetheless, given 
that the aim here was to assess the functional activity of gremlin-Myc proteins, present 
at low amounts in crude culture supernatants, it is clear that this assay was not suitable.  
It was demonstrated that gremlin-His treatment of undifferentiated C2C12 cell 
cultures alone did not induce SMAD1/5/8 phosphorylation in the SMAD1/5/8 
phosphorylation assay. This was in line with findings reported by Sudo et al. (2004) 
using a luciferase-secreted reporter assay in P19 embryonal carcinoma cell cultures in 
which the levels of gremlin-induced luciferase expression were comparable to the 
background activity in untreated cell cultures.  
Instead, attention was turned towards the same SMAD1/5/8-specific luciferase-
secreted reporter assay established by Sudo et al. (2004) to demonstrate functional 
activity of the BMPs -2, -4 and -7 and also that of purified PRDC and purified gremlin-
His proteins. In this current study, this was established by transfecting undifferentiated 
C2C12 myoblastic cell cultures with the same 12XSBE-Oc-luc+-pGL3 construct 
employed by Sudo et al. (2004). This functional assay is more quantitative than the 
potential functional assays considered so far in this study. In the assay, these BMPs 
induce SMAD1/5/8-mediated transcriptional activation and up-regulation of luciferase 
expression whereas both Myc- and His-tagged gremlin antagonist proteins, down-
regulate BMP-induced response thus is suitable to help assess the functional activity of 
expressed wildtype gremlin-Myc and its low-heparin binding mutant proteins, MGRs 3, 
5 and 6. Given their low expressions in crude CHO-S culture supernatants, these 
gremlin-Myc proteins were concentrated 20-fold prior to use in this functional assay.   
This work would also aim at comparing the functional activity of purified gremlin-His 
protein versus that of the expressed wildtype gremlin-Myc.  
Initially, graded BMP-4 dose response curves were established on a consistent 
basis. Such responses were observed using two different transfection reagents, 
Lipofectamine 2000 and Fugene 6. A high signal-to-background signal ratio was 
generated following both experimental protocols.  
Next, the functional activity of concentrated wildtype gremlin-Myc and two out of 
three low-heparin binding mutants, MGRs 5 and 6, were demonstrated. Concentrated 
wildtype gremlin-Myc protein was more functionally active than both MGRs 5 and 6. 
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The functional activity of concentrated MGR6 is inconsistent with previous 
observations on its BMP-4 binding capability in the Myc-capture GREM1/BMP4 
double sandwich ELISA. In contrast, ELISA of crude MGR6 culture supernatants did 
not generate significant BMP-4 immunoreactivity which had previously indicated that 
MGR6 lacks BMP-4 binding activity.  
The lack of any functional activity of MGR3 in both double sandwich ELISA and 
luciferase reporter assay may have been as a result of its very low expression in the 
crude CHO-S cell culture supernatant. Even after a 20-fold concentration, the MGR3 
concentration remained at least 20 – 40-fold lower than that of concentrated wildtype 
gremlin-Myc and MGRs 5 and 6.  Until MGR3 concentrations can be increased 
significantly, conclusive observations cannot be made on the functional activity of this 
mutant.    
In the luciferase reporter assay, commercially purified wildtype gremlin-His was 
shown to be functionally active, in line with findings by Sudo et al. (2004). Moreover, 
its antagonism of BMP-4 activity occurred in a dose-dependent manner. A direct 
comparison of the functional activity of wildtype gremlin-His versus concentrated 
expressed wildtype gremlin-Myc was made. The former appeared to be more 
functionally active than the latter. This difference was likely caused by the discrepancy 
in concentrations tested. As the aim of this study was to establish whether wildtype 
gremlin-Myc and its mutants, MGRs 3, 5 and 6 are functionally active, investigating 
further this difference between His- and Myc-tagged wildtype gremlin was not essential 




CHAPTER 6:  General discussion and conclusion 
6.1 Mapping of the heparin binding site on gremlin 
The primary aim of this study was to map experimentally the heparin/HS 
binding site on gremlin. Because gremlin has no experimentally determined structure, 
this study was based on knowledge from its predicted three-dimensional structure. 
Before this study was underway, within the CAN family, only the NMR structure of 
sclerostin had been resolved (refer to Figure 1.7), (Veverka et al., 2009). On this 
resolved sclerostin structure, a heparin binding site was also mapped experimentally; 
the only one within the CAN family. As discussed fully in Chapter 1, Section 1.8.2, the 
experimental mapping of the heparin binding site on sclerostin was achieved by NMR 
spectral analyses which monitored backbone changes in amide signals on sclerostin on 
addition of heparin oligosaccharides. In parallel, docking calculations of heparin 
binding were also performed (Veverka et al., 2009). The heparin binding site on 
sclerostin was mapped as a linear positively charged patch of largely arginine and 
lysine residues side chains, with eight of the residues located on the β-finger loop 2 (f2 
loop) and four in the disoriented loop of the wrist region (refer to Figures 1.7B and 
6.1), (Veverka et al., 2009).  
It follows that the initial homology modeling upon which this current study was 
based, employed the NMR structure of sclerostin to generate predicted models of all 
CAN family members (Rider and Mulloy, 2010). Their docking calculations predicted 
that all CAN family members except for DAN and Cerberus, but including gremlin, 
would possess heparin binding capabilities. It is these predictions which led to the 
hypothesis that gremlin possesses a specific heparin binding site, which would be 
constituted largely of positively charged arginine and lysine residues. As revealed in 
this study, these were present within the primary sequence of the gremlin precursor as 
three main basic clusters, basic clusters I (86 – 91), II (145 – 148) and III (166 – 177). 
Also notable is the analysis that two out of three basic clusters (basic clusters II and III) 
are located on the f2 loop (refer to Figure 3.4) within the cystine-knot domain which 
spans amino acid residues 94 – 184 (Pearce et al., 1999). Interestingly, these three basic 
clusters are absent in both DAN and Cerberus (refer to Figure 3.4). On this basis, 
strategic site-directed mutagenesis was targeted on these basic clusters of wildtype 
gremlin which involved substituting predicted contact arginine and lysine residues with 
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mostly polar and nonpolar residues possessing neutral side chains, taken from the 
homologous sequence clusters on either DAN or Cerberus.  
As was discussed earlier in Chapter 3, Section 3.3, a standard strategy to site-
directed mutagenesis is alanine-scanning mutagenesis which in this context introduces 
clusters of alanine residues possessing relatively smaller side chains in place of the 
targeted basic clusters on gremlin (Morrison and Weiss, 2001).  The substitution with 
alanine residues in tandem is not ideal in this case particularly, as it introduces fairly 
hydrophobic residues at the surface of the gremlin protein and may allow for much 
flexibility in the β-finger loops because of the small size of the alanine side chains. 
Therefore this might lead to misfolded gremlin mutants with incorrect cysteine-cysteine 
pairing. On the other hand, it seems the approach of homologous substitution is ideal as 
it allows for better chances to retain the conserved cysteine partners within the cystine-
knot motif in appropriate orientations and spacing so that the correct disulfide bridges 
are also retained in the expressed mutants.  
The use of such strategic site-directed mutagenesis within the cystine-knot 
domain of gremlin has a precedent which also argues in favour of the likelihood of 
correct folding of the gremlin-Myc mutants expressed in this current study. Sun et al. 
(2006) when mapping the BMP-4 binding site on wildtype gremlin-His, cloned and 
expressed eight different gremlin mutants by substituting sequence clusters along the β-
finger loops bonded by cysteine residues. These substitutions were done with sequence 
clusters from homologous regions of the Mucin-2 cystine-knot domain. Mucin-2 is a 
distant homologue to CAN family members possessing a similar eight-membered 
cystine-knot ring, although it is not a BMP antagonist (Forstner et al., 1979). 
Importantly, in spite of substituting sequences up to 74 amino acid long that spanned 
across both β-finger loops and which represents approximately 40% of gremlin, an 
active gremlin chimera capable of BMP-4 binding was still generated. This implied that 
despite substituting such large sequence cluster on gremlin, its overall tertiary fold was 
not perturbed (Sun et al., 2006). Moreover, the same results was achieved even by 
deletion of a sequence cluster of 60 amino acids (32% of the entire structure)  in the N-
terminal region outside its cystine-knot domain thus yielding a truncated gremlin 
protein but with a correctly folded cystine-knot motif (Sun et al., 2006). 
Comparatively, in this current study, the largest combined substitutions encompassed a 
total six amino acid residues, which represents only approximately 3% of the entire 
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structure. Therefore, it is highly unlikely that the mutations carried out in this study 
changed the overall tertiary structure of the gremlin-Myc mutants expressed.  
Markedly reduced binding to heparin was demonstrated in six C-Myc-tagged 
gremlin mutants, MGRs 1 – 6, possessing different mutations of the basic clusters I – 
III compared to the wildtype gremlin-Myc (refer to Table 3.2 and Figures 4.11 and 
4.16). This was observed using both the heparin-binding ELISA, and analytical heparin 
affinity chromatography. In the latter, the wildtype peak immunoreactivity eluted on 
average at 0.8 M NaCl which was in line with the previously reported high NaCl 
molarity required for its elution (Stabile et al., 2007). In their work the major peak of 
activity of gremlin eluted at 1 M NaCl from a preparative column of heparin-
Sepharose. It is highly probable that this discrepancy in gremlin elution peaks might 
have been due to the column loadings; 2 ml wildtype gremlin-Myc CHO-S culture 
supernatant in the current study versus 21 L conditioned medium of FGF2-T-MAE 
cells. Moreover, the difference in column sizes might have equally contributed to the 
discrepancy; 200 µl AF heparin HC650M bead column used in this current study 
versus 10 ml heparin-Sepharose column used by Stabile et al. (2007). A similar elution 
peak ranging from 0.8 – 1 M NaCl was reported previously for the NaCl elution of the 
wildtype BMP antagonist Noggin from an analytical heparin-Sepharose column (Paine-
Saunders et al., 2002). Because Noggin has an established physiological relevant 
interaction with HS in vivo in restricting diffusion of BMP morphogens, this strongly 
suggests that wildtype gremlin-Myc may also bind to HS on cell surfaces to yield a 
relevant physiological response (Paine-Saunders et al., 2002).  
In contrast to wildtype gremlin-Myc, the elution peaks for all the gremlin-Myc 
mutants was between 0.32 – 0.42 M NaCl which represented approximately 47.5 – 
60% reduction in heparin binding of the wildtype. Paine-Saunders et al. (2002) 
demonstrated that a functionally active low-heparin binding Noggin deletion mutant, 
hNogΔB2, that showed no detectable binding to HS on cell surfaces, eluted between 
0.2 – 0.4 M NaCl from a heparin-Sepharose column. This represented approximately 
50 – 80% reduction in heparin binding of wildtype Noggin, thus demonstrating that 
complete abrogation of heparin binding in the gremlin mutants is not a prerequisite for 
further investigation of their interaction with HS. By markedly affecting the heparin 
binding of wildtype gremlin using targeted site-directed mutagenesis, these results 
demonstrated that all of its three contact basic clusters, I – III, contribute to the putative 
heparin binding site.  
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As shown in Figures 6.1 and 6.2A, these key arginine and lysine residues within 
the heparin binding site on gremlin are located mostly on both its β-strands 3 (basic 
clusters II) and 4 (basic cluster III) that form the f2 loop. The two contact residues of 
basic cluster I, which constitute the few, are located just outside the β-strand 1 on the 
disordered N-terminal tail loop (refer to Figures 6.1 and 6.2A).  
 
6.2 Mapping of the heparin binding site on the predicted gremlin model based 
on the crystal structure of PRDC 
Whilst this study was underway, the crystallographic structure of a second CAN 
family member, PRDC, the closest homologue to gremlin, was elucidated (refer to 
Figure 1.8), (Nolan et al., 2013). On this structure, those workers were able to map 
experimentally the BMP binding site on PRDC and also predict its heparin binding site 
(refer to Chapter 1, Section 1.8.3). The heparin binding site was predicted by scanning 
its electrostatic surface during which positively charged patches constituted of similarly 
charged basic amino acid residues were mostly located on the f2 loop with a few 
residues in the α1 N-terminal helical tail region (refer to Figures 1.8 and 1.9), (Nolan et 
al., 2013).These recent findings necessitated the remodelling of the gremlin structure 
based on this new PRDC template with fresh docking calculations. These were then 
compared against the sclerostin-based mapping predictions upon which this current 
study was based.  
Shown in Figures 6.2 A and B are the predicted monomeric gremlin structures 
as based on either sclerostin or PRDC, respectively. Noticeably, the PRDC-based 
gremlin monomer (Figure 6.2B) possesses more extended β-finger loops and a 
shortened disordered loop in the wrist region compared to the sclerostin-based model 
(Figure 6.2A). Also present in the former predicted structure, is a flexible and 
disordered N-terminal tail possessing an α1 helical coil. Importantly, it can be seen that 
both predicted structures agree on the location of the putative heparin binding site on 
gremlin in that it is located mostly on both its β-strands 3 and 4 that form the f2 loop 
with a the few located just outside the β-strand 1 on the disordered N-terminal tail loop 










Figure 6.1: Polypeptide sequence alignment of the experimentally mapped heparin 
binding site on Noggin, gremlin and sclerostin.  
Highlighted in light blue are the amino acid residues that form their putative heparin binding 





























































































































































































































































































































































































































































































































































































































































































6.3 Comparison of experimentally mapped heparin binding sites within the 
BMP antagonist family 
Altogether, this work establishes gremlin as the second CAN family member 
after sclerostin and third BMP antagonist including Noggin, to possess an 
experimentally mapped heparin binding site. A sequence alignment highlighting the 
experimentally mapped contact amino acid residues forming the heparin binding site on 
Noggin, gremlin and sclerostin is shown in Figure 6.1. Despite exhibiting high 
structural similarity, some differences are observed in the location and distribution of 
the heparin binding site on these BMP antagonists. In Noggin, all contact residues are 
located outside its cystine-knot domain and based on the three-dimensional structure of 
its dimer, are clustered exclusively in the wrist region at the tip of the associating α-
helical loops where the two monomer heads join thus forming a single heparin binding 
site (Groppe et al., 2002). By contrast the CAN family members, sclerostin and gremlin 
share much closer resemblance in the location of their heparin binding sites with the 
majority of the key contact residues located on the f2 loop (Figure 6.1). However in 
addition to observing subtle differences in the distribution of the basic contact residues 
within the f2 loop, the N-terminal tail loop on gremlin is also involved in heparin 
binding (Figure 6.2B) whereas in sclerostin, its disordered loop in the wrist region is 
involved instead (Veverka et al., 2009). These findings indicate that the heparin 
binding site on BMP antagonists has not remained conserved through evolution unlike 
their structural tertiary folds. This may perhaps explain the diverse roles of HS 
observed in its interactions with BMP antagonists and other cytokines.   
 
6.4 Nature of the binding interaction between gremlin and heparin 
As a highly acidic biomolecule, HS binds to a diverse spectrum of growth 
factors, cytokines and morphogens such as FGFs, epidermal growth factors (EGFs), 
interleukins -2, -6 and -12, IFNγ, TGFβ-1, and some neurotrophic factors, BMPs and 
BMP antagonists (Rapraeger et al., 1991; Lortat-Jacob, 1996; Hsu et al., 1998; 
Mummery and Rider, 2000; Alfano et al., 2007; Kuo et al., 2010). It is widely believed 
such binding interaction is stabilised mainly via purely electrostatic interactions 
between the exposed positively charged residues on protein surfaces and the side chain 
carboxylate and sulfate acidic groups on HS polysaccharides. However, some findings 
strongly indicate that these heparin binding proteins may exhibit a strong element of 
specificity with particular heparin/HS centered on a specific sequence context. A 
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classic example of this is the unique pentasaccharide recognition sequence on heparin 
that is required for binding to and full activation of antithrombin III which is centered 
on a rare 3-O-sulfated glucosamine (Rosenberg and Lam, 1979; Lindahl et al., 1980). 
Considering heparin is highly heterogeneous, the discovery of such specific sequence 
was evidence that the sequence of heparin/HS can contain biochemical information. 
This recognition sequence on heparin for antithrombin III, remains to date uniquely 
specific of the interaction of heparin-binding proteins with heparin. Despite extensive 
studies on other heparin-binding proteins, particularly the FGFs, a consensus sequence 
counterpart to the antithrombin III pentasaccharide recognition sequence on heparin has 
yet to be defined. 
On the other hand, the mapping of a specific heparin binding site on the heparin-
binding proteins themselves, has contributed considerably to the argument in favour of 
specific binding of heparin/HS to these proteins. These have been well documented 
elsewhere (Hileman et al., 1996; Xu and Esko, 2014). Together, these share the notion 
that the heparin binding site is constituted largely of basic arginine and lysine residues 
and that its binding interface with heparin is stabilised mainly by specific ionic 
interactions. This forms the basis for surrogate measurements of binding affinity and 
specificity of gremlin to heparin in this current study by varying the ionic strength at 
constant pH.  
This study further showed that elution peaks of both the wildtype and its 
mutants, ranged between 0.2 – 0.42 M NaCl on columns of the simple cationic 
exchanger SP-Sepharose. These demonstrated weaker binding of gremlin-Myc proteins 
to SP-Sepharose columns compared to heparin. A similar study was conducted by 
Proudfoot et al. (2001), in which the elution of the chemokine RANTES (regulated on 
activation normal T cell expressed and secreted) and its various mutants possessing 
mutations in the predicted heparin binding site was compared on heparin columns and 
Mono S cation-exchanger columns. Here too, higher elution peaks on the heparin 
column hence stronger binding to heparin compared to binding onto the Mono S 
column was observed in the wildtype and most of its mutants. By subtracting each 
elution peak value on the Mono S column from the corresponding elution peak value 
on the heparin column, a positive difference was indicative that mutated residues 
incorporated by the mutants played a role in specific interaction with heparin 
(Proudfoot et al., 2001). Interestingly, applying similar analyses to this current study 
would demonstrate a positive difference between the elution peaks of all gremlin 
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mutants on the heparin and SP-Sepharose columns (refer to Table 4.1, Chapter 4). 
Therefore, this strongly indicates that the three targeted basic clusters present on 
wildtype gremlin-Myc favour its specific ionic binding to heparin.  
Furthermore, the findings that increasing the ionic strength inhibited binding of 
wildtype gremlin-Myc to the heparin-BSA capture layer in heparin-binding ELISA 
were a further strong demonstration that their binding interaction is mainly coulombic. 
This is consistent with previous findings in which a similar nature of interaction has 
been demonstrated between heparin and several heparin-binding proteins such as 
Noggin, sclerostin, RANTES, betacellulin, IL-12 and GDNF (Mummery and Rider, 
2000; Proudfoot et al., 2001; Paine-Saunders et al., 2002; Alfano et al., 2007; Veverka 
et al., 2009). These argue in favour of electrostatic interactions as the main stabilising 
bonds being specific between sulfate groups on heparin and positively charged arginine 
and lysine side chains on the proteins. Therefore, by validating the hypothesis that there 
is a specific heparin binding site on gremlin, which is constituted largely of arginine 
and lysine residues, mapping of the heparin/HS binding site on gremlin has been 
achieved successfully in this study.  
 There is however a potential weakness in studies, such as this current study, 
that rely on changes in ionic strength at constant pH as a surrogate measure of heparin 
binding affinity. These assume that the contribution of nonionic interactions towards 
heparin binding, is not significant. This point is well argued in the findings of 
Thompson et al. (1994) using a combination of site-directed mutagenesis, heparin 
affinity chromatography and isothermal titrating calorimetry to analyse the contribution 
of individual bFGF amino acid residues at the binding interface of a bFGF-heparin 
pentasaccharide co-crystal. Although 7 out of 11 contact amino acids were positively 
charged, the pure electrostatic interactions with sulfated groups on heparin contributed 
to only 30% of the free binding energy. As mentioned earlier in Chapter 1, Section 
1.13, this unexpectedly low free binding energy contribution by electrostatic 
interactions alone may be explained. It may have reflected changes to the bFGF 
structure following its electrostatic attraction to heparin thus leading to a more rigid 
protein structure as new bonds are formed. As such, specific nonionic interactions such 
as Van der Waals and hydrogen bonding at this interface contributed the majority thus 
demonstrating the significant contribution of nonionic interactions in heparin binding. 
Therefore, by assessing only the ionic interactions of gremlin and heparin, our analysis 
of this interaction is limited. However, overall the experimental mapping of the heparin 
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binding site on gremlin also validated the mapping predictions made by Rider and 
Mulloy, (2010) with respect to gremlin. This achievement indicates that the molecular 
dynamic simulation on which the prediction was based, is a powerful tool for 
predicting the heparin/HS binding sites on heparin-binding proteins.  
 
6.5 Effects of Myc and His tags on gremlin binding to heparin/HS 
Since the commercially purified 10X polyHis-tagged wildtype gremlin and the 
expressed wildtype C-Myc-tagged gremlin showed a similar IC50 value of 10 µg/ml, 
this study suggests that neither Myc nor polyHis tags on wildtype gremlin are likely to 
affect its heparin binding. This was shown by immunoassay of both proteins using the 
heparin-binding ELISA in its competitive format with soluble unfractionated heparin. 
Because a Kd value of 20 nM has previously been reported by Chiodelli et al. (2011) 
for high affinity binding of gremlin to immobilised heparin on SPR biosensor chips, it 
can be assumed that the wildtype gremlin-Myc protein will share similar binding 
affinity. The potential risk of using the polybasic 10X His-tagged wildtype gremlin in 
this heparin binding study has been discussed fully in Chapter 4, Section 4.10. In short, 
reports by Lacy and Sanderson (2002) and by Alfano et al. (2007) both demonstrated 
that the presence of a polyHis tag on heparin-binding proteins can generate an 
artefactual heparin/HS binding site. Although these reported results represent a novel 
finding, they are not generalizable to all heparin-binding proteins emphasising need for 
similar investigations on an individual basis. Nonetheless, it was deemed important in 
the current study to avoid the use of the polyHis tag in the investigations of the heparin 
binding properties of gremlin.  
 
6.6 Effects of soluble heparin on gremlin interaction and its BMP ligands 
Binding of Noggin to HS on cell surfaces of CHO-K1 cells has been observed in 
vitro (Paine-Saunders et al., 2002).  This binding was argued to restrict the diffusion of 
Noggin hence HS forms a local depot for circulation cytokines. Using pulse-chase 
experiments, addition of soluble intact heparin to cells rapidly displaced Noggin from 
the plasma membrane thus accumulating in the medium. This implied that HS is 
required for the cellular uptake of Noggin. When using the low-heparin binding 
hNogΔB2 mutant, its accumulation in the medium in the absence of soluble intact 
heparin was indicative of its lack of HS binding activity. Since hNogΔB2 remained 
functionally active as a BMP antagonist, this demonstrated that the heparin binding 
200 
 
domain on the wildtype is independent of its BMP antagonist activity (Paine-Saunders 
et al., 2002). Based on these findings, a model may be proposed in which formation of 
a trimeric BMP:Noggin:HS complex favours the HS- and Noggin-mediated restricted 
diffusion of BMP activity gradients. In this current study, the same question was posed 
as to whether a trimeric BMP:gremlin:heparin/HS complex was also possible, and 
whether this either promotes or inhibits the interaction of gremlin and its BMP ligands.  
In this study, it was revealed that addition of soluble unfractionated heparin in 
the Myc-capture GREM1/BMP-4 double sandwich ELISA neither promoted nor 
inhibited the binding interaction of wildtype gremlin-Myc and BMP-4. These findings 
allow for the formation of a trimeric BMP:gremlin:heparin/HS  complex but does not 
answer the question on its effect on the interaction of gremlin and its BMP ligands.  
However, the fact that these experiments were conducted on an immobilised heparin-
BSA capture layer, which is different from the dynamic binding interactions on cells 
may limit these observations. Our findings contrast with those of Nolan et al. (2013) on 
PRDC. They demonstrated in SPR experiments that pre-incubation of PRDC with 
increasing concentrations of both soluble unfractionated heparin and tinzaparin (5.5 – 
7.5 kDa) inhibited its binding to immobilised BMP-2 ligands. On the PRDC crystal 
structure, the experimentally mapped BMP binding site and predicted heparin binding 
site are located in close proximity on its cystine-knot domain. To explain these 
findings, a regulatory mechanism was suggested in which heparin ligand binding to its 
binding site on PRDC triggered allosteric modifications of the nearby BMP binding site 
thus inhibiting its binding to BMP-2 ligands (Nolan et al., 2013). Therefore, the current 
findings that heparin neither inhibited nor promoted the binding interaction of wildtype 
gremlin-Myc and BMP-4 using the double sandwich ELISA strongly indicated at least 
that its BMP-4 and mapped heparin binding sites do not compete with each other for 
their ligands. Equivalent BMP-4 immunoreactivities using wildtype and MGR5 on this 
double sandwich ELISA, strongly demonstrated that their BMP binding activity is not 
affected by changes to the heparin binding domain; the same heparin binding property 
observed in Noggin (Paine-Saunders et al., 2002). Overall, this current study 
demonstrates that both BMP and heparin binding sites exist on gremlin and are 






6.7 Refining the location of the BMP binding site on gremlin 
The crystal structure of the Noggin-BMP-7 complex was discussed in Chapter 1, 
Section 1.6. In this complex, binding of the BMP dimer to the Noggin dimer occurs at 
the convex interface of the β-finger loops projecting on opposite sides of its head-to-
head oriented homodimer (refer to Figure 1.6). This binding interaction is stabilised 
mainly by hydrophobic interactions involving the insertion of a hydrophobic side chain 
from a flexible backbone segment on Noggin into a hydrophobic pocket on BMP-7 
(Groppe et al., 2002). In contrast, Sun et al. (2006) in their experimental mapping of 
the BMP binding site on gremlin, claimed that it is constituted largely of positively 
charged arginine and lysine residues and that the binding interaction between gremlin 
and BMPs is mainly electrostatic. The experimental mapping of the heparin binding 
site on wildtype gremlin in this current study using site-directed mutagenesis enabled 
partial verification into the claims made by Sun et al. (2006). Within the primary 
sequence of gremlin, Sun et al. (2006) identified a 30 amino acid region as the putative 
BMP-4 binding site that ranged between amino acids 146 – 175 within the cystine-knot 
domain.  According to Figure 3.4, Chapter 3, this represents the full β-strand 3 and 
almost half of β-strand 4 of the f2 loop on gremlin which seems an impressively large 
region to serve as a legitimate binding site on any protein. Also, it can be seen from the 
same figure and Figure 6.1, as well, that this region largely incorporated both basic 
clusters II (145 – 148) and III (172 – 177) on gremlin, which had been substituted in 
MGRs 3 – 5. Tests using both IP and the double sandwich ELISA indicated that MGR5 
and arguably MGR3, both possessed BMP-4 binding capabilities in spite incorporating 
substitutions within this same 30 amino acid region. The added fact that these 
substitutions here were of arginine and lysine residues which Sun et al. (2006) claimed 
mediated charge type interactions between gremlin and its BMP ligands, eliminated 
them as potential contact residues for BMP binding. These refinements would, 
therefore, confine their mapped BMP-binding site to an 18-amino acid region, spanning 
amino acids 149 – 166, which is largely constituted of a hydrophobic cluster instead; 
FTTMMVTLNCPELQPPTK. In addition to concurring with findings from the Noggin-
BMP-7 complex discussed earlier, these novel refinements also concurs with 
experimental mappings by Nolan et al. (2013) on the nature of BMP binding site on 
PRDC whose structure was fully discussed in Chapter 1, Section 1.8.3. The BMP 
binding site on the PRDC dimer is constituted of Trp-93, Tyr-119, Phe-125, Tyr-126 
and Phe-138 that form a hydrophobic patch on the convex binding surface of its 
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cystine-knot domain thus strongly indicating binding to its BMP ligands via mainly 
hydrophobic interaction (refer to Figure 1.9, Chapter 1). Interestingly, as all of these 
residues are conserved in the primary sequence of gremlin, it is possible that these 
together with those in the refined BMP binding site above, may form the putative BMP 
binding site on gremlin. Eitherway, the claim by Sun et al. (2006) that a sequence of 30 
amino acids forms the putative BMP binding site on gremlin through ionic interactions 
with BMP ligands is doubtful. The experimental mappings of the BMP binding site on 
the PRDC crystal structure (Nolan et al., 2013) and now of the heparin binding site on 
gremlin achieved in this current study, have both demonstrated otherwise.  
Interestingly, according to the Nolan et al. (2013) mapping, the BMP binding 
site on the PRDC-based gremlin structure appears to be located mainly on the concave 
surface of the f1 loop (refer to Figure 1.14). This differs from its experimentally 
mapped heparin binding site which is more confined to the f2 loop and N-terminal tail 
loop (refer to Figures 6.1 and 6.2 A and B) thus supporting the physically distinct 
nature of both binding sites on gremlin, as argued previously.  
 
6.8 Significance of the BMP antagonist activity of wildtype gremlin-Myc versus 
mutants  
In the current study, it was established that concentrated wildtype gremlin-Myc 
and MGRs 5 and 6 mutants were all functionally active, as shown by their antagonism 
of BMP-4-SMAD1/5/8-induced signalling, in vitro, using the secreted luciferase 
reporter assay established in C2C12 myoblastic cells. A major caveat in these analyses 
was the difficulty to measure accurately the concentration of these gremlin-Myc 
proteins present in their culture supernatants. However from best estimates, it seems the 
concentrated wildtype gremlin-Myc possessing an intact heparin/HS binding site is 
more functionally active than both mutants which both possess a mutagenized heparin 
binding site. This indicates that the heparin/HS binding domain on the wildtype may 
play some role in the BMP antagonist activity of gremlin. Thus, it would be interesting 
to re-investigate in this functional reporter assay, the effect of soluble heparin on the 
BMP antagonist activity of gremlin. All in all, the results demonstrate that cloning of 
gremlin-Myc mutants possessing reduced heparin binding capabilities but yet 






6.9 Gremlin binds to heparan sulfate on cell surfaces 
 In this study, binding of wildtype gremlin-Myc to heparin at physiological 
ionic strength (0.18 M NaCl) and pH (pH 7.4) was demonstrated, but its binding to HS 
was not investigated. Nonetheless, there is convincing evidence that gremlin does bind 
HS. Chiodelli et al. (2011) demonstrated wildtype gremlin bound to the cell surface of 
CHO-K1 cells and that this binding was inhibited by soluble heparin and HS. 
Moreover, binding of gremlin to bovine aortic endothelial cells was prevented by 
pretreatment with either heparitinase II or chlorate thus demonstrating that HS is 
essential for gremlin binding to cell surfaces (Chiodelli et al., 2011). More recently, 
this was also demonstrated by a fellow postgraduate in our laboratory investigating 
binding of the wildtype and mutant gremlin-Myc proteins expressed in this current 
study to the cell surfaces of C2C12 cells and mouse kidney tissue sections using 
immunohistochemistry. At equalised gremlin-Myc immunoreactivities on the basis of 
the Myc-capture gremlin ELISA, 9E10 anti-Myc immuno-fluorescence generated by 
MGRs 3, 5 and 6 on the cells was considerably weaker than that of wildtype gremlin-
Myc at physiological conditions (Askew, unpublished observations). Furthermore, their 
binding to both C2C12 cells and kidney tissue sections was abolish by pre-incubation 
with intact heparin. Therefore, our laboratory has demonstrated a marked decrease in 
the binding of these gremlin-Myc mutants to cell surface HS as a direct consequence of 
the strategic site-directed mutagenesis conducted herein. Unless the individual domain 
specificity along heparin and HS chains are not known, it will be misleading to attribute 
differences in protein binding affinities to their overall sulfation patterns as HS can be 
more or less sulfated.     
 
6.10 Does gremlin forms a dimer? 
As earlier introduced, Noggin and CV2 (refer to Chapter 1, Section 1.6), and 
including most BMPs themselves (refer to Figure 1.3), form covalently-linked dimers 
via their unpaired cysteine residue located just outside the cysteine-knot motif. As 
stated by Veverka et al. (2009), sclerostin is an atypical member of the cystine-knot 
family as it showed no evidence suggesting it dimerizes unlike several of its 
experimentally resolved cystine-knot homologues that form typically, homo- and 
hetero-dimeric structures via an interchain unpaired Cys:unpaired Cys bridge (Rider 
and Mulloy, 2010). More recently, it is now known that PRDC forms a homodimer in 
its crystal (PDB file: 4JPH; Nolan et al., 2013). However, the PRDC dimer in itself is 
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not without peculiarity; it forms a head-to-tail oriented dimer that oddly, is stabilised by 
noncovalent interactions not via the unpaired cysteine residue (Nolan et al., 2013). It is 
interesting that in spite of possessing the same unpaired cysteine residue (refer to 
Figure 1.9), PRDC does not follow the common mechanism of dimerization. This as 
well may help explain how the family of closely related BMP antagonists have evolved 
structurally to exhibit diverse biological activities. Since PRDC is the closest 
homologue to gremlin, which also possesses the unpaired cysteine residue (refer to 
Figure 1.9), this raises the important question as to whether gremlin also exists as a 
dimer based on the novel mode of dimerization.  
As was introduced earlier in Chapter 1, Section 1.16, the gremlin model based 
on PRDC forms a homodimer (refer Figure 1.14 and 6.2C).  Notably, the contact amino 
acid residues at the binding interface joining both monomers in PRDC (F96 – I106) are 
conserved in gremlin (F117 – I127), (refer to Figure 1.9). This is a further argument in 
favour of the PRDC-based gremlin model over the sclerostin-based gremlin model, the 
first on basis of structural homology. This brings into question whether there is a single 
or two separate heparin binding sites on gremlin, if a dimer. According to the dimeric 
gremlin model, two separate heparin binding sites are present which are located on 
opposite sides of the dimer (refer to Figure 1.14; not shown in Figure 6.2C). This is 
relevant, as it indicates that heparin/HS may not play a role in promoting gremlin 
oligomerization unlike observations with most chemokines as a classic example. At 
physiological concentrations, these chemokines exist in dynamic equilibrium shifting 
between the monomeric and dimeric conformations. However their interactions with 
HS have been shown to drive the equilibrium toward the formation of dimers or high-
order oligomers (Hoogewerf et al., 1997; Proudfoot et al., 2003; Lortat-Jacob, 2009; 
Salanga and Handel, 2011).  
A simple approach to testing whether a protein dimerizes is by carrying out 
SDS-PAGE under both non-reducing and reducing conditions. In this current study on 
gremlin and that of Kattamuri et al. (2012) on PRDC, ambiguous results were produced 
on such tests; it was difficult to assess accurately the difference in migration of both 
proteins in both non-reducing and reducing polyacrylamide gels. Further work 
investigating whether gremlin forms a dimer is currently underway in our laboratory. 
Essentially, this work employs the experimental approach published by Kattamuri et al. 
(2012) of cross-linking 3 µg PRDC protein samples with 0.01% (v/v) glutaraldehyde. 
Attempts to cross-linking wildtype gremlin-Myc with glutaraldehyde have used varying 
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concentrations (0.01 – 0.05% (v/v)), neutralizing with 1 M Tris pH 8. The samples 
were then separated by SDS-PAGE under non-reducing conditions followed by 
Western blotting using a polyclonal gremlin primary antibody as were described earlier 
in Chapter 2, Sections 2.23 and 2.25, respectively. By using this approach, the crude 
wildtype gremlin-Myc culture supernatants pose two difficulties: firstly, the low 
amounts of wildtype gremlin-Myc protein present in crude culture supernatants may be 
limiting to this work. This may be resolved by using concentrated material instead. 
Secondly, the presence of an unknown 50 kDa protein in the cell culture supernatants 
may confound these tests as its molecular weight matches that expected of the gremlin 
dimer. Thus far, it has been demonstrated that this unknown protein does not bind to 
SP-Sepharose matrices (refer to Chapter 4, Section 4.4). Thus the issue of dimerization 
may be resolved by running a large volume of the crude culture supernatant on an SP-
Sepharose column and eluting at an NaCl concentration just above the known elution 
peak of the wildtype, as was determined in this current study (refer to Chapter 4, 
Section 4.9). The cross-linking work could then be performed on the dialysed eluate 
containing the partially-purified wildtype gremlin-Myc protein.  
Preliminary results support dimerization of wildtype gremlin-Myc. In cross-
linked samples, the disappearance of the gremlin immunoreactive band at 25 kDa is 
consistent with a loss of the monomer however detection of the expected gremlin dimer 
immunoreactive band at 50 kDa has yet to be achieved. It is plausible that the cross-
linking may occur in a way that blocks access of the gremlin antibody to its epitopes on 
the gremlin dimer. Nonetheless, more work is needed to resolve this issue.  
 
6.11 Limitations of this study 
    A major limitation in this study was the relatively low levels of expression of 
gremlin-Myc proteins in crude CHO-S cell culture supernatants. This was persistent 
throughout the study and therefore, limiting to its findings. It is generally known that 
cysteine-rich proteins are difficult to express in both bacterial and mammalian 
expression systems (Sermadiras et al., 2013). The fact that proteins such as wildtype 
gremlin and its mutants possess a cystine-knot motif, which forms a complicated 
tertiary structure makes their recombinant expressions even more challenging 
(Schmoldt et al., 2005).  Correct folding requires that three disulfide bonds form 
between the six cysteine residues that form the native cystine-knot motif. Therefore, 
this limitation in gremlin-Myc levels of expression is a problem for all cysteine knot 
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proteins, not affecting this study alone. Moreover, given that bacterial expression 
systems are not suitable for proteins that undergo extensive post-translational 
modifications including disulfide bridge formation, the expression of gremlin-Myc 
proteins in their native glycosylated and phosphorylated forms was achievable only in 
mammalian expression systems (Topol et al., 2000a; de Marco, 2009). The total 
volume of crude gremlin-Myc culture supernatants harvested following transient 
transfections was limited by the scaling up of the transient transfection cultures. The 
alternative of stable transfections could have been considered except that this is not 
practicable for protein expressions intended for use on analytical basis. Transient 
transfections provided a rapid and cost effective method of expressing several different 
gremlin-Myc proteins for comparison of their heparin binding capabilities following 
site-directed mutagenesis.   
Furthermore, a loss in wildtype gremlin-Myc immunoreactivity is observed 
upon long term storage of the partially-purified form over two weeks at -20 °C without 
multiple freeze-thawing. This suggests that recombinant gremlin-Myc proteins may be 
prone to proteolytic degradation and may be unstable in the absence of protease 
inhibitors and carrier protein when in crude or partially-purified forms, respectively. 
These findings together with the use of only transient transfections, limited the work in 
this study using purified gremlin-Myc proteins instead.  
 
6.12 Future work 
The successful expression of functionally active wildtype gremlin-Myc and its 
mutants, MGRs 5 and 6 both possessing reduced binding to HS, raised the issue into 
future experiments investigating the role of HS in the interaction of gremlin and its 
BMP ligands. Such tests can be conducted using the same C2C12-luciferase reporter 
assay that was successfully established in this study. The role of HS can then be tested 
by treating cells with heparitinase and chlorate that will strip them off their cell surface 
HS and block sulfation in general, including that in nascent HS chains, respectively. It 
should be interesting to compare side-by-side the wildtype to both MGRs 5 and 6, 
which will demonstrate further whether HS is essential for gremlin antagonism of BMP 
signalling activities in vitro. When using the double sandwich ELISA, it was 
demonstrated that heparin neither inhibited nor promoted the binding interaction of 
wildtype gremlin-Myc and BMP-4. It would be interesting to test whether this remains 
the case in the dynamic setting of the cell surface that this functional assay offers as 
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well. In previous findings by Kuo et al. (2010), a catalytic coreceptor role of HS was 
suggested in promoting heteromeric types I and II receptor complexes, but not 
remaining stably associated with the BMP-receptor signalling complex. In their study, 
reduced BMPs -2 and -4-induced SMAD1/5/8 phosphorylation was observed in both 
heparitinase- and chlorate-treated C2C12 and PC12 cells. Interestingly, a non-heparin 
binding BMP-2 mutant, EMBMP2, was resistant to the same treatments, which rather 
indicated that BMP-2 binding to HS is not essential for BMP-2 signalling (Kuo et al., 
2010). However, the fact that this BMP-2 mutant was expressed in bacteria that are 
unable to incorporate the post-translational modifications present in the native BMP-2 
protein itself, makes the findings uncertain. The comparative use of wildtype and low 
heparin-binding gremlin-Myc mutants incorporating similar post-translational 
modifications makes this an insightful investigation.  
 
 6.13 Conclusion 
Overall it can be said that the findings in this study herein have advanced our 
understanding on the heparin binding properties of gremlin. Gremlin can now be 
included alongside sclerostin and Noggin in the repertoire of BMP antagonists with an 
experimentally mapped heparin binding site. In these BMP antagonists, the heparin 
binding site is constituted largely of interspersed basic clusters of arginine and lysine 
residues which drive their specific ionic interactions with acidic sulfate groups on 
heparin and HS chains. Although the structural folds of these BMP antagonists have 
remained conserved through evolution, it is now apparent that the location of the 
heparin binding site on these structures has not remained so. This may be reflective of 
the diverse biological roles of HS within this family of closely related BMP 
antagonists. In gremlin, the heparin binding site has been mapped on its predicted f2 β-
stranded paired loop and α1 helix in the flexible and disordered N-terminal loop; 
differing from that of the predicted BMP binding site situated mainly on the concave 
binding surface of its f1 β-stranded paired loop. This shows that heparin and BMP 
binding sites on gremlin are physically distinct. 
 Biochemically, it appears heparin is not essential in the binding interaction of 
wildtype gremlin and its BMP ligands, as it neither promoted nor inhibited their 
interaction. However, functional cell signalling studies offering dynamic binding 
interactions on cell surfaces may yet indicate otherwise. 
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There is strong evidence that the physically distinct BMP and heparin/HS 
binding site on wildtype gremlin-Myc are independent of each other. Two functionally 
active C-Myc-tagged gremlin mutants, MGRs 5 and 6 possessing markedly reduced 
binding to heparin retained their BMP-4 antagonist activity comparable to the wildtype. 
Also, evidence from another in vitro study in our laboratory (Askew, unpublished 
work), indicates that the mutants show markedly reduced binding affinities to some HS 
under physiological conditions. Therefore, the wildtype and both these gremlin-Myc 
mutants will serve as powerful tools in future investigations of the biological role of HS 
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